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ANTIMICROBIAL USE IN FOOD-PRODUCING ANIMALS 
1. DEFINING ANTIMICROBIALS IN LATU OR STRICTU SENSU 
Antimicrobials in broad sense are defined as all compounds with a direct action on micro-organisms. They 
include antibacterial, antiviral, antifungal and antiprotozoal compounds (EPRUMA, 2013). Antibacterial 
compounds or antibiotics are then determined as compounds with a direct action on bacteria, both naturally 
occurring and (semi)synthetic chemical compounds, such as β-lactams and quinolones, respectively. Next to 
antibacterial activity, certain antibiotics such as sulfonamides and pyrimidines show activity against coccidia 
(Giguère, 2013). Throughout this review, we will speak both of antimicrobials and antibiotics or antibacterial 
agents/compounds when referring to substances with antibacterial activity. 
2. DIFFERENT AIMS FOR THE USE OF ANTIBIOTICS IN FOOD-PRODUCING ANIMALS 
The use of antibacterial compounds in veterinary practice started soon after they became available for the 
treatment of human diseases in mid 1940s (Aryal, 2000). Sulfonamide was the first antibiotic to be formally 
introduced to food animal medicine in the 1940s, but penicillin was most likely already used before as the first 
antibacterial compound to treat bovine mastitis (Gustafson and Bowen, 1997; Aryal, 2000). Currently, in 
veterinary medicine, antibiotics are used to prevent and to treat bacterial infections of an individual animal or 
a group of animals (Table 1). Preventive treatment or prophylaxis is defined as the treatment before clinical 
signs of disease, in order to prevent the onset of disease or infection (EPRUMA, 2013), which might result in 
decreased production results. Prevention is based on a high probability of disease to occur, at key time points 
where animals are generally recognized as more susceptible to infections (Schwarz and Chaslus-Dancla, 
2001). Current livestock production systems rely on the application of antibiotics to groups of animals. 
Examples of when these strategic treatments are performed are prevention of diarrhoea in weaned piglets or 
veal calves through medicated feed or medicated milk replacer respectively, necrotic enteritis in broilers, 
caesarean section or other surgery, transport and mixing of animals, or intra-mammary dry cow treatment at 
the end of lactation in dairy cattle (Schwarz and Chaslus-Dancla, 2001). The treatment of an ill animal or 
group of animals preceded by a diagnosis of a disease or infection is called curative or therapeutic 
(EPRUMA, 2013). In veterinary medicine, curative treatment is historically linked to the individual animal, as 
large groups of animals are often already treated before infection is spread to all animals. A third common 
practice is metaphylaxis or control treatment. This can be defined as the treatment of a group of animals 
after the diagnosis of clinical disease in part of the group, with the aim of treating the clinically sick animals 
and controlling the spread of disease to animals in close contact and at risk which may already be 
(subclinically) infected (EPRUMA, 2013). Metaphylaxis may not only reduce the number of sick or dead 
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animals. It could also decrease the total amount of antibacterial agents needed to treat a large number of 
symptomatically ill animals, consequently reducing treatment costs (Schwarz et al., 2001). 
The introduction of antibiotics to cure or prevent diseases and infections came along with the discovery of 
advantageous production effects in animals of small amounts of antibiotics in feed, after experimental 
observations of feeding fermentation waste from tetracycline production to chickens (Gustafson and Bowen, 
1997). The mechanisms behind the benefits of using antibacterial growth promoters (AGP) are only partially 
revealed (Edqvist and Pedersen, 2000; Reti et al., 2013). Though, the use of antibacterial compounds at a 
low, subtherapeutic dose over long periods of time, showed to promote growth rates and feed conversion, to 
improve egg production, to increase litter size in sows and to prevent a reduced milk yield associated with 
ketosis in dairy cows (Edqvist and Pedersen, 2000; Page et al., 2005). Furthermore, they provided protection 
against certain diseases promoted by intensification of animal production. As a result, AGP became soon an 
integrated part of several industrialised animal husbandry production systems. 
Table 1. Reasons for antibiotic use in food-producing animals individually or at group level and the most 
frequently applied administration routes. 
 Antibiotic administration: Individual or group 
treatment in food-
producing animals? 
Administration route 
Preventive treatment or 
prophylaxis 
Before clinical signs of 
disease 
Group of animals Oral, via feed or water 
Topical 
Curative or therapeutic Preceded by a diagnosis 
of a disease or infection 
Mostly individual Parenteral  
Metaphylaxis or control 
treatment 
After the diagnosis of 
clinical disease in part of 
the group 
Subgroup of animals Oral, via feed or water 
Growth promotion*  To promote growth rates 
and feed conversion, to 
improve production 
Group of animals Oral, via feed 
* The use of the last 4 antibacterial growth promoters have been banned in the European Union in 2006 
(European Commission, 2005). 
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3. ANTIBIOTIC CLASSES IN VETERINARY MEDICINE 
The number and variety of antibacterial compounds available for veterinary use have increased rapidly since 
penicillin was used as the first antibiotic in veterinary medicine. In total around 26 different antibiotic classes 
are currently licensed in the world. An antibiotic class can be defined as a group of agents with a similar 
mechanism of action, regardless of chemical structure (Collignon et al., 2009). Within classes, divergent 
subgroups or generations might be present with activity against different spectrums of bacteria. For instance, 
3th generation cephalosporins have decreased Gram-positive but increased Gram-negative antibacterial 
activity compared to the 2nd generation (Prescott, 2013). Yet, in general, newer generations have been 
developed to improve pharmacodynamic and pharmacokinetic traits and to overcome resistance problems 
(Chopra and Roberts, 2001).  
Besides working mechanism and spectrum, classes of antibiotics are characterized by several features and 
these might differ or match to various degrees between and within classes. These characteristics include oral 
bioavailability, tissue penetration, elimination routes, toxicity and interaction with heavy metals or other 
antibacterial compounds. The latter can result in either synergism or antagonism. As the characteristics of 
antibiotics are not a part of this thesis, they will not be further discussed.   
4. ROUTES OF ADMINISTRATION  
Antibacterial drugs, as all veterinary drugs, can be administered via various routes. Local or topical use in 
food-producing animals involves cutaneous (through the skin), nasal, intra-articular, intra-ocular, intra-
auriculair, and finally intra-mammary and intra-uterine as the main routes. Systemic use is defined as each 
administration via oral or parenteral routes. The latter includes then intravenous, intramuscular, intraperitoneal, 
transdermal and subcutaneous injection (EPRUMA, 2014). 
Oral administration in food-producing animals is performed either by medicated feed or water. Medicated 
premixes or water soluble drugs are then mixed in feed and water under controlled conditions. Also, oral 
powders are available and can be mixed into the feed on the farm.  
As mentioned above, in animals for food production, the number of animals treated is often consistent with 
what wants to be achieved by giving antibiotics, prevention, metaphylaxis or treatment. This can however be 
expanded to the routes of administration (Table 1). The preventive and metaphylactic treatment of groups of 
animals by oral administration through feed or water has been reported for veal calves (Pardon et al., 2012) 
and poultry (Persoons et al., 2012). Nevertheless, in dairy cattle, at the end of the lactation period, dry-cow 
therapy is applied via intra-mammary injection and thus topical therapy is here used to a large number of 
animals (Schwarz et al., 2001). In intensive livestock farming, parenteral therapy might be the route of choice 
in order to cure sick individual animals (Schwarz et al., 2001). 
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Furthermore, concerning dosing and administration routes, in veal calves, it has been seen that orally 
administered antibiotics are often underdosed compared with the recommendations on the prescription leaflet 
(Pardon et al., 2012). In poultry, orally administered doses were generally more respected (Persoons et al., 
2012). Parenteral treatment was more often overdosed (Pardon et al., 2012). Uncorrect dosing might have 
specific implications regarding development and selection of resistant mutants depending on the antibiotic 
used and the bacteria on which selection pressure is exerted. Potential effects on the prevalence of 
resistance related to dosing are more explained into detail in Chapter 1.3. of this thesis.    
5. IMPACT OF ANTIMICROBIAL RESISTANCE EMERGENCE ON THE ANTIMICROBIAL 
USE POLICY 
The potential risks associated with the extended use of antibiotics, and more in particular of penicillin were 
already expressed by Alexander Fleming in 1945. Indeed, for many antibiotics the time coincidence between 
the discovery and production of antimicrobial agents, their introduction into clinical use as well as the 
emergence of resistant bacteria is unmistakable (Schwarz and Chaslus-Dancla, 2001). For decades, 
scientists, public health services as well as organizations dealing with animal health have warned for the 
threats associated with resistance, namely a decreased animal welfare, endangered animal and human health 
as well as a continued food production under pressure (Vose et al., 2001; EFSA-ECDC, 2013). 
5.1. THE SWANN REPORT  
In 1969, a joint committee of scientists expressed their concerns on a potential higher risk of the prevalence 
of resistant pathogenic bacteria in man associated by giving antibiotics to animals (Swann Report, 1969). 
Clear recommendations on the use of antimicrobial compounds in animal husbandry were formulated to 
inform policymakers. They urged for a control of antibiotics in feed, as well as therapeutically used. Global 
surveillance of animal and human related resistant bacteria and research on possible other ways to reduce 
the burden of infectious diseases was proposed (Swann report, 1969).  
5.2. THE BAN ON ANTIMICROBIAL GROWTH PROMOTERS (AGPs) 
Following the Swann Report, a broader debate on the potential hazards of antibiotic resistance linked to 
antibiotic use was initiated in both animals and humans. The prospective farm study by Levy in 1975 (Levy et 
al., 1976) and many other studies in the following decades clearly demonstrated the selective nature of low-
dose, nontherapeutic AGP on both the pathogenic and commensal flora of food animals such as poultry, 
swine and cattle (Marshall and Levy, 2011). In Sweden, findings on the risks associated with AGP, led to the 
use of antibacterial compounds solely allowed for therapy and on veterinary prescription from 1986 onwards 
(Wierup, 2001). The European Union followed with the ban of the growth promoter avoparcin in 1997 and 
bacitracin, spiramycin, tylosin and virginiamycin in 1999 (Casewell et al., 2003). Still, the last 4 antibiotics 
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permitted as feed additives to help fatten livestock have only been banned in the EU in 2006, which was the 
final step of phasing out all antibiotics used for non-medical purposes (European Commission, 2005). 
Outside Europe, the use of antibiotics as growth promoters and without veterinarian prescription is still 
accepted for a large range of compounds, such as tetracyclines, macrolides, bambermycine and 
streptogramins (Chopra and Roberts, 2001; Reti et al., 2013). Yet, their use is under increasing regulatory 
and political scrutiny in both the United States (US) and China. The use of antibiotics for growth promotion, 
increased performance, and improved feed efficiency would no longer be permitted in the US (Allen et al., 
2013). Recently, the Center for Veterinary Medicine of the American Food and Drug Administration (FDA) 
announced the withdrawal of 16 antimicrobial drug applications in 2014 in order to phase out antibiotic use for 
production purposes, necessary for assuring health in food-producing animals (FDA, 2014). Additionally, 
certain antibiotics of critical importance, such as 3th generation cephalosporins, are likely to be restricted to 
human use in the near future even if they are important for animal disease treatment (FDA, 2013). 
Furthermore, they urge on the requirement for veterinarian involvement in the decision to use antibiotics 
(FDA, 2012).  
5.3. CLASSIFICATION OF ANTIBIOTICS ACCORDING TO ANIMAL AND PUBLIC HEALTH  
Many antibacterial classes and/or subgroups within classes are used both in human and veterinary medicine 
(Moulin et al., 2008; Collignon et al., 2009). Currently, last line agents like carbapenems, lipopeptides and 
oxazolidinones have no veterinary equivalent. Colistin and even some of the carbapenems, although used as 
last resort in the treatment of extended-spectrum β-lactamase producing Escherichia coli (ESBL) infected 
patients in human medicine, are in a more or lesser extent used in veterinary medicine, in the framework of 
the cascade legislation (Gibson et al., 2008). As a result , the use of certain antibiotics give particular rise to 
debate regarding the impact of increased resistance in human and/or veterinary medicine and the potential 
transmission of resistant determinants between animals and humans. In 2005, the World Health Organization 
(WHO) developed criteria to rank antibiotics according to their importance in human medicine (‘critically 
important’ – ‘highly important’ or ‘important’) to ensure that critically important antimicrobials (CIA) are used 
prudently both in human and veterinary medicine (2011). These lists aim at helping regulators and 
stakeholders to determine which types of antibacterial agents could be used in food animal production and to 
determine how these agents might be managed (e.g., single animal therapy or mass treatment via water, 
prohibiting extra-label use, etc.). Meanwhile, a second and third revision of the list have been made in 2007 
and 2011 respectively to re-evaluate the classification of antimicrobials and update the list on the basis of 
recent developments (WHO, 2011). Similarly as in human medicine, in 2007, the World Organisation for 
Animal Health (OIE) established a criteria based list of all antibacterial agents used in food-producing animals 
with the objective to safeguard the efficacy and availability of veterinary antimicrobial agents for animal 
diseases where they are few or no antimicrobial alternatives (OIE, 2007). The list furthermore intended to help 
ANTIMICROBIAL USE IN FOOD-PRODUCING ANIMALS CHAPTER 1.1 
12 
 
veterinarians in their therapeutic choice. A revision of the list occurred in 2012 and within the One Health 
concept, a joint expert group of the OIE, the Food and Agriculture Organisation (FAO) and the WHO assigned 
specific recommendations to the fluoroquinolones and the 3rd and 4th generation of cephalosporins (OIE, 
2014). Among the Veterinary Critically Important Antimicrobial Agents (VCIA) in the OIE List, these two 
classes are considered to be critically important with respect to transmission of resistance.   
Only very recently, a French group of experts established a methodology in order to evaluate and recognize 
antibiotic use practices at risk in order to decrease human and animal health threats associated with 
resistance determinants selection (ANSES, 2014). The method does not solely take into account the 
importance of a certain class to treat infections in animal and human health, according to OIE and WHO 
respectively, but equally the routes (local, parenteral, oral and other routes) and reasons for administration 
(curative, metaphylactic or preventive). Furthermore, additional factors specific per animal species and 
production stage to which antibiotics are administered and the potential for alternatives are taken into 
account. This methodology resulted into a categorization per animal production sector of antibiotic 
(sub)classes in 4 groups : ‘Les pratiques à risque à abandonner sans délai, ‘Mesures visant à abandonner la 
pratique à terme’, ‘Les pratiques à encadrer’ and ‘Les pratiques sans encadrement supplémentaire’.  
Furthermore, in Belgium, AMCRA, the Belgian “centre of knowledge on antimicrobial use and resistance in 
animals”, launched in 2012, has developed colour codes assigned to active substances licensed in veterinary 
medicine. The aim of the colour codes ‘yellow’, ‘orange’ and ‘red’ is to inform veterinarians, farmers and policy 
makers on their importance for human and animal health. Also, the colour codes represent conditions, 
presented in table 2, which have to be fulfilled before the active substance can be used. The assignment of 
the colour codes is based on the WHO and OIE lists ranking antibiotics with importance for human and 
animal health (WHO, 2011; OIE, 2014). Also the advice of the Health Council of the Netherlands has been 
taken into account. When producing the lists priority was given to human health. Within the red-coloured 
substances, the fluoroquinolones and 3rd and 4th generation cephalosporins, can be found, emphasizing their 
relevance in human and veterinary medicine (AMCRA, 2014a). 
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Table 2. Conditions for use of active substances with colour code ‘yellow’, ‘orange’ or ‘red’, proposed by 
AMCRA (2014a). 
Can the active 
substance be used 
for preventive 
reasons? 
Can the active substance 
be present in the stock of 
2 months at the herd? 
Should an additional 
diagnostic laboratory 
test be done?  
Should an antimicrobial 
susceptibility test be 
performed? 
No Yes It is preferred It is preferred 
No Yes Condition for use It is preferred 
No No Condition for use Condition for use 
 
5.4. MEASURE TO MANAGE 
Antibiotic consumption data are a key element in the establishment of strategies for containing resistance. At 
national and/or regional levels such data are vital for detecting trends in use, assessing the effect of 
responsible use campaigns, risk management measures such as legislative restrictions of use, and 
implementation of animal health prevention measures. 
As a result, surveillance of antimicrobial use has been widely recommended internationally in recent decades 
and data collection promoted in all sectors of use (human medicine, veterinary medicine and agriculture) 
(FAO/OIE/WHO, 2003).  
6. QUANTITIES OF ANTIBIOTICS USED  
6.1. HOW TO MEASURE?  
Sweden and Denmark, followed by Norway and the Netherlands were the first to start collecting national sales 
data from the nineties onwards (Ungemach et al., 2006; NORM-VET, 2012; SWEDRES-SVARM, 2012; Bos et 
al., 2013; DANMAP, 2013; MARAN, 2013). Different indicators and technical units of measurement for 
antibiotic use in food-producing animals can be used with advantages and disadvantages for each of them 
(Table 3). In the above reports, the total use is expressed in kg or tons of active substance and the actual 
biomass of the animal population at risk is used as denominator data (Ungemach et al., 2006; NORM-VET, 
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2012; SWEDRES-SVARM, 2012; Bos et al., 2013; DANMAP, 2013; MARAN, 2013). This method allows a 
crude estimation of how usage evolves in time and between countries or geographical areas. More detailed 
denominator data equally make it possible to compare animal species or production stages within one 
species, farmers or food animal producers, and veterinarians (Grave et al., 2010). Yet, many of the veterinary 
antimicrobial products are licensed for several species, and an approximation is required to reallocate the 
amounts sold to the different species. The relative use does still not take into account differences in potency 
of an active substance (Jensen et al., 2004). For instance, 3th  and 4th generation cephalosporins have a 
higher potency compared to old substances as tetracyclines and trimethoprim, resulting in different dosages 
per kilogram of body weight between and within antibiotic classes (LEI, 2011; Silley et al., 2012). Therefore, 
an alternative way to quantify consumption data is by expressing the use in terms of number of dosages 
applied in an animal species. Yet, differences in daily dose between antibiotic agents, pharmaceutical forms, 
animal species and countries give rise to the need of standardized doses or defined daily dose animals 
(DDDA), as proposed by the European Surveillance  of Veterinary Antimicrobial Consumption (ESVAC). The 
ESVAC consortium has defined the Defined Daily Dose Animal (DDDA) as “The assumed average 
maintenance dose per day per kg body weight for the main indication in a specified species”. The DDDA is 
not defined at product level but for each antimicrobial agent, administration route and animal species and 
when appropriate, also age group, and is not related to one country. As these standardised DDDAs are 
currently missing, a group of experts recently attempted to assign standardised DDDAs for antibiotics 
authorized in pig production in Belgium, Germany, France and Sweden (Postma et al., 2015). Ideally, to allow 
on comparison of countries, the use of DDDAs is combined with reliable usage data per animal species, 
because a country overall average is influenced by animal demographics and therefore an inaccurate 
indication of true differences of exposure, per species (Bondt et al., 2012).  
In order to take into account simultaneously dose and duration of treatment, ESVAC equally defined the 
Defined Course Dose Animal (DCDA) as a second technical unit. Whereas the DDDA and the DCDA have 
the potency of being harmonised between countries, the Prescribed Daily Dose for Animal (PDDA) and Used 
Daily Dose for Animal (UDDA) are units expressing the prescribed and real dose administered under field 
conditions. The UDDA reflects valuable information regarding the precise amounts of antibiotics exerting 
selection pressure and allows to estimate the correctness of administered doses relative to the DDDA. As a 
result, it would be in conflict with their nature to standardise them between countries. For European 
comparisons, numbers of DDDA or DCDA used by animal species or specific weight group divided by the 
number of animals produced or livestock by country and year, has been proposed by ESVAC as the indicator 
for reporting consumption. This presents then the number of standardized daily doses or course doses 
respectively administered for an animal species of a specific weight group in year by country (EMA, 2013a).  
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Table 3. Indicators and corresponding technical units of measurements of antibiotic use in food-producing 
animals. For each indicator, nominator and denominator data are shown. Pro’s and con’s are listed for the 
technical units of measurement.  
Indicator for 
antibiotic use 
Technical unit 
of 
measurement 
Nominator  Denominator  Pro’s Con’s  
Amount of 
active 
substance 
/biomass of 
animal 
population at 
risk 
Weight of 
active 
substance (kg) 
Total amount 
of active 
substance 
sold (kg) 
Number of live 
and slaughtered 
animals x 
standard weight 
at treatment 
- Direct 
accessible  
- Allows 
combining 
different 
animal species 
- Requires 
reallocation of 
the amounts of 
antibiotics sold 
to the different 
species 
- Differences in 
potency are not 
taken into 
account 
DDDA/1000 
animals/year 
DDDA Number of 
DDDA used 
by animal 
species or 
weight group 
Number of 
animals 
produced or 
livestock per 
time span (year) 
- No bias due 
to differences 
in potency  
- Requires 
harmonization 
for 
comparisons 
UDDA/1000 
animals/year 
UDDA Number of 
UDDA used 
by animal 
species or 
weight group 
Number of 
animals 
produced or 
livestock per 
time span (year) 
- Estimates 
correctness of 
the 
administered 
dose relative 
to the DDDA 
 
- Requires 
detailed data at 
the herd level 
DCDA/1000 
animals/year 
DCDA Number of 
DCDA used 
by animal 
species or 
weight group 
Number of 
animals 
produced or 
livestock per 
time span (year) 
- Takes into 
account both 
dose and 
number of 
days of 
treatment 
- Requires 
harmonization 
for 
comparisons 
PDDA/1000 
animals/year 
PDDA Number of 
PDDA used 
by animal 
Number of 
animals 
produced or 
livestock per 
- Estimates 
correctness of 
the 
prescribed 
- Requires 
detailed data 
at the level of 
the individual 
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species or 
weight group 
time span (year) dose relative 
to the DDDA 
 
veterinarian 
 
Besides which technical units of measurement and indicator might be used, ESVAC also reported on which 
data sources on consumption are appropriate (EMA, 2013a). Different data sources fulfil to a more or lesser 
extent the objectives set when collecting data (FAO/OIE/WHO, 2003). Ideally, data are continuously collected 
at the level of the farm or veterinarian. As mentioned above, data collection systems aim at targeted and 
accurate action, namely where high usage patterns are observed. Detailed information on both quantitative 
and qualitative aspects of use are then required. Animal species or production stage specific information on 
used quantities, on which active substances, for which indications, and through which routes administered, 
are preferable (Silley et al., 2012). Thereto, collection at the level of the farm is essential (EMA, 2013a). 
Surveillance systems at the national level, unless provided by marketing authorisation holders (MAHs), do not 
provide the species specific information. Yet, despite these shortcomings, they might serve as validation of 
other data sources (FAO/OIE/WHO, 2003). 
6.2. TRENDS IN OVERALL USAGE IN ANIMAL HUSBANDRY 
IN EUROPE 
Only few countries started collecting data from the nineties onwards and trends of their antibiotic consumption 
during time can be studied. Only qualitative between country comparisons will be made, in order not to 
conflict with the abovementioned assumptions of comparisons. Data from the United Kingdom, the 
Netherlands and Denmark showed a substantial increase in the use of antibiotics for food animals from 1999 
onwards (Casewell et al., 2003; DANMAP, 2013; MARAN, 2013). In Finland, the overall consumption 
increased between 2001 and 2008 (Finnish Food Safety Authority, 2011). The overall increase coincides with 
the ban of growth promoters, whereas this ban can be seen as a first attempt to decrease veterinary use of 
antimicrobials. Also the Fédération Européenne de la Santé Animale (Fedesa) reported an increase in 
antimicrobial use in veterinary medicine in the European Union and Switzerland by 408 tons for the year 
1999, while in the meantime the non-therapeutic use of antibiotics as growth promoters in farm animals 
declined by 51% to 786 tons (Ungemach et al., 2006). A ban on AGP was predicted by sceptics to increase 
the number of both subclinical and clinical infections (Castanon et al., 2007). Indeed, after the ban, infections 
associated with Lawsonia intracellularis in pigs and with Clostridium perfringens in poultry were amongst the 
increased reported diseases in Denmark (WHO, 2002). The above mentioned data confirmed that the ban 
had most likely led to, at least partially, an increase in use for therapeutic reasons (Casewell et al., 2003). 
Remarkably, Norway reported no increase at all, but even succeeded in a continued decrease in antibiotic 
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use in food producing animals from 1995 to 2012 by approximately 36%, while the total animal population 
remained more or less stable (Norm-Vet, 2012). This has been explained by a reduction target of 25% from 
1995 onwards, set by Norwegian husbandry organisations and simultaneously prudent use campaigns. 
In 2010, The Netherlands, at that time among the top of high users of antimicrobials in European Union 
(EU)/European Economic Area (EEA) countries (EMA, 2012), declared to respond to its antibiotic resistance 
crisis with a mandate to reduce their use in food animals by 50% by 2013 and 70% by 2015 and furthermore 
to establish a registration process for veterinary prescriptions of antibiotics. Indeed, the MARAN report 
showed for 2012 a decrease with the pre-established objective of 50% (MARAN, 2013). Furthermore, a 
decrease in the sales of antimicrobial compounds between 2010 and 2011 for both food producing (including 
horses) and companion animals has been reported for 19 out of the 20 EU/EEA countries that provided data 
to the European Medicines Agency (EMA, 2013b). Suggested explanations provided by the countries for the 
decline in sales are, among others, implementation of responsible-use campaigns, restrictions of use, 
increased awareness of the threat of antimicrobial resistance, and/or the setting of targets (EMA, 2013b). 
IN BELGIUM 
In Belgium, national sales data are annually reported from 2007 onwards and consist of all veterinary 
antibiotics sold to a veterinarian or pharmacist in Belgium and of antibacterial premixes incorporated in 
medicated feed intended to be used in Belgium (BelVet-SAC, 2015). Data include thus consumption data for 
farm animals as well as companion animals. The denominator for animal production is the biomass (in kg) 
calculated as the sum of the amount of beef, pork and poultry meat produced in 2010, plus the number of 
dairy cattle present in Belgium times 500 kg of metabolic weight per individual head. Since the onset of the 
data collection in 2007, the highest usage was also observed for that year (168.66 mg active substance per 
kg biomass). Figure 1 shows the evolution of national sales data for antibacterial pharmaceuticals and 
premixes (BelVet-SAC, 2015). When looking at the data from 2007 onwards, a decrease of 14,3% in total 
consumption can be observed by 2011. A substantial part of this decrease was realized between 2007 and 
2008 (11.4%), but the level of use remained more or less stable between 2008 and 2011.  
After an overall reduction (in terms of mg per kg of biomass produced) of 12.7% between 2011 and 2013, in 
2014, a small increase of 1.1% was recorded. When using 2011 as a reference, still a reduction of 11.8% is 
achieved, distributed over a reduction of 12.2% in antibacterial pharmaceuticals and 10.0% in antibacterial 
premixes (BelVet-SAC, 2015). Yet, additional efforts will be needed to be in line with the recently set objective 
of a 50% reduction in antimicrobial use in animals by 2020 (2011 is the reference year), proposed by the 
partners of AMCRA (AMCRA, 2014b). Additionally, a reduction of 75 % in CIA 3rd and 4th generation 
cephalosporins and fluoroquinolones has been proposed by AMCRA by 2020. Compared with 2011, the use 
of quinolones dropped with 18.9% in 2013, but increased again by 5.3% in 2014 compared to 2013. The use 
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of 3th and 4th generation cephalosporins can be considered decreasing with 6.7% between 2011 and 2014 
(AMCRA, 2015).  
 
Figure 1. Evolution of national sales data for antibacterial pharmaceuticals and premixes expressed in mg 
active substance per kg biomass for all animals in Belgium (BelVet-SAC, 2015). 
7. ANTIMICROBIAL USE IN PIG PRODUCTION 
Pig production is characterized by 3 major production stages, based on the function, weight and age of the 
animals. Average animal weights for a certain production category and at the end of fattening period, before 
slaughter can differ between countries. This might result in different weights used when calculating incidences 
of antimicrobial treatment. Sows are breeding animals and used for the production of piglets. Sows and 
piglets are housed in the farrowing unit until piglets are weaned, generally between the age of 21 and 28 
days. After weaning, piglets are placed in the so called ‘nursery unit’. From 10 weeks onwards, the growing 
pigs are raised until slaughter. In general, pig production management consists of open, closed or semi-
closed herds. Closed herds breed and rear fattening pigs (farrow to finish). Semi-closed farms may have 
animal supply, for instance, the purchase of gilts. Ideally, the number of sources should be limited to minimize 
the odds for infectious agents to enter, compared to closed farms. Open herds solely breed or raise pigs. Sow 
herds raise the piglets and these are moved at weaning or at the onset of fattening to fattening pig herds that 
only receive piglets from these sow herds. 
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7.1. IN EUROPE 
The pig production sector is believed to be amongst the highest users of antimicrobials in intensive animal 
husbandry production (Bondt et al., 2012; Bos et al., 2013; DANMAP, 2013). In pig production, as well as in 
broiler and veal calf production, animals have a short lifetime and younger animals demand relatively more 
treatment with antibiotics, as they are more susceptible to diseases (Bondt et al., 2012). This might partially 
result into a relatively higher use per time period in pigs compared to sectors with longer production cycles, 
for instance in beef cattle. Denmark used to compare antibiotic usage in pigs with other species based on 
kilograms of meat produced (DANMAP, 2013). However, this measure overestimates the selection pressure in 
species with long lives (e.g. cattle), while underestimating the selection pressure in species slaughtered at an 
early age (e.g. broilers). Also, comparing different animal categories or production stages have their pitfalls, 
as these categories have inherent differences in farm management, including antibiotic administration. 
Suckling and weaned piglets, for instance, are more susceptible to enteric diseases than other age groups. 
Consequently, results on antimicrobial use data in pigs of different ages should be interpreted with a certain 
background knowledge.  
As mentioned above, data on a specific animal species are needed to indicate the true levels of exposure 
(Bondt et al., 2012), and these data can be collected at different levels. Detailed information on pigs, animal 
categories (sows, piglets, fattening pigs) and individual herds can be obtained by means of single surveillance 
studies, eventually repeated in time. Both Canada and France gathered information on quantitative as well as 
qualitative aspects of antibiotic use in pigs, through a survey of Canadian swine producers and French pig 
veterinarians respectively (Dunlop et al., 1998a; Dunlop et al., 1998b; Chauvin et al., 2002). 
Secondly, well-established surveillance systems on a continued basis can be used and this demands sources 
such as feed mills, pharmacies and veterinarians to deliver this data. Sweden has antibiotic sales data for 
pigs expressed in mg active substance per kg slaughtered pig (SWEDRES-SVARM, 2012). A decrease of 
13% was seen between 2008 and 2012. In 2012, the sales of CIA/VCIA fluoroquinolones for pigs were 32% 
lower than in 2008. Sales of CIA/VCIA 3th generation cephalosporins were insignificant (SWEDRES-SVARM, 
2012).  
So far, only two countries register and report data on pig sector consumption of antimicrobials based on 
veterinarian prescriptions (Jensen et al., 2004; Bos et al., 2013). Denmark collects prescription based data 
since 2001 and reports annually per animal species, including pigs (DANMAP, 2013). The Danish national 
reports used to express the ‘on prescription based consumption data’ as the ADD related to total biomass per 
year at risk, kg meat produced or number of animals produced (DANMAP, 2013). Yet, from 2012 onwards, 
the Defined Animal Daily Dose (DADD) is used in order to cope with different ADDs between products with 
the same active compound, route of administration and formulation. The urge for such country-independent 
standardized doses has been expressed by the ESVAC (standardized DDDA as defined above) (EMA, 
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2013a). Yet, DADD has been specifically defined for use in DANMAP and is currently not standardized with 
other countries. DADDs are expressed per 1000 animals per day (DAPD). The DAPD is the proportion (in 
thousands) of animals treated daily with an average maintenance dose of a particular antimicrobial agent.   
During the last decade, the DAPD in pig production increased by 49% from 2003 to 2009. However, in 2010 
and 2011, a decrease in DAPD by 23% compared with 2009 was observed, probably as a response to the 
Danish Veterinary and Food Administration (DFVA) implementation of the “yellow card initiative” – a special 
provision for reduction of antibiotic consumption in pig production. Yet, continued efforts on awareness are 
needed as in 2012, again an increase by 8-9% in antibiotic use was seen for the production of a slaughter pig 
(total DAPD equalled 30). Highest DAPDs are observed in the weaned pigs (100), whereas the DAPDs in 
sows and finishers are more similar in magnitude (20). The DAPD increased the most in weaners (15%) and 
finishers (10%) and less in sow herds (2.9%), and this was almost entirely (97%) associated with an 
increasing use of primarily tetracyclines and macrolides in all age groups. The DAPD of tetracycline increased 
by 15%, while the use of macrolides increased by 19%. No use of CIA’s and VCIAs cephalosporins and 
quinolones has been reported in one of the pig categories in 2012. 
The Netherlands reported data on an annual basis from 1999 onwards for all animal species. Data on pigs 
are available from 2004 onwards, for a selection of pig herds, based on stratified sampling (Bondt et al., 
2012). Meanwhile, Dutch large animal production sectors recently implemented centralised registration 
systems, monitoring the use on all farms (Bos et al., 2013). From the data on all farms, it was seen that the 
outcomes based on the sample of farms may give a biased estimate of antimicrobial consumption (Bos et al., 
2013). Furthermore, information on all farms allow to get insight in the shape and width of the distribution of 
individual herd use and large variations in use between herds were observed (Bondt et al., 2012; Bos et al., 
2013). In the Netherlands, data on antimicrobial consumption in pigs are expressed as ADD per animal year 
(dd/ay) for the stratified sample (Bondt et al., 2012), and more recently for all pig herds, the Animal Daily 
Defined Dose per year (ADDD/Y) is used (Bos et al., 2013).  
As mentioned above, the Dutch government set a policy objective for 2013 and 2015, namely a 50% and 
70% reduction in antibiotic use in animals compared to 2009. The 50% objective was already achieved in 
2012, partially due to a decrease in use in pig sector. Between 2004 and 2012, annual variation in the dd/ay 
in sows and piglets was seen, with a strong decrease as from 2009, which seemed to level off slightly in 
2012. In 2012, the average use in sows/piglets is estimated to be 10 dd/ay and most antimicrobials are likely 
used for the treatment of the piglets, and only incidentally for the sows. In fattening pigs, an increase in dd/ay 
was seen until 2008, and a strong decrease from 2008 to 2012 (6 dd/ay) (Bondt et al., 2012). Regarding the 
use of CIA’s and VCIA’s, since 2009, the use of macrolides decreased substantially. In 2012, the use of 3th 
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and 4th generation cephalosporins and the use of fluoroquinolones in sows, piglets and fattening pigs dropped 
to zero.  
In order to achieve the 50% and 70% goals, thresholds for veterinary antimicrobial use on individual livestock 
herds were determined in 2011 by the  Veterinary Medicines Authority (SDa). These thresholds were based 
on the 50th and 75th percentiles of the distribution of DDDA over all pig herds in The Netherlands and were 
translated into signal and action categories, respectively (Bos et al., 2014). These levels are now used to 
benchmark each pig herd in the Netherlands and to identify herds that need to take action to reduce their 
use. Additionally, the SDa has recently started with describing the veterinary prescription patterns. Based on 
this, again thresholds were determined based on the percentage of herds exceeding the farm action 
benchmark threshold for all farms for which the veterinarian is the contracted veterinarian (Bos et al., 2015). 
By setting benchmarks, it is expected that veterinarians will mirror their use with colleagues and that this will 
trigger discussions between veterinarians. Also, by making prescription patterns transparent, farmers can 
make informed decisions regarding the veterinarian who they will contract. 
 
Comparing antibiotic consumption in pigs between the Netherlands and Denmark requires equal indicators for 
reporting. Bondt et al. (2012) used sales data and animal census data, combined with average dosages, to 
estimate the average number of treatment days per average animal per year (NADD/y), for several animal 
species, including pigs, in order to make comparisons between both countries. They concluded that the 
overall use in pigs was 35% higher in the Netherlands than in Denmark.  
7.2. IN BELGIUM 
During the last decade, Belgium has increased efforts to gather more information on animal specific 
antimicrobial consumption. For pig production, a first attempt was made in 2003 by Timmerman et al. (2006). 
Data on antibiotic group treatments in fattening pigs were retrospectively collected for 50 randomly selected 
herds with a closed or semi-closed production system (Timmerman et al., 2006). In this first report, treatment 
incidences (TI) based on the animal daily dose pig (ADDpig) and the used daily dose pig (UDDpig) were 
introduced to report herd specific data for pigs. Additionally, the ratio UDDpig/ADDpig was calculated in order to 
get an estimation of the correctness of dosing. Qualitative aspects of use, namely which antibiotic classes and 
administration routes were used, and for which indications, were equally collected. Based on the obtained 
information in 2003, in Belgium, for the first time, clear recommendations on correct dosing were asked, 
concern on the high number of prophylactic group treatments in pig production were expressed, and the 
replacement by other disease-preventive measures was proposed (Timmerman et al., 2006). 
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Surveillance studies, as performed by Timmerman et al. (2006), have to be repeated, as different factors may 
influence use in time. Although restricted in both number of times and cooperating herds they might partially 
compensate for the absence of well-established continuous surveillance programmes. 
From January 1st 2014, antibiotic use data on the level of the individual pig herd are collected by the private 
quality label Belpork. The input of data is delivered by the veterinarian, who is responsible for prescribing 
veterinary antimicrobials and antimicrobial premixes. AMCRA is operational in the analysis of the data through 
an independent scientific unit. Their tasks consist of safeguarding the quality of the data collection (input), 
managing and analysing the data and to set thresholds in order to benchmark between herds and 
veterinarians. Finally, communication and feedback to the animal sector is crucial in order to achieve a 
sustainable reduction in use. 
Recently, a review study of Filippitzi et al. (2014) has attempted to extrapolate the results of several in depth 
studies on antibacterial use in pigs, poultry and veal calves in Belgium towards the whole population in order 
to make a rough estimate of the proportion of use in the different species. Findings of this study are 
discussed in relation with antimicrobial use data from Belgian pig herds in the discussion of this thesis 
(Chapter 7). 
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MONITORING ANTIMICRIOBIAL RESISTANCE IN COMMENSAL, PATHOGENIC 
AND ZOONOTIC ESCHERICHIA COLI AND STREPTOCOCCUS SUIS FROM PIGS 
In addition to the collection of antimicrobial consumption data, the monitoring of antimicrobial resistance in 
bacteria in food-producing animals is unmistakable an important first step in strategies aiming to contain 
resistance.  
Monitoring of resistance in bacterial pathogens aims at effective interventions to counter the problem of 
resistance for animal health or welfare threatening infections and at developing guidelines on the appropriate 
choice of therapy in a clinical setting. Resistant bacteria with a zoonotic aspect are of interest as they might 
compromise animal and/or human health, but equally might transfer their acquired resistance genes to human 
commensal or pathogenic bacteria through direct contact between animals and humans or indirect via the 
food chain or the environment. Finally, resistance in commensal bacteria is thought to reflect the magnitude of 
the selection pressure enforced by the use of antimicrobials. These commensal bacteria are therefore referred 
to as ‘indicator bacteria’.  
1. COMMENSAL, PATHOGENIC AND ZOONOTIC ESCHERICHIA COLI FROM PIGS 
The rationale of monitoring antimicrobial resistance in commensal Escherichia coli (E. coli) is that these form a 
reservoir of mobile resistance genes that can be transferred to other bacteria, thereby playing a key role in 
the dissemination and persistence of resistance (Marshall and Levy, 2011). Several studies have indicated the 
capability of E. coli to acquire and spread antimicrobial resistance associated with antimicrobial drug 
administration. E. coli is one of the bacterial species with an exceptional capacity of exchanging resistance 
genes (Smith et al., 2007). Moreover, E. coli, commonly present in the intestinal tract of pigs, other animals 
and humans (Sörum and Sunde, 2001), are exposed to antimicrobials, directly after oral treatment, and 
potentially indirectly via the enterohepatic circulation after parenteral treatment (Guggenbichler et al., 1985). 
Finally, E. coli is easy to isolate and identify. These aspects make E. coli an internationally used indicator for 
resistance of (intestinal) Gram-negative bacteria (Wray and Gnanou, 2000).  
Some E. coli strains are also major pathogens in several animal species, including pigs. In pigs, 
enterotoxigenic E. coli (ETEC) are associated with neonatal diarrhea, diarrhea in 2 to 4-week old pigs as well 
as with post-weaning diarrhea, whereas Shiga toxin-producing E. coli (STEC) are responsible for oedema 
disease (Martins et al., 2011). 
Some strains of E. coli are examples of zoonotic bacteria which can infect people by the food-borne route. 
From a zoonotic point of view, Shiga toxin-producing E. coli (STEC) is the only group of intestinal pathogenic 
E. coli of major interest, as the Shiga toxin-producing strains are able to cause bloody diarrhea, potentially 
evolving into a hemolytic uremic syndrome in humans, when being transmitted through the food chain from 
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their animal reservoirs (Wasteson, 2001). A restricted range of serotypes (i.e. O157, followed by O26, O103, 
O91, O145 and O111) are associated with public health risks and O157 is the serotype most frequently 
associated with severe human infections in the European Union (ECDC and EFSA, 2011). Pigs have not 
been identified as a major source of STEC for human infection in Europe, whereas ruminants, and more 
particularly cattle, are recognised as the main natural reservoir of STEC, in particular for STEC O157 
(Wasteson, 2001; ECDC and EFSA, 2011). Within the different serotypes associated with public health risks, 
isolates are not necessary pathogenic when recovered from food-producing animals. Therefore, serotyping 
alone when applied to STEC isolates from food and animals is not the optimal method of identifying public 
health risks (EFSA, 2007). The role of additional virulence factors, next to the main virulence factors known, is 
currently being included for the assessment of the human pathogenic potential of different STEC serotypes 
(ECDC and EFSA, 2011). 
Recently, it has been suggested that extra-intestinal pathogenic E. coli (ExPEC) of food-producing animals, 
particularly chicken and to a lower extent pigs and cattle, are involved in urinary tract infections in humans 
following direct contact or contamination of meat (Jakobsen et al., 2010; Bélanger et al., 2011; Tan et al., 
2011). Extra-intestinal pathogenic E. coli is by far the most common agent infecting the human urinary tract 
and is equally involved as a major pathogen in meningitis and bloodstream infections in humans (Stenutz et 
al., 2006; Bélanger et al., 2011).  The sharing of apparently clonal ExPEC between humans and animals 
suggests a possible role as a reservoir for these animals, especially avian species. Yet, the demonstration of 
these clonal relationships should be more robust through the use of sensitive methods, such as genome 
sequencing (EFSA, 2014). As a result, a clear zoonotic nature of ExPEC human infections can not yet been 
hypothesized.  
2. COMMENSAL, PATHOGENIC AND ZOONOTIC STREPTOCOCCUS SUIS FROM PIGS 
Streptococcus suis (S. suis) is part of the normal microbiota of the pig. It can be found in the upper 
respiratory, alimentary, and urogenital tract of healthy pigs (Staats et al., 1997). Primarily, S. suis is known as 
an important swine pathogen causing meningitis, arthritis, septicemia, endocarditis, polyserositis, 
bronchopneumonia, and abortion (Higgins and Gottschalk, 1990; Amass et al., 1996; Staats et al., 1997). 
Within the bacterial species of S. suis 35 serotypes based on antigenic differences in its capsule 
polysaccharides are described. All serotypes, except 17-19 and 21, have been isolated from clinical cases 
(Gottschalk et al., 1989). Serotype 2 is the most prevalent type isolated from diseased pigs, followed by 
serotypes 1 and 9. S. suis colonizes piglets at birth and the pathogen is known to affect pigs of different ages. 
Yet, disease incidence decreases with age after weaning (Amass et al., 1996; Staats et al., 1997). 
Management, husbandry and preexisting injury may predispose to infection (Neumann et al., 2009).  
Furhermore, S. suis has been reported as an emerging zoonotic pathogen evidenced by a few large-scale 
outbreaks of severe S. suis epidemics in Asia (Ye et al., 2006; Yu et al., 2006; Mai et al., 2008).  
Due to its economic and zoonotic importance, reports include results on the monitoring of antimicrobial 
susceptibility mainly of clinical isolates of S. suis (Kataoka, 2000; Martel et al., 2001; Marie et al., 2002; 
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Wisselink et al., 2006), whereas S. suis from clinically healthy animals are only seldom included (Marie et al., 
2002). 
 
 
Monitoring resistance identifies trends in the emergence, spread and persistence of resistance to 
antimicrobials and is therefore a prerequisite for understanding the epidemiology of resistance. In the next 
chapter, the key aspects and drivers of the stages in the epidemiology of antimicrobial resistance in animal 
production are reviewed (Chapter 1.3.). 
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SUMMARY 
In the epidemiology of antimicrobial resistance a succession of 4 stages can be distinguished: development, 
selection and spread, persistence and reversion or reduction. Resistance, a self-defense of bacteria against 
antibiotic-producing organisms in their surroundings, or against antibiotics produced by bacteria themselves, is 
inherent to the bacterial nature. Yet, anthropogenic antimicrobials equally play a role in the emergence of 
resistance, as they might induce mutations and facilitate gene transfer. In the next stage, resistance 
determinants are selected and spread through a bacterial population due to the exertion of a selection 
pressure. Antimicrobial use at large scale in animal production is believed to contribute substantially to the 
rapid spread and persistence of resistance determinants. However, selectors other than antimicrobials are 
also involved, as well as evolutionary adaptations in bacteria with reduced fitness, rendering the persistence 
of resistance determinants without antimicrobial selection pressure possible. A reversion to susceptibility 
involves a decreased growth rate of bacteria harboring resistance determinants or the loss of determinants. 
This entails every selection pressure to be discontinued and mechanisms interfering with the spread of 
resistance determinants through a bacterial population. This paper reviews key aspects and drivers of the 
stages in the epidemiology of antimicrobial resistance in animal production. 
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INTRODUCTION 
Since their discovery, antimicrobials have become indispensable tools in countering bacterial diseases in both 
humans and animals, and to a lesser extent in horticulture. Yet, their use has become overshadowed by a 
phenomenon that has become increasingly more threatening over the last decades, namely antimicrobial 
resistance. Antimicrobial resistance in pathogenic and zoonotic bacteria results in decreased efficiency and/or 
therapeutic failure, and commensal bacteria may play a key role in the dissemination and persistence of this 
resistance. Antimicrobial resistance is a complex issue, both in origin as well as spread. A plethora of 
resistance mechanisms and transfer systems have been described (Levy and Marshall, 2004; van Hoek et al., 
2011). Understanding these mechanisms is crucial for explaining phenomena in the past and to predict future 
tendencies. In addition, the development of appropriate strategies to stop further selection of resistance 
against the current available antimicrobial agents, the development of new agents as well as the refinement of 
infection control measures should be based on thorough knowledge of both basic mechanisms of resistance 
development and transmission and epidemiologic aspects of antimicrobial resistance selection and spread.  
Many in-depth studies on resistance mechanisms have been conducted in the past. Recently, the number of 
studies approaching antimicrobial resistance from an epidemiological perspective is increasing.  
In the epidemiology of antimicrobial resistance a succession of 4 different stages can be distinguished: 
development, selection and spread, persistence and finally reversion or reduction of antimicrobial resistance 
(Figure 1). This review aims to focus on the key aspects and drivers of each of these stages. Firstly, the 
emergence of antimicrobial resistance determinants in a certain pathogenic or commensal bacterium is 
essential, which we refer to as the development of antimicrobial resistance. Secondly, antimicrobial resistance 
is selected for and may spread within a bacterial species, but also across species. Once antimicrobial 
resistance is selected for, it may persist in a population. Therefore, a continuous selection pressure might be 
needed, even though in some cases resistance persists in the absence of any antimicrobial selection 
pressure. Finally, in the absence of a selection pressure, reduction of antimicrobial resistance may occur, due 
to the loss or silencing of resistance genes or due to replacement of resistant bacteria by susceptible ones.  
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Figure 1. Stepwise process of the epidemiology of antimicrobial resistance. Green, blue and red dots: 
susceptible, intermediate and resistant isolates. 
 
Before describing these 4 stages, antimicrobial resistance must be well defined. Resistance to an 
antimicrobial is either intrinsic or acquired. Intrinsic or natural resistance is caused by a structural or functional 
feature inherently associated with a certain bacterial taxonomic group, resulting in the inability of the 
antimicrobial to exert its effect. In addition, bacteria can acquire antimicrobial resistance (extrinsic or acquired 
resistance). This is the phenomenon that bacteria, previously susceptible to a specific antimicrobial, become 
resistant due to genomic alterations in a part of the population of a bacterial genus or species. Bacteria have 
developed various resistance mechanisms to neutralize the action of the antimicrobial (Schwarz and Chaslus-
Dancla, 2001; Cloete, 2003). They can be divided into three major categories: enzymatic inactivation, a 
reduced intracellular drug accumulation, and target site alteration (Schwarz and Chaslus-Dancla, 2001). One 
resistance mechanism can mediate resistance to different antimicrobial classes because of the alteration of a 
common target site within the bacterial cell. For instance, methylation of adenine residues in the 23S rRNA of 
the 50S ribosomal subunit prevents macrolides, lincosamides and group B streptogramins to bind to their 
target site (Schwarz and Chaslus-Dancla, 2001). Different mechanisms conferring resistance to the same 
antimicrobial agent have been described. The main tetracycline resistance mechanism is the extrusion of the 
drug from the cytoplasm via efflux (Chopra and Roberts, 2001). Also, resistance genes coding for protection 
of the target site via ribosomal protection proteins, for enzymatic inactivation and for another, still unknown 
mechanism have been detected in various Gram-positive and Gram-negative bacteria (Taylor and Chau, 
1996). In addition to active efflux, a diminished intracellular drug accumulation can be achieved by a reduced 
drug uptake (Kumar and Schweizer, 2005). Impaired uptake can be due to changes in the charge of the 
lipopolysaccharides of the outer membrane of Gram-negative bacteria. Also, outer membrane proteins, an 
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entry of antimicrobials to the bacterial cell, can be lost or down-regulated, resulting in reduced influx (Kumar 
and Schweizer, 2005). The abovementioned examples report only briefly the existence of resistance 
mechanisms. A detailed overview of resistance mechanisms towards antimicrobial classes related to a 
specific taxonomic group can be consulted from a variety of reviews on this topic (Chopra and Roberts, 2001; 
Schwarz and Chaslus-Dancla, 2001; Butaye et al., 2003; Cloete, 2003; Kumar and Schweizer, 2005).  
To classify bacterial isolates as resistant, 4 different criteria, each with its own threshold value, are available. 
First, the clinical criterion for resistance evaluates the outcome of treatment of an infection with a specific 
pathogen compared to its Minimum Inhibitory Concentration (MIC). This is the lowest concentration of an 
antimicrobial necessary to prevent growth of the bacterial strain considered under specific in vitro conditions. 
An isolate is considered resistant to a specific antimicrobial agent, when symptoms of disease are not 
resolved, while the antimicrobial is used according to the standard therapeutic protocol. As a consequence of 
the definition, this criterion is uniquely used to describe resistance in pathogenic bacteria in a specific animal 
species for a specific diagnosis. Second, the microbiological or epidemiological criterion evaluates the in vitro 
susceptibility of a specific isolate, compared to the wild type population (Kahlmeter et al., 2003). The latter 
does not exhibit any mechanism of resistance that increases the MIC. When an isolate shows a considerably 
higher MIC to an antimicrobial than the wild type population, it is considered to have acquired resistance and 
these bacteria are then defined as “non-wild type”. Third, the genetic criterion for resistance is based on the 
detection of resistance genes (Cai et al., 2003). The phenotypically detectable antimicrobial resistance may 
be encoded by acquired genes or gene mutations. Yet, identical phenotypic bacteria (identical MIC) can 
reflect different genotypes, because different mutations in different genes or mobile elements can reflect 
similar antimicrobial resistance phenotypes (Martinez and Baquero, 2000). Finally the pharmacological 
criterion evaluates the relationship between antimicrobial concentration in blood or tissue and the MIC of the 
respective bacterial species or isolate (Guardabassi and Courvalin, 2006). Thus, bacterial antimicrobial 
susceptibility and the antimicrobial’s pharmacodynamic and pharmacokinetic properties are taken into 
account. A bacterium is considered resistant in the pharmacological criterion if the in vitro MIC of the 
antimicrobial tested is higher than the concentration of the antimicrobial in the plasma or tissue. 
For interpretation of results of minimum inhibitory concentration (MIC) determinations of antimicrobials, either 
epidemiological cut-off values (ECV) or clinical breakpoints (CBPs) can be used (Schwarz et al., 2010). CBPs 
aim to predict how a patient will respond to a treatment and they classify bacteria as susceptible, intermediate 
or resistant (Schwarz et al., 2010). These breakpoints are mainly based on pharmacological and clinical 
criteria. They try to correlate the in vitro susceptibility of a bacterium towards a certain antimicrobial agent (the 
MIC value) with the chance to successfully treat an animal with the normal, recommended dose of this 
antimicrobial agent (Turnidge and Patterson, 2007; Schwarz et al., 2010). ECVs are mainly based on the 
microbiological criterion, sometimes in combination with the genetic criterion and allow to distinguish wild type 
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populations of bacteria from those with acquired resistance (non-wild type). They do not necessarily predict 
how a patient will respond to antimicrobial therapy (Schwarz et al., 2010). In the absence of a clear bi- or 
multimodal distribution of MICs for different isolates within a bacterial species, the epidemiological cut-off 
value can be difficult to establish (Kronvall et al., 2011). For practical use in monitoring of antimicrobial 
resistance both in humans and different animal species, this cut-off value should be fixed for one antimicrobial 
agent within a bacterial species, independent of time, country, animal or organ (Aarestrup et al., 2007). 
Although determined by a different approach, CBP and ECVs may be very similar or even identical for some 
bacteria/drug combinations. Yet, they can also diverge, resulting in misleading conclusions when comparing 
resistance results based on discordant ECVs and CBP (MARAN, 2005). ECVs are often used in monitoring 
and surveillance programs for describing evolutions in resistance prevalence or detecting emerging resistance 
in commensal bacteria. They are also very valuable in detecting small changes in the population distribution 
indicating the acquisition of new resistance mechanisms, of which the clinical implications are not yet clear. 
Isolates are said to have “a decreased susceptibility” when they have MICs that are above ECV, but less than 
or equal to the susceptible clinical breakpoint (Simjee et al., 2008). Although infections caused by these 
isolates may be treatable, they can be of concern as they represent an introductory step to full resistance, for 
example due to consecutive stepwise mutations. 
 
Throughout this review resistance refers to the epidemiological criterion, unless otherwise mentioned, as this 
is of particular interest with regard to studying the epidemiology of antimicrobial resistance. 
1. DEVELOPMENT OF ANTIMICROBIAL RESISTANCE IN A BACTERIAL SPECIES 
The origins of resistance genes are often found in bacteria or fungi producing antimicrobial compounds in 
order to protect the organisms themselves from the compounds produced (Benveniste and Davies, 1973). 
These natural products are defined ‘antibiotics sensu stricto’, and are ubiquitously present (Waksman and 
Woodruff, 1940; D'Costa et al., 2011). Bacteria in the direct environment of antibiotic producing organisms will 
only survive and multiply in the presence of antibiotic concentrations if they can circumvent the potential effect 
of the antibiotic. Multidrug resistance efflux pumps are commonly observed in large numbers in antibiotic 
producing bacteria of natural environments (Martinez, 2008). These are likely the source of drug efflux pump 
genes found in pathogenic bacteria (Vecchione et al., 2009). For instance, Pseudomonas aeruginosa (P. 
aeruginosa) is known as multidrug-resistant by nature, insensitive to a large number of antimicrobial classes, 
such as various β-lactams, tetracyclines, potentiated sulfonamides and some aminoglycosides (Ferrara, 
2006).  
The first resistance mechanisms might have evolved from pathways involved in other physiological processes, 
such as detoxification of metabolic intermediates, virulence, and other functions (Piddock, 2006). It might 
explain the ancient nature of antimicrobial resistance, existing in nature long before the presence of 
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anthropogenic antimicrobials, defined as antimicrobials produced and used by humans (Allen et al., 2009; 
D’Costa et al., 2011). The “antibiotic resistome” can be defined as the collection of all resistance determinants 
in bacterial strains that might confer phenotypic resistance (Wright, 2007). The resistome encompasses 
diverse genes having original functions that are not exclusively for avoiding the effects of antibiotics (Gillings, 
2013). 
Unlike intrinsic resistance, acquired resistance is associated with specific isolates of a particular bacterial 
genus or species. Bacterial isolates can obtain resistance by genetic changes in the bacterial genome. It 
results from mutations (endogenous resistance), from horizontal acquisition of foreign genetic information 
(horizontal gene transfer, exogenous resistance) or a combination of both mechanisms (Martinez, 2000; 
Normark and Normark, 2002).  
1.1. MUTATIONAL RESISTANCE 
Antimicrobial resistance genes can originate from mutations in the bacterial genome. Mutation of genes has 
for a long time been believed to be a random and spontaneous process only. Yet, bacteria exposed to 
sublethal stress factors show increased mutation rates (stress-induced mutagenesis) (Shapiro, 1997), which 
might be a well-regulated phenomenon in order to generate heterogeneous populations with clones able to 
adapt and to survive adverse conditions. These stress factors can be diverse: depletion of nutrients, new 
environments, inhibitory effects of host defense mechanisms, temperature, pH, osmotic pressure as well as 
antimicrobial treatment. Bacteriostatic (sublethal) food preservation systems with increased salt or reduced pH 
conditions has been shown to increase antimicrobial resistance in Escherichia coli (E. coli), Salmonella 
enterica subspecies enterica serovar Typhimurium (Salmonella Typhimurium) and Staphylococcus aureus (S. 
aureus), with some of the strains showing a continued expression of higher resistance levels after removal of 
the stress factors (McMahon et al., 2007). Low concentrations of certain antimicrobials such as 
fluoroquinolones and β-lactams, have been reported to stimulate mutagenesis (increased mutation rate) 
(Couce and Blázquez, 2009), whereas high concentrations of fluoroquinolones might reduce the mutation rate 
(Martinez and Baquero, 2007). Furthermore, antimicrobials may also select cells with increased frequency of 
mutation and recombination (so called hypermutators) (Gustafsson et al., 2003). Antimicrobials are thus not 
only acting as mere selectors of resistant clones, but they also affect development of mutational resistance. 
In veterinary medicine, antimicrobials for which resistance by mutations have been described are numerous. It 
has limited the clinical use of streptomycin, rifampin, erythromycin and it is increasingly limiting the use of 
fluoroquinolones (Gershwin, 2013). Mutations in the multiple antimicrobial resistance (Mar) locus are involved 
in an efflux system responsible for the resistance towards a variety of drugs in E. coli and other 
Enterobacteriaceae, including tetracycline, chloramphenicol, ampicillin, nalidixic acid, and rifampin (Alekshun 
and Levy, 1999).  
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Although the widespread presence of resistance genes is mainly due to the horizontal transfer of resistance 
genes, mutation processes are central in the diversification of the acquired genes and thus in the evolution of 
antimicrobial resistance. An example can be found in extended-spectrum-beta-lactamases (ESBL) producing 
organisms. Mutations have led to a diversification of enzymes responsible for resistance to different 
generations of cephalosporins, after the initial penicillin resistance (Woodford and Wellington, 2007; Smet et 
al., 2009). AmpC β-lactamases are clinically important cephalosporinases encoded on the chromosomes of 
many of the Enterobacteriaceae and a few other organisms, where they mediate resistance to cephalothin, 
cefazolin, cefoxitin, most penicillins, and β-lactamase inhibitor-β-lactam combinations. In many bacteria,  
AmpC enzymes are inducible and can be expressed at high levels by mutation (Jacoby, 2009). For instance, 
mutational inactivation of AmpD, which expresses an enzyme preventing the overexpression of AmpC, is the 
main mechanism found to lead to the constitutive hyperproduction of chromosomal AmpC, and consequently 
to clinically relevant β-lactam resistance, in Enterobacteriaceae (Juan et al., 2006). Furthermore, specific 
spontaneous mutations in the promoter or attenuator region of the chromosomal AmpC gene have recently 
been reported in E. coli from cattle, which may be an emerging mechanism contributing to resistance towards 
extended spectrum cephalosporins in the animal population (Haenni et al., 2014).  
The frequency of mutations required (single or multiple-step resistance) for clinical resistance to occur is 
dependent on the antimicrobial agent, the bacterial species and mechanism of resistance. For streptomycin, a 
1000-fold increase in the MIC can be the result of a single mutation (Springer et al., 2001). In 
Enterobacteriaceae, mutational resistance to fluoroquinolones is a stepwise process where an increasing 
number of mutations generally is linked with increasing MICs (Woodford and Ellington, 2007) and thereby, 
clinical resistance occurs less readily. However, for C. jejuni and P. aeruginosa, a single nucleotide change at 
a particular site in the gyrA DNA gyrase gene can lead to clinical resistance by altering the target site for the 
fluoroquinolone (Gershwin, 2013).  
1.2. HORIZONTAL GENE TRANSFER OR ACQUISITION OF RESISTANCE DETERMINANTS 
Horizontal gene transfer (HGT) is the most common way for bacteria to acquire antimicrobial resistance 
genes (Ochman et al., 2000). Horizontal acquisition can be described as the acquisition of DNA from another 
organism by any of 3 mechanisms.  
(1) Bacteria can exchange mobile genetic elements through physical contact (conjugation). It is thought to be 
the most important mechanism for spread of resistance (Schwarz and Chaslus-Dancla, 2001). Different mobile 
genetic elements can be transferred. Plasmids are circular or linear extrachromosomal DNA molecules of 
variable size, capable of autonomous replication (Stokes and Gillings, 2011). Transposons are linear DNA 
elements of variable size that mediate their excision and random incorporation into a recipients chromosomal 
or plasmid DNA (Iyer et al., 2013). Integrons contain collections of incorporated genes (gene cassettes) in 
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their attachment site, a promoter that drives expression of incorporated genes and integrase (Partridge et al., 
2009). Unlike transposons, integration of integrons, mediated by integrase, is site specific and highly stable 
(Demarre et al., 2007). Class 1 integrons in particular, are associated with transfer of resistance (Partridge et 
al., 2009). 
The horizontal transfer of a conjugative plasmid carrying multiple antimicrobial resistance genes has been 
described between different bacterial genera among the enteric microbial flora. This has for example been 
demonstrated in calves with resistant E. coli and susceptible Salmonella Typhimurium prior to apramycin 
treatment and E. coli and Salmonella Typhimurium carrying the same resistance genes after treatment 
(Hunter et al., 1992). This has equally been shown in the avian gastrointestinal tract between E. coli and 
Salmonella Newport, without anthropogenic selection pressure (Poppe et al., 2005). Also, transfer of 
resistance determinants from a (transiently) colonizing animal strain to human commensal microbiota has 
been observed, even in the absence of selective pressure, emphasizing the importance of this mechanism of 
resistance transfer in vivo (Dahl et al., 2007; Smet et al., 2011).  
(2) Under specific conditions, bacteria are capable of incorporating exogenous DNA from the environment into 
the their genome (transformation of a competent receptor bacterium). This may require proteins involved in 
the assembly of type 4 fimbriae and type 2 secretion systems, as well as a DNA translocase complex at the 
plasma membrane (Chen and Dubnau, 2004). Some bacteria, such as Helicobacter pylori and probably also 
zoonotic, animal-associated gastric Helicobacter species use a type 4 secretion system for natural 
competence (Alverez-Martinez and Christie, 2009; Haesebrouck et al., 2009; Vermoote et al., 2011; Smet et 
al., 2013). Compared to mobile genetic elements the efficacy of transformation may be rather low, especially 
for bacterial species that are not naturally competent. However, antimicrobials may enhance transformation as 
has been shown for ciprofloxacin that induces expression of competence genes in Helicobacter pylori (Dorer 
et al., 2010).  
(3) Bacterial viruses, called bacteriophages, can accidentally package host DNA in their capsid and 
subsequently infect another bacterium, introducing bacterial DNA into the recipient (transduction) (Ochman et 
al., 2000). Transduction is mainly observed between bacteria of the same species, but can equally occur 
between bacteria of different species and genera (Ammann et al., 2008). Transduction has been considered 
as a rare event, occurring around once every 107–109 phage infections. Yet, recent studies showed 
transduction to occur at frequencies of several orders of magnitudes greater (Kenzaka et al., 2010). 
Moreover, a potential major role of bacteriophages in the transfer of resistance genes from natural 
environments, such as water and soil, to human and animal microbiomes has been suggested (Muniesa et 
al., 2013). 
The rate of horizontal transmission of resistance genes is dependent on the properties of the genetic element 
it is encoded on. Resistance genes on a (conjugative) plasmid have a higher rate of horizontal transfer 
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compared to resistance genes incorporated in the chromosome. Yet, the segregational stability of the 
chromosome is higher than that of plasmids, meaning that resistance genes encoded on the chromosome are 
less likely to be lost in the absence of selective pressure compared to those encoded on a plasmid 
(Wassenaar et al., 2005). 
In vivo rates of HGT are probably higher than in vitro rates for both chromosomal and plasmid located 
resistance genes (Dahl et al., 2007). At a high rate of HGT, resistance genes may disseminate quickly 
between bacteria, slowing down a potential reversion to susceptibility (Levin et al., 1997; Johnsen et al., 
2009). 
2. SELECTION AND SPREAD OF ANTIMICROBIAL RESISTANCE 
Once antimicrobial resistance has emerged, the number of isolates with resistance determinants might 
increase under a certain selection pressure. Resistance genes can be multiplied within the population by 
vertical dissemination and/or isolates can pass resistance determinants to other members of the population 
and to different populations (spread). 
Selection and spread are therefore the second step in the epidemiology of resistance. This selection occurs 
under the driving force of a selection pressure which can be multiple.  
Three conditions are required to allow spread of antimicrobial resistance in a bacterial population: at first, the 
presence of resistance genes; secondly, the viability of the resistant clone in case of mutations, or the mobility 
of resistance genes (transferability of genes) allowing vertical or horizontal spread of the resistance genes; 
and thirdly a selection pressure (Schwarz et al., 2001). Selection pressure alters populations by both selecting 
as well as affecting the rate of spread within and between the exposed animals (Olofsson et al., 2007). As a 
result, selection and spread are not independent and are therefore described here as one event.  
2.1. ANTIMICROBIAL RESISTANCE SELECTION PRESSURE AND SPREAD THROUGH THE 
USE OF ANTIMICROBIALS 
The rate at which existing resistant strains increase in prevalence has been described as a function of the 
level of antimicrobial exposure in bacterial populations. The pharmacodynamic and pharmacokinetic aspects 
of antimicrobial administration, possibly together with the presence or absence of other selecting factors affect 
whether the present strains will be cleared or selected. Describing the relationship between antimicrobial use 
and antimicrobial resistance selection is often challenging, because the association can be influenced by a 
large number of factors.  
A first approach involves the effect of specific antimicrobial use on the resistance development against that 
particular antimicrobial.  A direct relationship between the use of a specific antimicrobial and the emergence 
of resistance determinants to the antimicrobial concerned in bacterial populations has been described at 
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several levels (Stamey et al., 1976; Chaslus-Dancla and Lafont, 1985; Wray et al.; 1986; Cloeckaert and 
Chaslus-Dancla, 2001; Asai et al., 2005; Akwar et al., 2007; Dewulf et al., 2007; Harada et al., 2008; 
Chantziaras et al., 2013).  
Describing and quantifying the association between use and resistance is more complicated when accounting 
for antimicrobial use factors, involving volumes used, number and category of animals treated, dose and 
duration of administration and qualitative factors such as administration route. Furthermore, mechanisms such 
as cross-resistance and co-selection may participate in the emergence and maintenance of antimicrobial 
resistance (Harada et al., 2008) and render the relationship between use and resistance more difficult to 
interpret. 
2.1.1. TOTAL AMOUNT OF ANTIMICROBIALS USED 
Levy et al. (1994) introduced the threshold theory, suggesting that a certain level of antimicrobial drug 
consumption is required to trigger the emergence of resistance in a particular environment. This theory is 
based on the equilibrium between a number of susceptible and resistant bacteria and the potential of the 
population of susceptible bacteria to return to their original number after an antimicrobial treatment. Austin et 
al. (1999) supported this theory by describing the sigmoidal rise in resistance over time in the presence of a 
constant rate of antimicrobial consumption. Again, a critical level of drug consumption is required to trigger the 
increase of resistance to certain levels. When this occurs, a crucial variable is time for the resistance to 
change from its low starting prevalence to a certain prevalence of resistance. This highlights the importance 
of reacting on emerging resistance at the onset of the resistance development. Moreover, the strength of the 
association between use and resistance and the time required to observe certain levels of resistance is most 
likely antimicrobial specific and related to the underlying resistance mechanism.  
The concept of Austin et al. (1999) also suggests that at a certain level the resistance prevalence arrives at a 
maximum level where further use will no longer result in a substantial increase in the resistance prevalence. 
This is in agreement with the conclusions of Handel et al. (2006) who reported that small changes in the 
volumes of antimicrobials, used in a population with a low level of antimicrobial resistance, lead to much 
larger changes in resistance when compared with changes in antimicrobial volumes used at a high level of 
resistance. In vivo studies in cattle (O’Connor et al., 2002) and pigs (Dunlop et al., 1998b) aiming to evaluate 
the effect of different administration routes on the selection and spread of resistance observed that in animals 
already receiving an in-feed antimicrobial, no further increase of the resistance prevalence was observed after 
an additional subcutaneous administration of the same antimicrobial. Though, resistance prevalence to 
antimicrobials not present in the feed increased after administering them via subcutaneous injection. Berge et 
al. (2006) equally observed no resistance increase in high level resistant E. coli from pre-weaned calves after 
individual antimicrobial treatment concurrently with antimicrobials administered in the milk replacer. The calves 
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not receiving in-milk antimicrobials but treated with individual antimicrobial therapy transiently shed a more 
resistant E. coli population than the untreated calves (Berge et al., 2006). This again suggests that the in-feed 
antimicrobials might have increased the level of resistance to a saturation level, and additional treatments did 
not result in a further increase of the prevalence of resistance (Dunlop et al., 1998b; O’Connor et al., 2002). 
This non-linearity of the association between use and resistance may partially explain the often observed 
weak, or even apparent absence of a link between antimicrobial use and resistance selection (Checkley et al., 
2008).  
2.1.2. ANTIMICROBIAL DOSE AND DURATION OF TREATMENT 
One way to apply treatment strategies to manage selection and spread is to control the dose and duration of 
therapy, ideally at the moment a compound is introduced on the market for a certain indication. The influence 
of dosage regimens on the emergence of certain resistance mechanisms has only recently been recognized 
and emphasized (Drusano, 2003; Olofsson and Cars, 2007). Appropriate dosage regimens should aim for the 
highest microbiological and clinical efficacy of a treatment as well as minimize the selection of resistance 
(Roberts et al., 2008) both in the targeted pathogens as well as commensal bacteria. This requires a good 
understanding of resistance mechanisms involved as well as the antimicrobial pharmacodynamics and kinetics 
(Roberts et al., 2008). However, diverging results between in vitro and in vivo studies on the impact of 
different dosage regimens on resistance selection and spread complicate the understanding of the 
relationship (Smith et al., 2003; Roberts et al., 2008). The appropriate dosage regimens are diverse for 
different antimicrobial classes and bacterial species. In the current literature, the relationship between the 
dosage on the one hand and selection and spread of antimicrobial resistance on the other hand has only 
been well described for mutational stepwise resistance (Smith et al., 2003). This is well illustrated for many 
fluoroquinolones, where many of the evaluated resistance mechanisms were the same in vitro as in the 
clinical setting (Smith et al., 2003). In bacteria where the majority of known resistance mechanisms occur via 
single or multi-stepwise mutations, such as in Brachyspira spp. (Pringle et al., 2012; Hillen et al., 2014), the 
correlation between MIC’s and clinical efficacy is high, as has been seen for B. hyodysenteriae in swine (Vyt 
and Hommez, 2006). This allows determining the dosage that limits the selection of resistant mutants, also 
referred to as the “mutation prevention concentration” (MPC). Tam et al. (2005) demonstrated the possibility 
of combining optimal treatment dosages and the suppression of resistance emergence for garenoxalin, a 
quinolone, in P. aeruginosa in an in vitro infection (Tam et al., 2005). The inverted “U” shape relationship 
between exposure and resistance selection indicated that a range of antimicrobial concentrations might favor 
isolates with higher MIC’s and cause a considerable amplification of the resistant subpopulation (Baquero et 
al., 1997; Tam et al., 2007). When a maximal value of resistance selection was attained, a further increase in 
concentration of quinolones caused a decline in the number of resistant colonies towards baseline resistance 
(Tam et al., 2007). A critical minimal concentration is also required to select resistant strains in vitro and is 
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called the “minimal selective concentration” (MSC) (Drusano et al., 2010). The MPC concept has encouraged 
the use of high dose regimens to reduce the likelihood of selection of resistant mutants. Lubbers et al. (2011) 
demonstrated that doses above the MIC were equally effective in suppressing the transfer of antimicrobial 
resistance plasmids between donor (Salmonella Typhimurium) and recipient (E. coli) bacteria in vitro. 
Insight into the concept of the “mutation selection window” (MSW), defined at the top by the MPC and at the 
bottom by the MSC, for mutational stepwise resistance, gave rise to the establishment of single and high 
treatment dose regimens (above the MPC) instead of lower and repeated doses, in order to reach a 
maximum time of the antimicrobial concentration above the MPC. In grass carp (Ctenopharyngodon idella), 
0.010µg/g, 0.020µg/g and 0.030µg/g doses of enrofloxacin were compared in order to choose the most 
appropriate dosage to control infection and prevent mutant selection in Aeromonas hydrophila. The time 
above the MPC, needed to prevent selection of resistant mutants, appeared to be prolonged after a single 
day of 0.030µg/g enrofloxacin administration compared to twice daily of 0.020µg/g (Xu et al., 2013). Similar 
findings were seen for ciprofloxacin, enrofloxacin and marbofloxacin treatment of canine pyoderma caused by 
Staphylococcus pseudintermedius isolates, where only the highest doses within the clinically recommended 
dose ranges could achieve sufficient high concentrations to cross the MPC based on a 24 h interval (Awji et 
al., 2012).  
Smith et al. (2003) commented on overstretching the MPC measurements beyond its limits and suggested 
that the measurement of MPC only applies to fluoroquinolones and not to aminoglycosides, β-lactams and 
macrolides. This has in turn been questioned by Blondeau et al. (2012), by defining the measurement of the 
MPC as a concentration that does not further allow for selection and amplification of resistant sub-
populations, regardless of the mechanisms of reduced susceptibility and antimicrobial drug class. In this 
respect, the MPC and MSW against Rhodococcus equi have been determined for 10 antimicrobial agents 
from different classes (Berghaus et al., 2013). The authors concluded that the combination of a macrolide with 
rifampin considerably decreases the emergence of resistant mutants, based on the achievement of much 
lower MPCs of the antimicrobial combination in vitro and antimicrobial concentrations in the lungs above the 
MPC. However, at present, no results have been reported on the in vivo validation of the MSW for preventing 
the selection of resistant strains to other antimicrobials than fluoroquinolones (Cui et al., 2006; Almeida et al., 
2007). 
The use of antimicrobial growth promoters in livestock is clearly in contrast with the concept of the 
establishment of single and high treatment dose regimens, as growth promoters can be regarded as under-
dosed antimicrobial compounds. For commensal bacteria, not only mutational resistance is of concern, but 
especially the organization of multi-drug resistance clusters as demonstrated, e.g. in Enterobacteriaceae 
(Leverstein-van Hall et al., 2002). This type of resistance is frequently encoded by genes located on mobile 
genetic elements, such as plasmids or transposons. The acquisition of such resistance genes may lead to a 
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100 to 1000-fold increase of the MIC and thus underdosing is less likely to speed up the selection of isolates 
with such increased MICs. Nevertheless, numerous studies have linked the use of antimicrobial growth 
promoters to the occurrence of antimicrobial resistance among Gram-positive and Gram-negative commensal 
bacteria (Sunde et al., 1998; van den Bogaard et al., 2000; Swartz, 2002; Alexander et al., 2008). In contrast, 
several studies in swine E. coli (Langlois et al., 1984; Wagner et al., 2008), Salmonella enterica (S. enterica) 
(Wagner et al., 2008) and anaerobes (Holman and Chénier, 2012) after administrating different dosages of 
tetracycline did not confirm the statement that underdosing would lead to a higher degree of resistance in 
comparison to correct dosing. Moreover, the study of Langlois et al. (1984) found a significantly higher 
resistance level in the group receiving the higher dosage compared to the group receiving the lower dosage 
during first weeks after administration. However, this turned to the opposite from 30 days after first 
administration to the last sampling at 84 days, suggesting the time period after administration also needs to 
be taken into consideration. Contrary, feeding sub-therapeutic concentrations of tylosin to pigs on a 
continuous basis resulted in a significant and rapid increase in the proportion of tylosin resistant anaerobes 
(Holman and Chénier, 2012). Alexander et al. (2008) described the effect of the sub-therapeutic 
administration of chlortetracycline in combination with sulfamethazine to cattle feedlot. The number of animals 
shedding tetracycline and ampicillin resistant E. coli increased as well as the number of resistant E. coli from 
one animal (Alexander et al., 2008). The authors noted that their findings on changed resistance prevalence 
may have been related to additional environmental factors such as diet.  
These contrasting results for Enterobacteriaceae, anaerobes and different antimicrobials tested emphasize 
that different outcomes on the relation between dose and resistance selection can be expected, depending on 
the antimicrobial used, the resistance mechanism and bacteria involved.   
Several authors have questioned the MPC concept and the derived dosage regimes for preventing the 
emergence of antimicrobial resistance, as this concept suggests that there is no selection for mutants at 
concentrations less than the MSC (Courvalin, 2008; Canton and Morosini, 2011; Macia et al., 2011). This is 
contradictory to observations that concentrations below MSC may facilitate hypermutation and HGT (Canton 
and Morosini, 2011; Macia et al., 2011). Furthermore, resistant mutants may have benefits compared to the 
susceptible strains at sub-MSC levels, as long as their fitness cost is lower than the growth reduction of the 
susceptible isolates (Gullberg et al., 2011). Gullberg et al. (2011) used in vitro models demonstrating the 
evolution of low to high level resistance for streptomycin resistant Salmonella Typhimurium mutants and for 
ciprofloxacin resistant E. coli after 500-600 generations in sub-therapeutic doses, up to several hundred-fold 
below the MIC of susceptible strains.  
More objections towards dosage regimens have been raised. As mentioned above, dosage regimens are 
generally determined in function of good clinical treatment and preferably also minimal antimicrobial resistance 
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selection for specific pathogens. Yet, even if the correct dosing regimen - to treat specific pathogens while 
avoiding resistance selection as much as possible - is known and applied in the field, at the same moment 
the commensal microbiota of the animal, for which the treatment dose is not specifically adapted, is also 
exposed to these treatment doses. Therefore, what is a correct dosing for a specific pathogen in a specific 
organ may be an over- or underdosing for a commensal present in the same or another organ. 
Since no general applicable conclusions can be drawn on the link between dosage and resistance selection, 
the use of specific dosing regimens as a potential way of reducing resistance emergence might be restricted 
to specific antimicrobial-bacterial relations. A dosing regimen adapted to control mutant selection of one 
strain, might undesirably encourage development of resistance in other strains by mutation or horizontal gene 
transfer. 
2.1.3. CHOICE OF ANTIMICROBIAL AGENT 
Antimicrobial agents are characterized by several features that may play a role in the selection and spread of 
resistance. In addition to their working mechanism (and thus activity against spectrum of bacteria) and 
whether they have bacteriostatic or bactericidal effects, they might have diverging pharmacodynamic and 
kinetic parameters, such as plasma half-life and tissue persistence, which is important for their time- or 
concentration-dependent activity. 
The use of broad-spectrum antimicrobial agents rather than narrow spectrum antimicrobials affects a higher 
number of different bacterial taxa and thereby increases the risk for selection of bacteria carrying resistance 
genes and for suppressing or eliminating broadly the susceptible commensal microbial flora, which generally 
out-competes resistant strains (Levy and Marshall, 2004). Thus, these broad-spectrum agents might 
encourage the survival of more resistant strains.  
The type of antimicrobial agent also influences the antimicrobial selection and spread. A bacteriostatic agent 
only inhibits growth and thus gives more chance for selecting resistant sub-populations (Dagan et al., 2011) 
compared to bactericidal agents killing the bacteria. Yet, the latter may eradicate fully susceptible populations 
giving the opportunity for resistant strains to colonize certain ecological niches (Catry et al., 2008). The 
distinction between bactericidal and bacteriostatic effect is far from being absolute and depends on both the 
drug concentration at the site of infection and the bacterial species involved (Giguère, 2013). Sub-lethal 
antimicrobial concentrations might induce stress in the targeted bacteria. As previously mentioned, stress 
might result in a transient decrease in antimicrobial susceptibility due to increased copy numbers of resistance 
genes (McMahon et al., 2007). 
Resistance to macrolides, lincosamides and streptogramin B (MLSB resistance) encoded by erm genes can be 
either constitutive (permanently expressed) or inducible (expressed after antimicrobial exposure). This 
inducible resistance can have clinical implications as in vivo exposure to macrolides may result in resistance 
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higher than predicted by in vitro determined MIC’s in the absence of the inducer (Chancey et al., 2011). In 
staphylococci, within the macrolides class, only the 14- and 15-member rings are good inducers for resistance 
expression (Chancey et al., 2012). Thus, isolates harboring inducible MLSB resistance and exposed to 16-
membered antimicrobials can remain susceptible, whereas constitutive MLSB resistance refers to all macrolide 
members (Chancey et al., 2012). 
For time-dependent antimicrobials, such as β-lactams, tetracyclines, macrolides, sulfonamides and 
lincosamides, the antibacterial effect is highest when the concentration is maintained above the MIC 
throughout the dosing interval. Long-acting formulations, based on long half-lives, result in prolonged plasma 
concentrations, and offer a solution for the required repeated administrations inherent to treatment regimens 
of time-dependent antimicrobials. Such long-acting formulations have been developed for certain third-
generation cephalosporins (for example cefovecin) or macrolides (azithromycin, tulathromycin). They are 
characterized by a long half-life and a slow release after tissue binding, resulting in a pronounced post-
treatment effect (Van Bambeke and Tulkens, 2001). For azithromycin, this effect has been shown to 
significantly select more for macrolide-resistant streptococci until about 4 weeks after the end of therapy than 
clarithromycin, characterized by a shorter plasma half-life and tissue persistence (Malhotra-Kumar et al., 
2007). Moreover, concentrations of macrolides below the MIC and long-term presence due to a long half-life, 
can induce mutational resistance at concentrations below the MIC, as has been shown in vitro for S. 
pneumoniae (Pankuch et al., 1998; Nagai et al., 2000). 
Along with different pharmacodynamic and kinetic parameters, differentiated underlying resistance 
mechanisms as well as cross- and co-resistance mechanisms might play a role in different resistance 
outcomes observed after the use of antimicrobials belonging to the same class. Clarithromycin, but not 
azithromycin, perturbs the distribution of macrolide resistance genes erm(B) and mef in streptococci 
(Malhotra-Kumar et al., 2007). This is the result of clarithromycin’s greater efficacy against mef carrying 
streptococci up to 8 μg/ml (Noreddin et al., 2002), whereas azithromycin is far less potent and produces only 
a bacteriostatic effect against mef isolates with MIC’s up to 2 μg/ml (Zhanel et al., 2003). In vitro 
pharmacodynamic studies have shown that both macrolides failed to eradicate erm(B) strains, which generally 
have MICs of 32 μg/ml or higher (Noreddin et al., 2002; Zhanel et al., 2003). The higher efficacy of 
clarithromycin against mef isolates results in a steeper decrease of mef carrying macrolide-resistant 
streptococci, which in turn allows for an expansion of erm(B) isolates (Malhotra-Kumar et al., 2007). 
Furthermore, due to equal resistance mechanisms, the erm(B) gene confers equally resistance against 
lincosamides and streptogramin B antimicrobials (co-resistance), whereas mef genes only encode resistance 
to 14- and 15-member macrolides. Moreover, the erm(B) gene is often located on the same mobile genetic 
element as the tetracycline resistance determinant tet(M). As a result, clarithromycin use might restrict the use 
not only of all macrolides, but also of lincosamides, streptogramins B, and even of tetracyclines (Malhotra-
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Kumar et al., 2007). The phenomena of co- and cross-resistance are explained more in detail in following 
text. 
 
In conclusion, the choice of a specific antimicrobial should not be based exclusively on the elimination of the 
target pathogen, but should equally take into account all aspects aiming at a minimal selection of resistance 
determinants. For example, the different risks for selection and spread are not restricted to different classes, 
but are also present within one class. One specific antimicrobial agent might play a role in the shift towards 
resistant strains with higher MIC’s and might even select for resistance to other classes due to genetic 
linkage, whereas other similar antibiotics do not have the same selective effects. 
2.1.4. ADMINISTRATION ROUTE 
Different factors might play a role in the effect of different administration routes on resistance selection and 
spread. At first, the route of administration will affect tissue/intestinal content concentrations (Baggot, 2006) 
and thus also the degree of the selection pressure exerted on both pathogens and commensal bacteria. Oral 
administration of antimicrobials exerts a selection pressure on the intestinal microbiota that is, most likely, 
higher than seen for parenteral injections, except for parenterally administered antimicrobials which undergo 
enterohepatic circulation to a high extent, such as tetracyclines (del Castillo, 2013). Nevertheless, the extent 
and pattern of antibiotic tissue distribution might equally be involved in the exertion of a selection pressure. 
Distribution into the intestinal lumen varies between antimicrobial agents of different classes due to 
differences in their chemical nature (Baggot and Giguère, 2013). In this respect, parenterally administered 
antimicrobials, not undergoing enterohepatic circulation might possibly achieve selective concentrations in the 
intestinal lumen.  
The intestinal microbiota is often described as a commensal reservoir of resistance genes (Levy and Marshall, 
2004) and the oral administration of antimicrobials might be an increased risk (compared to parenteral 
administration) for selection of resistant commensal bacteria and spread of resistance genes to other 
commensal and pathogenic bacteria.  
Yet, only limited specific research data on the effect of different administration routes on resistance selection 
and spread are available. Zhang et al. (2013) described the development of resistance in intestinal bacteria of 
mice as significantly less or delayed when the same doses of antimicrobials were administered via 
intravenous injection rather than oral administration. Moreover, the difference in intravenous or oral therapy 
was more significant for ampicillin, eliminated via the kidney, than for tetracycline, excreted via both kidneys 
and the gastrointestinal tract. Wiuff et al. (2003) included a parenteral and an oral treatment group in their 
study and found no difference in the speed of selection for resistance in S. enterica infected pigs between 
intramuscular administration of enrofloxacin and oral administration of the same dose. Yet, a selection 
pressure might also have been present in the intestines following parenteral administration, as enrofloxacin 
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and its major metabolite, ciprofloxacin, is passing through the intestinal tract after excretion in the bile 
(Koningstein et al., 2010). From these studies, it appears that the effect of different administration routes on 
the resistance selection again depends on the antimicrobial used, as this is linked to a specific excretion 
route.  
In food producing animals, individual and group treatments often coincide with parenteral and oral 
administration routes, respectively (Pardon et al., 2012). Treatment of only one or a few animals (individual 
treatment) or an entire group of animals can effect observed resistance levels, since resistance selection, as 
the result of antimicrobial treatment of a single animal, may be partially diluted at the population level due to 
the presence of a susceptible microbiota excreted by the contact animals. In chickens, previously fed 
tetracycline feed, a decrease in the excretion of resistant E. coli was seen after housing them with larger 
numbers of cage mates that excreted susceptible microflora (Levy, 1978). However, when the entire 
population is treated, the odds of dilution to occur by susceptible bacteria will be lower and a commensal 
reservoir of resistance genes can be formed (Levy and Marschall, 2004). Moreover, the transfer of resistant 
bacteria might occur more rapidly to animals being treated, due to the inhibition of the commensal microbiota, 
which exert a protective effect against colonization and infection by exogenous organisms (Barza and 
Travers, 2002). Dunlop et al. (1998b) compared the effect of individual and group treatment on resistance in 
E. coli from swine using aminoglycosides and tetracycline and found lower resistance levels in the group 
receiving individual parenteral treatment compared to the group receiving oral administration. Feedlot bulls 
showed a higher proportion of resistant E. coli after the oral administration of tetracyclines compared to a 
subcutaneous treatment (Checkley et al., 2010), yet the prominent difference disappeared after a few weeks, 
showing that other factors were involved. The authors suggested an interaction between the groups, as all 
bulls were kept together. On the one hand, a dilution effect could have occurred in the animals treated with 
feed antimicrobials after the antimicrobial selection pressure dropped. On the other hand, resistance might 
have spread horizontally between the different groups of animals, explaining the rise in resistance after 
cessation of antimicrobial therapy in both the control and the parenterally treated group.  
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2.2. ANTIMICROBIAL RESISTANCE SELECTION PRESSURE AND SPREAD THROUGH 
FACTORS OTHER THAN ANTIMICROBIAL USE  
Besides the use of antimicrobials, other factors can also be involved in the selection and spread of resistance 
determinants. These factors can either be selection pressure originating from biocides or heavy metals or can 
be due to entirely different drivers as discussed below.  
2.2.1. BIOCIDES 
It is known that biocides and preservatives, such as quaternary ammonium derivates (QAD), triclosan and 
chlorhexidine, might have working mechanisms in common with antimicrobials (McMurry, 1998) through which 
similar mechanisms of bacterial insusceptibility may occur. Various studies in E. coli and S. enterica have 
demonstrated that efflux pumps play an important role in resistance to antimicrobials or disinfectants, 
including QAD and triclosan (Levy et al., 2002). This results in induced cross-resistance following increasing 
concentrations of a biocide or antimicrobial under laboratory conditions (Braoudaki and Hilton, 2004). Sub-
inhibitory concentrations of QAD and triclosan, due to poor disinfection procedures, can lead to the selection 
of Salmonella Typhimurium strains with reduced susceptibility or resistance to ampicillin, ciprofloxacin and 
tetracycline (Karatzas et al., 2007).  
Besides similar resistance mechanisms, the possibility of genetic linkage on plasmids between qac genes for 
QAD resistance and β-lactamase genes for β-lactam resistance has been described for S. aureus (Fraise, 
2002). This might also be the case for Gram-negative bacteria, such as S. enterica and E. coli from farm 
animal origin where qac genes are often together with sul1genes, encoding sulfonamide resistance, located 
on mobile genetic elements that can harbor various other resistance genes (Sidhu et al., 2001; Sidhu et al., 
2002; Chuanchuen et al., 2007; Cocchi et al., 2007). 
According to Russell (2003) the translation of biocide resistance laboratory studies to in vivo situations might 
lead to premature or even wrong conclusions, as the presence of resistant bacteria is not necessarily higher 
in settings with a higher biocide use. Karatzas et al. (2007) suggest a lower virulence of strains due to QAD 
and triclosan selection as a possible explanation. Nevertheless, QAD resistant staphylococci isolated from 
human patients with bacteremia showed a significantly higher prevalence of resistance to several 
antimicrobials than QAD sensitive staphylococci, indicating an association between biocide and antimicrobial 
resistance (Sidhu et al., 2002).  
A third factor, along with cross-resistance and co-selection, might be the selective stress exerted by biocides. 
The expression of the broad-specificity efflux AcrAB pump is up regulated by the mar operon responding to 
toxic substances, such as biocides and antimicrobials (Levy, 2002). Furthermore, stress induced by biocides, 
favors not only the expression of resistance mechanisms, but also their dissemination by horizontal 
transmission of integrons (Beaber et al., 2004) and plasmids (Feld et al., 2008), and thereby accelerating the 
spread of resistance. 
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Despite in vitro evidence for associations between biocide use and selection and spread of antimicrobial 
resistance through the abovementioned mechanisms, data related to the occurrence of bacterial resistance 
following exposure to biocides in the veterinary field are scarce. The correct use of biocides for biosecurity 
measures in animal husbandry as a part of disease prevention to avoid the need of antimicrobials is strongly 
arguing in favor of biocide use.  
These conflicting arguments in combination with the limited field data available indicate that there is a need 
for further studies to elucidate the potential interaction between the use of biocides in animal facilities and the 
emergence of antimicrobial resistance. 
2.2.2. HEAVY METALS 
Metal-containing compounds are widely used as feed supplements, both to address metabolic needs and for 
the prevention of gastro-intestinal diseases in food animals (Cavaco et al., 2011). 
Multidrug efflux systems have been shown to be important mechanisms of resistance against antimicrobials 
and other structurally unrelated compounds, such as heavy metals, in several bacterial genera from different 
animal species (Delmar et al., 2014).  
A correlation between copper resistance on the one hand and glycopeptide and macrolide resistance on the 
other hand in Enterococcus faecium isolates has been observed in pigs, but not in broilers, calves and sheep 
in Denmark (Hasman and Aarestrup, 2005). This might be partly due to higher copper exposure in pigs 
through feed additives compared to other livestock. Most likely, this has resulted in the co-selection of the 
tcrB, Tn1546 and the erm(B) gene, responsible for copper, glycopeptide and macrolide resistance 
respectively, as they are closely located to each other on a conjugative plasmid (Hasman and Aarestrup, 
2005). Cross-resistance has also been seen in Listeria monocytogenes by means of a multiple-drug 
resistance pump exporting metals in addition to antimicrobials (Mata et al., 2000). The czrC gene, conferring 
resistance to zinc and cadmium in S. aureus, was found to be located within the clonal complex SCCmec 
type V, prevalent in MRSA from pigs and veal calves (Cavaco et al., 2010).  
In fecal multidrug resistant Salmonella serotypes from swine, statistical associations were found between 
ampicillin, streptomycin, tetracycline and kanamycin resistance and the pcoA gene, conferring resistance to 
copper, and between ampicillin, chloramphenicol, streptomycin, sulfisoxazole, tetracycline and the czcD gene, 
conferring resistance to zinc (Medardus et al., 2014). 
2.2.3. HOST FACTORS 
Animals experiencing stress can show increased and prolonged shedding of bacteria, whereby the spread of 
resistance into the environment can be promoted (Sorum and Sunde, 2001; Verbrugghe et al., 2012). This 
has been observed for fecal E. coli from slaughter pigs, exposed to heat stress and without previous 
antimicrobial use (Moro et al., 2000). 
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Alongside an increased shedding of bacteria, a higher prevalence of resistance has been observed in animals 
exposed to stress. For instance, in pigs exposed to cold and overcrowding an increased resistance 
prevalence to apramycin in E. coli was observed (Mathew et al., 2003). Another example of a possible stress-
associated resistance effect was seen in a study on the effect of florfenicol injection in steers on 
multiresistance in fecal E. coli where cattle were rounded up from two pastures and transferred to a research 
institute. Higher levels of multi-resistance and prolonged resistance following a single injection of florfenicol 
was seen in calves that were immediately weaned prior to transfer to the research institute compared to 
calves from a source where they had been weaned one month prior to shipment (Berge et al, 2005b).   
Several studies support that increasing age is linked with a decreased prevalence of resistant E. coli in dairy 
cattle (Berge et. al, 2005a; Sato et al., 2005; Berge et al., 2010; Khachatryan et al., 2004) and in coliforms 
from pigs (Langlois et al., 1988; Dewulf et al., 2007; Akwar et al., 2008). In poultry, the prevalence of 
resistance for multiple agents in enterococci was significantly higher for the maximum 42 days old broilers 
compared to older laying hens (van den Bogaard et al., 2002). The higher antimicrobial use in the more 
susceptible younger animals is often suggested as the main reason. However, higher levels of resistance in 
young preweaned calves that had not had previous exposure to antimicrobials compared to adult animals has 
been noted, and the age-related resistance prevalence cannot completely be explained by increasing 
antimicrobial exposure (Berge et al, 2010). Also, for poultry, broiler production coincides with higher infection 
pressure and thus antimicrobial use compared to laying hens production systems (van den Bogaard et al., 
2002). Another possible explanation has been given by Walk et al. (2007). The authors suggest that the 
fitness cost of resistant bacteria becomes too large as the host gastrointestinal tract matures and competition 
with other microbes increases. 
2.2.4. HOUSING CONDITIONS 
Farm types or housing conditions have been identified as a significant factor in the prevalence of resistance in 
different animal sectors. These differences have often been assigned to divergent antimicrobial use however. 
Antimicrobials in the milk replacers throughout the pre-weaning period might provide a selective advantage to 
resistant enteric E. coli in calves. This could explain phenotypic resistance to more antimicrobials in E. coli 
isolated from calves from calf ranches than from dairy farms (Berge et. al, 2005a; Berge et al., 2010). 
Similarly, the fecal coliforms (Berge et al., 2001) and respiratory tract Pasteurellaceae (Mevius & Hartman, 
2000; Catry et al., 2005) from calves for fattening show a higher degree of resistance than isolates from dairy 
or beef calves. Most likely, the routinely administered in-feed medication exerting a selection pressure in the 
nasopharynx, through systemic distribution or through direct contact (nasopharynx or tonsils) with the 
microbiota of the upper respiratory tract, is responsible for the higher resistance levels (Catry et al., 2005). 
Other factors, different from antibiotic use, playing a role in the selection and spread of resistance in pigs and 
inherent to farm type were reported by Langlois et al. (1988). These authors may have been the first to report 
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the potential beneficial effect of moving animals towards outdoor production on the resistance prevalence. A 
greater proportion of E. coli isolated from pigs on pasture were sensitive to 13 antimicrobial agents tested 
than were isolates from pigs housed in a farrowing house or concrete-floored finishing unit (Langlois et al., 
1988). This phenomenon may be referred to as ‘environmental dilution’ and results in a microbial population 
with an equilibrium between susceptible and resistant subpopulations or even a predominance in susceptible 
bacterial populations. A comparable effect has been seen in broiler chickens and fattening pig farms where a 
lower hygiene standard in farms was associated with lower resistance in intestinal Enterobacteriaceae (Dewulf 
et al., 2007; Persoons et al., 2010). The authors suggested the possibility of a dilution effect by susceptible 
bacteria due to a soiled environment, resulting in a more diverse intestinal microbiota and thus less resistant 
strains. Apparently, hygienic measures play an ambiguous role in the prevalence of resistance. In disease 
control, hygiene and sanitation are very important and modifiable assets to prevent disease introduction and 
spread in a herd or flock and thus also to prevent antimicrobial intervention. Furthermore, good hygiene 
standards in a farm assume the prevention of the development of bacterial reservoirs. Yet, in contrast they 
might result in less dilution and thus exposure to a more homogeneous (resistant) bacterial population. 
2.2.5. DIET 
The possible impact of diet on the prevalence of resistant enteric bacteria in the feces has been suggested by 
several studies. As a result of a change in the composition of diets, environmental stressors, such as pH, can 
vary within the intestinal tract (Alexander et al., 2008). Cattle on a grain diet, previously treated with 
antimicrobials, showed a higher prevalence of tetracycline resistant E. coli in fecal samples, compared to 
control cattle on a silage diet (Alexander et al., 2008). A pH decrease in the rumen, after feeding the grain 
diet, might act as trigger for the expression of membrane-bound transporters, a common mechanism of 
tetracycline resistance in E. coli (Roberts et al., 1994). Alexander et al. (2008) suggested the presence of 
other environmental stressors, such as bacteriocins and osmolarity in the intestines, which might be able to 
induce genes linked to antimicrobial resistance genes. Khachatryan et al. (2006) assumed a multifactor 
selective system for streptomycin-sulfadiazine-tetracycline (SSuT) resistant E. coli strains from dairy cattle. 
Animals receiving a dietary vitamin D supplement showed a nearly twofold increase in the prevalence of 
SSuT resistant strains compared to animals that did not receive any supplement. The authors performed in 
vitro experiments, showing that SSuT resistant strains attained a higher density of cells at stationary phase 
than non-SSuT resistant strains in the presence of the vitamin D additive. They concluded that the 
relationship between the prevalence of SSuT resistant strains and the vitamin D additive may be related to 
genetic linkage of the SSuT determinants to other genes, so called ‘beneficial genes’, that confer a selective 
advantage in the presence of the vitamin D additive (Khachatryan et al., 2006). 
Further investigations are needed in order to determine how changes in diet composition may impact the 
prevalence of antimicrobial resistant enteric bacteria and thus the spread of resistance into the environment.   
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2.2.6. BACTERIAL FACTORS 
In certain bacterial strains there is substantial evidence for a common mechanism for virulence and resistance 
or a linked presence of particular virulence and resistance genes. The hazard of these common mechanisms 
or linked occurrence of virulence and resistance genes can be defined as the possibility of co-selection of 
virulence genes by use of antimicrobials and consequentially maintenance of resistance in populations of 
pathogenic bacteria (Boerlin et al., 2005). Yet, the mechanisms involved affect whether positive or negative 
associations between resistance and virulence are seen (Martinez and Baquero, 2002; Beceiro et al., 2013). 
The AcrAB-TolC efflux pump, widely distributed in Gram-negative bacteria, expels antimicrobial agents, but 
also host-derived compounds with bactericidal activity such as fatty acids and bile salts (Perez et al., 2012). 
Several studies have demonstrated that the efflux pump is required for bacteria to be pathogenic and to show 
resistance towards several classes, such as β-lactams, aminoglycosides, fluoroquinolones, tetracyclines and 
macrolides (Martinez et al., 2009). For Klebsiella pneumoniae it has been shown that porin deficiency can 
increase antimicrobial resistance, but decrease virulence at the same time (Tsai et al., 2011). Resistance to 
colistin in Gram-negative bacteria is caused by either the loss or by changes in their lipopolysaccharide 
(LPS), thereby preventing or reducing the affinity of polymyxins (Landman et al., 2008; Beceiro et al., 2014). 
A loss or change in LPS has been associated with a noticeable cost in terms of overall fitness and virulence  
in colistin resistant Acetinobacter baumanni (Lopez-Rojas, 2011; Beceiro et al., 2014).  
Besides common mechanisms of resistance and virulence, mobile genetic elements such as plasmids and 
integrative conjugative elements (ICE’s) may carry both virulence and resistance genes, which can be 
concurrently transmitted between and within bacterial species. For porcine enterotoxigenic E. coli (ETEC), 
diverse resistance and virulence genes profiles have been seen (Smith et al., 2010), which might explain the 
diverged outcomes on clustering of resistance and virulence genes. Only few or no associations between 
resistance and virulence genes were reported in porcine multidrug resistant ETEC by Smith et al. (2010). On 
the other hand, field data obtained by Boerlin et al. (2005) showed statistical associations between these 
genes for ETEC isolated from pigs. This has been supported by the clustered prevalence of the tetracycline 
resistance gene tetA and several virulence factors on a common plasmid in porcine ETEC (Goswami et al., 
2008). The latter confirmed the hypothesis that antimicrobial resistance is more common in ETEC than in 
other porcine E. coli (Boerlin et al., 2005). Yet, where positive associations were found for tetA, this was not 
the case for certain virulence factors and tetB. Other studies report the presence of a pTC plasmid, linking 
resistance and enterotoxin virulence genes in porcine ETEC (Fekete et al., 2012), in F18-positive strains 
(Olsz et al., 2005) and in an E. coli O149:H10 strain shown to have enhanced virulence (Goswami et al., 
2008). Studies on enterohemorrhagic E. coli (EHEC) in cattle (Valat et al., 2012) also aiming at investigating 
the possible link between resistance and virulence genes reported only few or no associations. Avian E. coli 
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strains have been shown to carry a conjugative R plasmid containing both tetracycline and ampicillin 
resistance genes and virulence genes (Johnson et al., 2002).  
Field studies have shown more phenotypic resistance in bacteria from diseased than in bacteria from healthy 
animals, such as in E. coli from Swedish dairy calves with diarrhea (de Verdier et al., 2012), in E. coli from 
dairy cows with mastitis (Suojala et al., 2010) and in Streptococcus suis from pigs with diverse clinical 
conditions (Li et al., 2012). Yet, findings on the statistical relationship between virulence factors and 
resistance phenotypes in the field should be interpreted with caution. Though phenotypic resistance to one or 
more antimicrobials was associated with the presence of virulence genes in E. coli, none of these virulence 
factors were associated with the respective disease (Suojala et al., 2010; de Verdier et al., 2012), suggesting 
that detection of virulence factors might not always predict virulence in field conditions (Li et al., 2012) and 
that other factors may explain higher resistance prevalences in diseased animals. Higher prevalence of 
resistance in pathogenic isolates from diseased animals as a consequence of antimicrobial treatment has 
been suggested by Harada and Asai (2010).  
Recently, another connection between virulence and resistance to antimicrobials has been described 
(Arnoldini et al., 2014; Diard et al., 2014). In Salmonella Typhimurium, the expression of a type three 
secretion system, encoded by genes on the Salmonella pathogenicity island (SPI) 1, triggers gut tissue 
invasion followed by intracellular growth retardation and antibiotic tolerance. This results in the so called 
‘persister cells’ with increased tolerance against antimicrobial agents and thus promoting persistence in an 
antimicrobial environment (Arnoldini et al., 2014; Diard et al., 2014). Upon cessation of antibiotic treatment, 
former persister cells reseed the gut lumen and thereby facilitate disease transmissibility to new hosts (Diard 
et al., 2014).  
Another bacterial factor is the fitness cost after having acquired a resistance determinant, either by mutation 
or HGT. This will be further discussed below.  
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3. PERSISTENCE OF ANTIMICROBIAL RESISTANCE 
3.1. PERSISTENCE OF ANTIMICROBIAL RESISTANCE IN THE PRESENCE OF 
ANTIMICROBIAL SELECTION PRESSURE 
When evaluating resistance monitoring results, often a relative steady state of the levels of resistance in a 
population can be observed. Rates of resistance in commensal E. coli from cattle, pigs and broiler chickens in 
Japan, remained stable at intermediate level for ampicillin and at high levels for streptomycin and tetracycline 
from 2000 to 2007, commonly used antimicrobials in Japan (Harada and Asai, 2010). Also, in pathogenic 
porcine and bovine E. coli in Belgium, tetracycline resistance remained stable between 2005 and 2011(VAR, 
2012). The MARAN data report relatively stable resistance levels in E. coli from different animal species over 
time, with a tendency to increase until 2011 (MARAN, 2014). From 2012 onwards, a limited decrease of 
resistance rates was recorded for most antimicrobials included, which is most likely the result of the 
substantial decrease in antimicrobial use in the Netherlands since 2009 (MARAN, 2014).  
Administering antimicrobials to an individual animal generally results in an increase in resistance level in the 
individual animal and by doing so maintains a resistance pool that can influence the entire population (Levy, 
1998). In calves, prior to treatment with apramycin, resistant E. coli were detected but all Salmonella 
Typhimurium strains were susceptible. Following treatment, apramycin-resistant Salmonella Typhimurium 
strains, carrying the same resistance genes as resistant E. coli, were isolated (Hunter et al., 1992). Levin et 
al. (1997) suggested a model where treatment of individual animals exerts sufficient selective pressure to 
maintain a commensal reservoir of resistance genes, which contributes to the spread and persistence of 
these genes at a population level. This, together with earlier described factors including vitamin D selection by 
milk intake, could explain why resistant E. coli are found in neonatal calves and piglets not previously exposed 
to antimicrobials. These young animals are exposed to a pool of resistant commensal bacteria in the dam, 
which thereafter is maintained by the treatment of other individuals (Berge et al., 2005a). 
 
The persistence of resistance can also be promoted by cross-selection, referred to as the selection of 
resistance to antimicrobial agents by any other antimicrobial of the same antimicrobial class, and by co-
selection, defined as resistance selection through the use of unrelated antimicrobials as a result of linkage of 
multiple resistance genes on the same genetic element. The latter will result in the collective positive selection 
of all genes in the presence of a selective pressure for one trait. Co- and cross-selection can explain the 
persistence of resistance, even though the actual antimicrobial has not been used for a certain period. This 
phenomenon is well known in veterinary medicine. For example, swine E. coli have been reported resistant to 
chloramphenicol in spite of the absence of a direct selection pressure exerted by chloramphenicol use for 25 
years, as this product was withdrawn from the market for food producing animals in 1989 in Europe 
(Berendsen et al., 2010). Cross-resistance to florfenicol and co-selection by the use of aminoglycosides, 
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tetracycline and sulfonamides may explain this persistent chloramphenicol resistance (Bischoff et al., 2005). 
Cefazolin-resistant E. coli strains, harboring extended spectrum class A or class C β-lactamases on plasmids, 
have been isolated from broiler chickens in Japan (Kojima et al., 2005). Since no cephalosporins are 
approved for use in poultry in Japan, the selection of these strains is most likely enhanced by the presence of 
other resistance genes on the same plasmid (Harada and Asai, 2010). Co-selection of strA and sul2 genes, 
conferring resistance to streptomycin and sulfonamides respectively, during the treatment of chickens with 
streptomycin has been reported by Faldynova et al. (2013). 
 
3.2. PERSISTENCE OF ANTIMICROBIAL RESISTANCE IN THE ABSENCE OF 
ANTIMICROBIAL SELECTION PRESSURE  
In the absence of a selection pressure exerted by antimicrobials, one could assume no evolutionary 
advantage anymore for the presence of antimicrobial resistance determinants, especially when a certain cost 
is associated with the resistance trait. It has been described that resistance achieved by both mutation of 
chromosomal genes (Wichelhaus et al., 2002; Giraud et al., 2003) and through acquired resistance genes 
(Johnsen et al., 2002) may impose a fitness cost both in vitro and in vivo. A loss in fitness can be reflected in 
a reduced growth rate (Andersson, 2006; Majcherczyk et al., 2008), a reduced transmission rate (Randall et 
al., 2008), a higher clearance rate (Gustafsson et al., 2003) and a decreased invasiveness (Fernebro et al., 
2008), which can make the resistant strains less competitive than the susceptible ones in the absence of 
antimicrobials. This should result in a gradual reduction of resistance prevalence if no selection pressure is 
present. However, it is often observed that a reduction or discontinuation of antimicrobial use in farm 
environments does not necessarily result in a decreased prevalence of antimicrobial resistant isolates, at least 
not in the short term (Enne et al., 2001; Khachatryan et al., 2004; Thakur and Gebreyes, 2005; Bunner et al., 
2007). The horizontal transfer of resistance genes in the absence of an antimicrobial selection pressure has 
for instance been described for the tetracycline resistance gene tetO between Campylobacter jejuni strains in 
the intestinal tract of chickens (Avrain et al., 2004) and for MLSB resistance in the Gram-positive nasal and 
tonsillar microflora of pigs (Martel et al., 2003). Recently, an in vivo chicken model showed the spread of 
genetic determinants of MLSB resistance independent of any antimicrobial pressure (Marosevic et al., 2014). 
Several mechanisms might be responsible for the persistence of resistance mechanisms in bacterial strains in 
the absence of antimicrobial use. These are described below.  
3.2.1. COMPENSATORY MUTATIONS AND OTHER MECHANISMS RESULTING IN PERSISTENCE OF 
ANTIMICROBIAL RESISTENCE  
Some resistance-conferring mutations bear low or no fitness cost or may even enhance the bacteria’s fitness 
(Luo et al., 2005). This was observed for a porcine E. coli isolate where the fitness impact imposed by the 
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carriage of antimicrobial resistance elements was generally low or non-existent (Enne et al., 2005). Moreover, 
carriage of transposon Tn1 A improved fitness in vitro and in pig infection models (Enne et al., 2005). Most 
likely, the insertion of Tn1 A disrupted a gene that imposed fitness cost or the transposon itself conferred 
fitness advantage (Enne et al., 2005). Enhanced fitness has been seen in fluoroquinolone resistant 
Campylobacter jejuni, directly linked to the single point mutation in gyrA, conferring high-level resistance to 
fluoroquinolones (Luo et al., 2005). 
Additionally, a mechanism of compensatory mutations has been described (Andersson and Levin, 1999) 
enabling a resistant strain to compensate for fitness loss and successfully compete with, or even prevail over 
susceptible strains (Handel et al., 2006; Johnsen et al., 2009). The level to which compensation is attained 
and the number of compensatory mutations depends on the bacterial strain, the resistance mechanism and 
the environmental conditions (Andersson and Hughes, 2010; Beceiro et al., 2013). In vitro experiments and 
animal models have revealed compensatory mutations for amelioration of fitness costs caused by 
chromosomal mutations, such as in Salmonella Typhimurium (Bjorkman et al., 1998), E. coli (Marcusson et 
al., 2009) and S. aureus (Nagaev et al., 2001).  
In E. coli, it has been observed that the addition of a fourth fluoroquinolone resistance mutation in low-fitness 
mutant strains caused a further reduction in susceptibility to fluoroquinolones and an increase in relative 
fitness in in vitro models as well as in vivo (Marcusson et al., 2009). 
Besides chromosomal mutations, plasmid encoded resistance genes might equally acquire compensatory 
mechanisms for fitness costs (Poole et al., 2011). Plasmids such as pCT, carrying the extended-spectrum-β-
lactamase (ESBL) resistance gene blaCTX-M-14 have evolved to impose little impact on host strains in vitro 
(Cottell et al., 2012). In clinical Salmonella Typhimurium strains, the biological cost of plasmid-encoded high 
level AmpC production is compensated by plasmid-encoded factors, other than the repression of AmpC 
expression (Hossain et al., 2004). The emergence of Salmonella populations resistant to extended-spectrum 
cephalosporins in animal reservoirs (Chen et al., 2004) supports the presence of such evolved mechanisms to 
compensate the loss of fitness associated with resistance to beta-lactams (Zhang et al., 2006). 
As a result of no- and low cost mutations, and compensatory evolution, antimicrobial resistance genes and 
their vectors are able to show a rapid emergence, stabilization and persistence in environments in the 
absence of antimicrobial use once established in bacterial populations (Enne et al., 2005; Cottell et al., 2012). 
3.2.2. REGULATION OF RESISTANCE MECHANISMS FOR PERSISTANCE OF RESISTANCE 
Antimicrobial resistance is in general only transiently advantageous to bacteria, namely in the presence of the 
antimicrobial. Therefore, bacteria can regulate the expression of resistance, following chromosomal mutations 
or acquisition of mobile genetic elements (Depardieu et al., 2007). Induction is the process where the 
phenotypic resistance is brought to expression after having acquired an antimicrobial resistance determinant 
(Chancey et al., 2013). The antimicrobial to which the resistance gene is targeted can be involved in the 
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induction of the expression of the gene (Butaye et al., 2003) and furthermore, can even induce the 
dissemination of the resistance determinant (Deparieu et al., 2007). This phenomenon has for instance been 
described for inducible MLSB resistance (Chancey et al., 2013) and for vanA- and vanB-type resistance 
(Arthur et al., 1992; Foucault et al., 2010) in Gram-positive bacteria, for AmpC β-lactam resistance (Jacoby, 
2009) in Gram-negative bacteria and for several resistance mechanisms, such as specific efflux systems 
(Butaye et al., 2003) and ribosome methylation (Chancey et al., 2013).  
Regulation of expression of resistance mechanisms in bacterial strains may explain why isolates are more 
resistant in vivo than in vitro (Chancey et al., 2012). It drastically reduces the biological cost associated with 
resistance (Andersson and Hughes, 2010) and therefore it can account for the widespread dissemination of 
such strains (Foucault et al., 2010). 
3.2.3. GENETIC LINKAGES AS A MECHANISM FOR PERSISTANCE OF RESISTANCE  
Co-selection does not solely occur by the use of antimicrobials of diverse classes. As previously described, 
resistance genes can be linked to a much broader spectrum of genes due to common mobile genetic 
elements, such as plasmids, transposons or integrons. These genes can attribute an advantage to bacteria in 
certain conditions, such as in the presence of heavy metals (Cavaco et al., 2011), biocides (Levy et al., 
2002), nutritional components in a diet (Khachatryan et al., 2006) and immune defense mechanisms 
(Goswami et al., 2008). As a result, selection of resistance genes can occur by other selectors, in the 
absence of an antimicrobial selection pressure. Specific efflux and multidrug efflux systems for antimicrobials 
can for instance be involved in additional physiological functions related to a wide range of potentially toxic 
substances occasionally including also antimicrobial agents (Wang et al., 2000; Butaye et al., 2003). This may 
confer advantages to bacteria even when antimicrobials are not present (Wang et al., 2000; Butaye et al., 
2003), resulting in the persistence of such systems.  
 
3.2.4. POST SEGREGATIONAL KILLING AS A MECHANISM FOR PERSISTANCE OF RESISTANCE 
Post segregational killing (PSK) systems imply the killing of bacterial cells after the loss of a plasmid, due to 
the imbalance between a toxic and an anti-toxic substance that are co expressed. The linked presence of a 
PSK system to antimicrobial resistance determinants on one plasmid has been reported for glycopeptides in 
Enterococcus faecium from poultry and poultry farmers (Sorum et al., 2006). The system also prevents the 
development of plasmid-free daughter cells (Johnsen et al., 2009) and thus contributes to persistence of 
resistance. In some cases the resistance genes themselves increase fitness (Groh et al., 2007) thus losing 
the genetic element they are located on presents a fitness cost, effectively selecting for resistance. 
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3.2.5. ENVIRONMENTAL RESERVOIRS OF RESISTANCE GENES  
Bacteria in soil, containing resistance elements, are phylogenetically diverse and many are closely related to 
pathogenic species, suggesting that they can play an important role as reservoir of resistance genes through 
horizontal gene transfer (Dantas et al., 2008).  
Resistance in Campylobacter spp. and S. enterica strains has been reported to persist in farm animals in 
antimicrobial-free and organic production systems (Rollo et al., 2010; Keelara et al., 2013). Identical 
resistance profiles were observed in S. enterica and Campylobacter spp. from pigs and their environment on 
farms and at slaughter (Quintana-Hayashi and Thakur, 2012a; Keelara et al., 2013). Moreover, results from 
multilocus sequence typing, genotypically characterizing bacterial strains, revealed a clear overlap between 
swine and environmental farm- and slaughterhouse-associated Campylobacter coli (C. coli) sequence types 
(STs). This demonstrates the swine environment to play a key role in the persistence of multidrug resistant C. 
coli strains on pig herds, even in the absence of antimicrobial selection pressure (Quintana-Hayashi and 
Thakur, 2012b).  
4. REVERSION TO SUSCEPTIBILITY 
A final possible phase in the epidemiology of antimicrobial resistance is the disappearance of resistance. 
From the above, it is clear that, despite the absence of an antimicrobial selection pressure, selection and 
spread of resistance through other mechanisms decrease the likeliness for a rapid reduction in resistance 
prevalence. However, some studies showed a decline in the resistance level of bacterial populations when 
antimicrobial selection pressure was removed. In a multi-resistance-plasmid-carrying E. coli population, a 
tetracycline-sensitive subpopulation emerged in the absence of antimicrobials (De Gelder et al., 2004). This 
was observed in an in vitro experiment aiming at constructing mathematical models for predicting the 
reversibility to a susceptible population in the absence of an antimicrobial selection pressure. The model 
incorporated the mutation rate (number of mutations per generation), and the selection coefficient (reduction 
in growth rate due to the fitness costs associated with harboring the multi-resistance plasmid). As expected, 
the time required to reduce the number of resistant bacteria appeared to be inversely related to the fitness 
cost. Consequently, relatively less time is needed for strains with a high fitness cost which can be seen e.g. 
for a constitutively expressed tetracycline operon on a high-copy number plasmid (Modi et al., 1991). Yet, in 
order to cope with this high cost, bacteria may adapt to the environmental condition in which they reside, 
allowing them to remain competitive with susceptible isolates in the absence of antimicrobials. This has been 
illustrated for amplification of the blaA gene in Yersinia enterocolitica, where the copy number of the plasmid 
carrying blaA is adjustable according to changes in the environment and as a result, only a basal resistance 
level remained once the selective pressure was removed (Seoane et al., 2003).  
In the abovementioned example, absence of resistance is the result of genetic alterations, yet exclusively in 
the absence of antimicrobials. The final step in the reversion to susceptibility leading to a continued reduction 
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in resistance prevalence, should be a decreased growth rate of bacteria carrying resistance determinants or 
even the disappearance of these determinants. Bambermycin or flavophospholipol, primarily used as a feed 
additive in poultry, swine and cattle (Butaye et al., 2003) because of its suppressive effect on Gram-positive 
bacteria, has been shown to be effective in inhibiting growth of Gram-negative intestinal bacteria carrying 
antimicrobial resistance plasmids both in vitro and in vivo (Pfaller, 2006). In addition, it can decrease the 
frequency of transfer of resistance plasmids via conjugation in E. coli, S. enterica, S. aureus and E. faecium in 
vitro and might thus be effective in the prevention of horizontal dissemination of resistance genes (Pfaller et 
al., 2006). Yet, the latter has not yet been confirmed for all mentioned bacterial species in vivo (Poole et al., 
2006). Nevertheless, flavophospholipol might play a role in decreasing the transferable antimicrobial 
resistance gene pool within the intestinal bacterial population. 
An additional role may be attributed to vaccination. In human medicine, the introduction of a vaccine against 
invasive pneumococcal disease has been shown to decrease the incidence of antibiotic-resistant invasive 
disease. By reducing the risk of carriage and transmission of vaccine-type resistant Streptococcus 
pneumoniae strains the number of resistant S. pneumoniae decreases in the population (Kyaw et al., 2006).  
Results of antimicrobial resistance monitoring programs in countries where during several years a substantial 
decrease of antimicrobial use in veterinary medicine was achieved, demonstrate that a reduction in resistance 
prevalence is possible after a few years (MARAN, 2013). It remains to be seen how long it will take before a 
substantial and stable decrease is reached.   
5. CONCLUSIONS 
Antimicrobial resistance is an old phenomenon with a widespread prevalence in animal production, mainly 
attributed to the use of antimicrobial agents for growth promotion, prophylaxis, metaphylaxis and therapy. As 
a result, one would expect that reducing the main selection pressure, namely the antimicrobial use, could 
result in a decrease in resistance prevalence. Yet, several non-antimicrobial factors may contribute to the 
selection, spread and persistence of resistance. Co-selection between a resistance mechanism and another 
selected determinant is believed to play a considerable role in the spread and persistence of resistance. 
Furthermore, bacteria have evolved mechanisms to cope with the potential fitness cost accompanying the 
acquisition of resistance determinants. Since these fitness costs are believed to be the main driving forces for 
reduction of the frequency of resistant bacteria in the absence of antimicrobials, it makes a decrease in 
resistance after cessation of antimicrobial administration uncertain. The role of antimicrobials in the treatment 
of bacterial diseases cannot be seen as anything but essential. Therefore, good insights in the epidemiology 
of resistance at the animal and population level is crucial as it can help to develop appropriate strategies to 
stop further selection of resistance. 
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Intensive pig production has been identified as subject to high antimicrobial exposure. The emergence of 
antimicrobial resistance in commensal, zoonotic, and pathogenic bacteria from pigs, mainly as a result of 
antimicrobial consumption, and potentially threatening treatment options in both human and veterinary 
medicine, is worrisome. 
Closely monitoring antimicrobial use and antimicrobial resistance levels are both important first steps in 
strategies aiming to contain antimicrobial resistance. Commensal bacteria, commonly present in animals, are 
exposed to any antimicrobial administration and therefore good indicators for antimicrobial resistance.  
The overall objective of this thesis was to gain insight in the extent to which antimicrobial agents are used in 
Belgian pig production, in the presence of resistance in commensal bacteria from pigs and in the relationship 
between the occurrence of resistance and the use of antimicrobials in sows and piglets. 
The specific objectives of this thesis were: 
(1) to collect and quantify herd level-data on the group use of antimicrobial agents in Belgian pig herds 
in 2010 and to compare the results to a similar study conducted in 2003 (Chapter 3) 
(2) to report the level of antimicrobial resistance in the Gram-positive indicator bacterium Streptococcus 
suis, isolated from clinically healthy fattening pigs at slaughter age (Chapter 4) 
(3) to report the level of antimicrobial resistance in the Gram-negative indicator bacterium Escherichia 
coli isolated from clinically healthy pigs at slaughter age (Chapter 5) 
(4) to investigate whether the presence of antimicrobial resistant Escherichia coli in sows and the 
administration of antimicrobials to sows and piglets during farrowing influenced the antimicrobial 
resistance in fecal commensal E. coli in sows and their offspring (Chapter 6)  
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ABSTRACT 
The monitoring of antimicrobial use is an essential step to control the selection and spread of antimicrobial 
resistance. Between January and October 2010 data on prophylactic and metaphylactic antimicrobial use 
were collected retrospectively on 50 closed or semi-closed pig herds. Ninety-three percent of the group 
treatments were prophylactic whereas only 7% were metaphylactic. The most frequently used antimicrobials 
orally applied at group level were colistin (30.7%), amoxicillin (30.0%), trimethoprim-sulfonamides (13.1%), 
doxycycline (9.9%) and tylosin (8.1%). The most frequently applied injectable antimicrobials were 
tulathromycin (45.0%), long acting ceftiofur (40.1%) and long acting amoxicillin (8.4%). The treatment 
incidences (TI) based on the used daily dose pig (UDDpig
1 or the actually administered dose per day per kg 
pig of a drug) for all oral and injectable antimicrobial drugs was on average 200.7 per 1000 pigs at risk per 
day (min = 0, max = 699.0), while the TI based on the animal daily dose pig (ADDpig
2 or the national defined 
average maintenance dose per day per kg pig of a drug used for its main indication) was slightly higher 
(average = 235.8, min = 0, max = 1322.1). This indicates that in reality fewer pigs were treated with the same 
amount of antimicrobials than theoretically possible. Injectable products were generally overdosed (79.5%), 
whereas oral treatments were often underdosed (47.3%). In conclusion, this study shows that prophylactic 
group treatment was applied in 98% of the visited herds and often includes the use of critically important and 
broad-spectrum antimicrobials. In Belgium, the guidelines for prudent use of antimicrobials are not yet 
implemented.
                                                          
1
 UDDpig or Used Daily Dose is equal to UDDD, as proposed by the European Surveillance  of Veterinary Antimicrobial 
Consumption (ESVAC) (EMA, 2013) 
2
 ADDpig or Animal Daily Dose is equal to ADDD, as proposed by the European Surveillance  of Veterinary Antimicrobial 
Consumption (ESVAC) (EMA, 2013) 
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INTRODUCTION 
The use of antimicrobials in modern pig production is of essential importance in maintaining animal health 
(McEwen and Fedorka-Cray, 2002). Yet, under some circumstances, the risks associated with their use could 
negate their benefits (Collignon et al., 2009). The potential risks, consisting of the exposure to antimicrobial 
residues in food or environment (WHO, 2002; McEwen and Singer, 2006; Wei et al., 2011), and in particular 
the selection of antimicrobial resistance in both animal and human related bacteria, might compromise animal 
and human health (Bywater, 2004; Ungemach et al., 2006). The demonstrated contribution of antimicrobial 
use in livestock in the emergence of both methicillin-resistant Staphylococcus aureus (MRSA) and extended-
spectrum beta-lactamase producing Escherichia coli (ESBL) in production animals has increased the public 
health concern over the consumption of antimicrobials in livestock (van Duijkeren et al., 2008a; Graveland et 
al., 2010; Horton et al., 2011).  
Over the years, several measures have been taken to safeguard the efficacy of antimicrobial agents and to 
prevent the emergence of antimicrobial resistance. In 2005, the World Health Organization (WHO) developed 
criteria to rank antimicrobials according to their importance in human medicine, to help preserve the 
effectiveness of currently available antimicrobials (Collignon et al., 2009). Guidelines for the responsible and 
prudent use of antimicrobials in food-producing animals have been suggested by several institutions (Stöhr et 
al., 2000; BTK and ArgeVet, 2000; CODEX, 2005), intended to prevent or reduce the selection pressure that 
contributes to the spread of antimicrobial resistant bacteria in humans and animals. German guidelines 
recommend the prescription of antimicrobials to animals only for therapeutic or metaphylactic reasons and 
only after the identification and antimicrobial sensitivity testing of the causal pathogen (BTK and ArgeVet, 
2000). According to the WHO guidelines (Stöhr et al., 2000) the prophylactic use of antimicrobials in control 
programs has to be regularly assessed for effectiveness and whether use can be reduced or stopped.  
The most far reaching change up to now, in order to decrease the antimicrobial use was the total ban of 
antimicrobial growth promoters in the European Union (Bengtsson and Wierup, 2006; Aarestrup et al., 2010). 
Sweden was the first to discontinue growth promoter use in 1986 (Phillips, 2007). The use of the four final 
growth promoting antibiotics had ceased in the entire European Union by 2006.  
The appropriate assessment of the selection pressure exerted by the use of antimicrobial agents is a crucial 
first step in the control of emergence of antimicrobial resistance (Chauvin et al., 2002; McEwen and Fedorka-
Cray, 2002; Aarestrup, 2005). This requires detailed knowledge on the reasons for antimicrobial use, the 
treatment duration and administered dose as well as the accuracy of dosing (Catry et al., 2003; Regula et al., 
2009). Furthermore, monitoring antimicrobial use allows to evaluate the appropriateness of antimicrobial drug 
application according to the prudent use guidelines as established by several institutions (Stöhr et al., 2000; 
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Ungemach et al., 2006; Regula et al., 2009). Moreover, data on antimicrobial use also provide an insight into 
disease burden. Finally, interventions cannot be evaluated properly unless a standardized monitoring system 
can measure the relationship between exposure and outcome.  
In 2003–2004 a detailed study of the antimicrobial use in pig production in Belgium was performed 
(Timmerman et al., 2006). A relatively high level of group treatments was noted and a considerable amount of 
broad spectrum antibiotics used for prevention was highlighted. Since 2003, little new information was 
collected and it was therefore not known whether the appropriateness of use has improved or not in the last 
seven years.  
The purpose of this study was to collect and quantify herd-level data on the use of antimicrobial agents in 
Belgian pig herds and to assess the changes in consumption of antimicrobial drugs in 2010 and to compare 
the results to a similar study conducted in 2003. 
MATERIALS AND METHODS 
Selection of herds and data collection 
A list of 140 pig herds that fulfilled the selection criteria were randomly selected from the Belgian farm-animal 
identification and registration database (SANITEL, 2010). The sampling frame consisted of all farrow to finish 
herds that used a closed or semi-closed production system and held at least 150 sows and 600 fattening 
pigs. Only farrow to finish herds were selected since these allow to collect data on the antimicrobial use of the 
fattening pigs during their entire lifespan. The sample was stratified by province (n = 5), proportional to the 
number of pig herds per province. Random selection was performed using a computer-generated list 
(Toolbox, Cameron, 1999).  
All selected herds were contacted by telephone and the first 50 herds that were willing to cooperate in the 
study were visited between January and October 2010. The herds were visited when the oldest fattening pigs 
were less than 2 weeks before slaughter (average body weight at slaughter varied between 105 and 110 kg 
at the average age of 206 days). In this way, we aimed to assess the antimicrobial use during the entire 
lifespan of the fattening pigs. One hundred thirty-two herds were contacted by telephone to obtain 50 
cooperative herds (response rate of 38%). Of the non-responders, 30% (25/82) had stopped their activities, 
28% (23/82) were not interested and 28% (23/82) were unable to participate due to lack of time. Thirteen 
percent (11/82) of the non-responders claimed other reasons. The number of sows and fattening pigs present 
in the non-responding herds (on average 181 and 1046 respectively) was significantly (p < 0.05) lower than in 
the responding herds (on average 289 and 1420 respectively).  
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Despite the high number of non-responders, a sufficient number of responders was available for the different 
provinces in order to fulfill the number of herds pro-posed after stratification. The herds were located in the 5 
different provinces of Flanders. 94% (47 of 50 herds) of the selected herds lay in the most dense pig areas of 
Belgium (West-, East-Flanders and Antwerp with 0.9 herds/km2, 0.3 herds/km2 and 0.2 herds/km2 
respectively). Three herds were located in the less dense regions of Limburg and Flemish-Brabant (0.1 
herds/km2 and 0.1 herds/km2 respectively). No herds from the southern part of Belgium were included since 
90% of the Belgian pig production is located in Flanders and the remaining herds (10%) located in Wallonia 
are mainly fattening sites that were not within the selection criteria for this study.  
Quantitative and qualitative data on group-level antimicrobial use in the sampled herds were collected by 
means of a questionnaire during a face-to-face on site interview with the farmer. All the interviews were taken 
by the same interviewer (first author) in order to avoid different interpretation of the answers provided by the 
farmer. The questions aimed to collect retrospective data on the antimicrobial group treatments applied 
between birth and time of the herd visit for the oldest group of fattening pigs present (within two weeks of 
slaughter). A group treatment was defined as each prophylactic or metaphylactic administration of 
antimicrobials to all the pigs of the same production group. Prophylactic use of antimicrobials was defined as 
treatment of healthy pigs to prevent disease from occurring, whereas metaphylactic use was defined as 
treatment of clinically healthy pigs belonging to the same group as animals that showed clinical symptoms of 
disease (Aarestrup, 2005). For each group treatment, following data were gathered: product name, indication, 
duration of therapy (in days), dose, administration route (feed, water or by injection (intramuscular)), age of 
the treated animals (in days) and body weight at time of treatment. To check for completeness, prescription 
documents or order forms were consulted if available. This was only possible for 10% of the herds.  
Indications for treatment were categorized by the interviewer based on the symptoms described by the farmer 
prior to the administration of antimicrobials. 
Quantification of drug consumption 
Antimicrobial drug consumption was quantified as treatment incidences (TI) based on the animal daily dose 
pig (ADDpig) and the used daily dose pig (UDDpig). The ADDpig is the national defined average maintenance 
dose per day per kg pig of a drug used for its main indication (Jensen et al., 2004). Values of the ADDpig 
were based on the dose recommendations in the Belgian Compendium for Veterinary Medicines and on the 
drug’s instruction leaflet. The UDDpig is defined as the actually administered dose per day per kg pig of a 
drug. In order to calculate the UDDpig, an estimate of the body weight at time of treatment was made. The 
average body weight (bw) between birth and the end of the nursery period (at 10 weeks) was standardized 
over the different herds using a standard growth table for a given age of the pigs (1.5 kg bw at birth and 6.1 
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kg bw at weaning age of 4 weeks). In order to estimate the body weight between the start of the fattening 
period and slaughter time, the average daily weight gain was consulted for the individual herd.  
The treatment incidence is defined as the number of pigs per 1000 that is treated daily with one ADDpig or 
UDDpig. The TIADDpig and TIUDDpig were calculated based on the acquired data, according to the method 
described by Timmerman et al. (2006). The following formula was applied: 
 
The number of days at risk was set as the total lifetime of slaughter pigs. 
A distribution (minimum, percentiles, maximum) of the treatment incidences was used because the data were 
not fully normally distributed (Table 1). The proportional TIADDpig and TIUDDpig for each individual antimicrobial 
drug was calculated by dividing the TIADDpig and TIUDDpig of each individual antimicrobial by the total TIADDpig 
and TIUDDpig for injectable and oral administrations, respectively (Timmerman et al., 2006). The UDDpig/ADDpig 
ratio of each antimicrobial drug gives an idea of the correctness of dosing. A variation of 0.2 under or above 1 
(=theoretically correctly dosed) was considered as within an acceptable range (0.8–1.2) of correct dosing 
(Timmerman et al., 2006). 
Data analysis 
Comparison of herd characteristics of responding and non-responding was performed by means of Student’s 
t-test. 
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RESULTS 
Prophylactic antimicrobial group treatments were responsible for 93% of all group treatments. Metaphylactic 
treatments constituted only 7% of all group treatments. In only one herd, no antimicrobials at group level were 
used. The forty-nine other herds applied at least one group-level treatment between birth and the time of the 
herd visit. Fig. 1 represents the distribution per herd of average treatment incidences based on either the 
ADDpig or the UDDpig for all group treatments.  
 
Figure 1. Distribution per herd of average treatment incidences based on ADDpig (TIADDpig) and UDDpig 
(TIUDDpig) for all group treatments in Belgian closed and semi-closed pig herds (between birth and two weeks 
within slaughter), for 2010. 
 
The distribution (minimum, percentiles, maximum) of the TIADDpig and TIUDDpig for the different oral and 
injectable antimicrobial agents as well as their relative importance, expressed as the proportional TIADDpig and 
TIUDDpig, are presented in Table 1. Penicillins were the most frequently used antimicrobial class (proportional 
TIUDDpig equals 27.6%), mainly due to the frequent use of amoxicillin both as injectable and oral administration, 
together with the less frequently used injectable penicillin and ampicillin. Polymyxins follow very closely with a 
frequency of 27.0%. Antimicrobial classes with a moderate rela-tive importance are the 
macrolides/lincosamides (17.7%), the trimethoprim-sulfonamides (11.5%) and tetracyclines (10.0%). 
Cephalosporins represent 5.3% of the total use and aminoglycosides (0.7%), phenicols (<0.1%) and 
quinolones (<0.1%) are less frequently used.  
During 47.7% of the time, animals were administered antimicrobials belonging to the WHO critically important 
list. The 3rd and 4th generation cephalosporins ceftiofur and cefquinome were used in 48% of the visited 
herds. Tulathromycin, a long acting 15-ring macrolide, was administered in 29% of the visited herds, mostly in 
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combination with iron mineral supplements that are given to prevent iron deficiency and anemia in newborn 
piglets.  
The average TIADDpig for all oral and injectable antimicrobial drugs was 235.8. In reality fewer animals were 
treated, as the TIUDDpig was 200.7. Animals were more often exposed to oral antimicrobial therapy (TIADDpig, 
oral = 183.5 and TIUDDpig, oral = 176.5) than injectable administrations (TIADDpig, injectable = 52.3 and TIUDDpig, 
injectable = 24.2). Discrepancies between TIUDD and TIADD are the result of incorrect dosing. On average, 
antimicrobials were mostly overdosed, since with the same amount of antimicrobials fewer animals were 
treated than based on the theoretically TIADDpig (TIUDDpig < TIADDpig).  
Injectable antimicrobials were mostly overdosed (79.5% overdosed, 8.2% correctly dosed, 12.3% underdosed) 
whereas oral administrations mostly were underdosed (47.3% underdosed, 23.3% correctly dosed, 29.4% 
over-dosed). The two most often oral administered antimicrobials, colistin and amoxicillin were underdosed in 
53% and 43% of the cases, respectively, whereas injectable amoxicillin was always overdosed. Tulathromycin 
was under-, correctly and overdosed in an equal number of treatment occasions. Ceftiofur was overdosed in 
88% of the administrations and cefquinome was always overdosed. 
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Table 1. Distribution of the oral and injectable drugs and the proportional TIADDpig or TIUDDpig administered as group treatments to fattening pigs between birth and slaughter 
age, in 50 Belgian closed or semi-closed pig herds expressed as treatment incidence per 1000 pigs at risk per day and based on animal daily doses or used daily doses 
(ADDpig or UDDpig/1000 pigs at risk/day). Antimicrobials are classified according to their importance in human medicine (WHO, 2007). Class I, critically important 
antimicrobials; Class II, highly important antimicrobials; Class III, important antimicrobials. 
Class according 
to importance 
in human 
medicine 
Active substance 
 
TIADDpig
a 
  
TIUDDpig
a 
 
Proportional 
TIADDpig % 
 
Proportional 
TIUDDpig % 
 
 Oral Min 
25th 
PCTb 
50th  
PCT 
75th  
PCT 
Max Min 25th  PCT 
50th  
PCT 
75th  
PCT 
Max   
 
I 
Amoxicillin 0 0 0 57.7 185.2 0 0 0 72.8 203.9 24.9 30.0 
Tylosin 0 0 0 0 197.1 0 0 0 0 305.8 8.5 8.1 
Oxytetracycline 0 0 0 0 4.9 0 0 0 0 135.9 0.1 1.5 
Tilmicosin 0 0 0 0 45.4 0 0 0 0 53.4 0.7 1.0 
 
 
II 
Colistin 0 0 14.4 52.5 532.2 0 0 41.3 101.9 203.9 32.3 30.7 
Trimethoprim-
sulfadiazine 
0 0 0 0 444.1 0 0 0 0 184.5 17.0 13.1 
Doxycycline 0 0 0 0 523.4 0 0 0 0 194.2 12.6 9.9 
Spectinomycin 0 0 0 0 55.4 0 0 0 0 68.0 0.6 0.8 
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a TIADDpig, treatment incidence based on ADDpig; TIUDDpig, treatment incidence based on UDDpig 
b PCT, percentile 
c LA, long acting
Lincomycin-
spectinomycin 
0 0 0 0 46.1 0 0 0 0 126.2 0.6 3.3 
III Lincomycin 0 0 0 0 143.6 0 0 0 0 68.0 2.7 1.6 
 Injectable             
 
 
 
I 
 
 
 
 
Tulathromycin 0 0 0 12.9 76.1 0 0 0 34 68.0 22.4 45.0 
Ceftiofur LAc 0 0 0 58.5 135.1 0 0 0 24.3 48.5 57.2 40.1 
Amoxicillin LAc 0 0 0 9.5 51 0 0 0 4.9 14.6 11.1 8.4 
Ceftiofur 0 0 0 0 27 0 0 0 0 4.9 2.9 2.5 
Cefquinome 0 0 0 0 18.7 0 0 0 0 9.7 1.0 1.2 
Procaïne-
benzylpenicillin 
0 0 0 0 46.2 0 0 0 0 4.9 4.0 1.2 
Ampicillin LAc 0 0 0 0 12.9 0 0 0 0 4.9 0.8 0.8 
Enrofloxacin 0 0 0 0 6.4 0 0 0 0 4.9 0.2 0.4 
II Florfenicol 0 0.2   8.7 0 0   4.9 0.4 0.4 
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Fig. 2 shows the distribution of the oral and injectable group treatments for the different antimicrobial classes 
used during the four production stages. These can be defined as the farrowing period (from birth until 
weaning between 21 and 28 days of age), the nursery period (from weaning age until 70 days of age), the 
grower period (from 70 until 126 days of age) and the finisher period (from 126 days of age until slaughter). 
Of all 206 group treatments, 90% (n = 186) was administered between birth and 10 weeks of age (farrowing 
and nursery period). Only 20% of all injectable and oral group treatments were administered during the 
fattening period (grower and finisher period).  
 
Figure 2. Distribution of oral and injectable group treatments for the different antimicrobial classes 
administered to fattening pigs for the different stages of production in 50 Belgian pig herds in 2010. IM, 
intramuscular (injectable group treatments); oral, water and feed antimicrobial medication; farrowing, from birth 
until weaning between 21 and 28 days of age; nursery, from weaning age until 70 days of age; grower, from 
70 until 126 days of age; finisher, from 126 days of age until slaughter; n, total number of injectable and oral 
group treatments for all used antimicrobial classes per unit on 50 pig herds (n total = 206); LS, lincomycine-
spectinomycine; TMS, trimethoprim/sulfadiazine. 
 
 
 NURSERY n=118 
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Results of the indications of treatment and the administered antimicrobial classes are shown in Table 2. 
Prophylactic group treatments were mainly applied shortly after birth, around castration and in prevention of 
piglet diarrhea during the farrowing period. Cephalosporins and broad-spectrum penicillins were the most 
frequently administered antimicrobials for these indications with 44% and 9.3% of the injectable administered 
treatments, respectively. Tulathromycin was administered in 22% of the injectable administrations to prevent 
suckling piglets from coughing and sneezing as main indication. Group injection with enrofloxacin and 
florfenicol after birth was recorded in one herd. In this study, the main indication for oral treatment with colistin 
was post-weaning E. coli infections, whereas amoxicillin was mainly administered as a preventive measure 
against streptococcal infections. Respiratory disease was mainly prevented with doxycycline and trimethoprim-
sulfadiazine followed by tylosin and tilmicosin.  
Table 2. Antimicrobial classes orally and injectable administered as group treatments to fattening pigs 
between birth and slaughter age, in 50 Belgian closed or semi-closed pig herds per age category for different 
indications. 
FARROWINGa (n= 68) NURSERYb (n= 118) 
Indication 
Antimicrobial class 
Number of treatments n 
% of used 
class per 
age group 
Indication 
Antimicrobial class 
Number of treatments n 
% of used 
class per 
age group 
Birth 
Cephalosporins 
13 
19.1 
Coughing 
TMSe 
8 
6.8 
Broad-spectrum penicillins 
11 
16.2 
Macrolides 
6 
5.1 
Fluoroquinolones 
1 
1.5 
Tetracyclines 
5 
4.3 
Castration 
Cephalosporins 
13 
19.1 
Diarrheae 
Polymyxins 
38 
32.5 
Broad-spectrum penicillins 
9 
13.2 
Broad-spectrum penicillins 
5 
4.3 
Macrolides 
5 
7.4 
Lincosamides 
3 
2.6 
Coughing 
Macrolides 
7 
10.3 
TMSe 
2 
1.7 
LSf 
2 
1.7 
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TMSe 
1 
1.5 
Macrolides 
1 
0.9 
Diarrheae 
Cephalosporins 
1 
1.5 
Cephalosporins 
1 
0.9 
Lincosamides 
2 
1.7 
Polymyxins 
1 
1.5 
Aminoglycosides 
1 
0.9 
Streptococcal 
infections 
Broad-spectrum penicillins 
4 
5.9 
Oedema 
disease 
(Escherichia 
coli) 
Polymyxins 
2 
1.7 
Macrolides 
1 
1.5 
Broad-spectrum penicillins 
1 
0.9 
Tooth cutting 
Cephalosporins 
1 
1.5 ARg 
Tetracyclines 
3 
2.6 
Broad-spectrum penicillins 
1 
0.9 
   
Streptococcal 
infections 
Broad-spectrum penicillins 
32 
27.4 
Polymyxins 
3 
2.6 
TMSa 
2 
1.7 
GROWERc (n= 17) FINISHERd (n= 3) 
Indication 
Antimicrobial class 
Number of treatments n 
% of used 
class per 
age group 
Indication 
Antimicrobial class 
Number of treatments n 
% of used 
class per 
age group 
Coughing  
Tetracyclines 
6 
35.3 
APPh 
TMSe 
1 
 
33.3 
 
TMSe 
4 
23.5 
Phenicols 
1 
33.3 Macrolides 
4 
23.5 
Diarrheae  Polymyxins 5.9 Coughing Macrolides 33.3 
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1 1 
APPh 
Tetracyclines 
1 
5.9 
Streptococcal 
infections 
Broad-spectrum penicillins 
1 
5.9 
 
a Farrowing, from birth until weaning between 21 and 28 days of age.  
b Nursery, from weaning age until 70 days of age. 
c Grower, from 70 until 126 days of age.  
d Finisher, from 126 days of age until slaughter.  
e TMS, trimethoprim-sulfadiazine.  
f LS, lincomycin-spectinomycin.  
g AR, Atrophic Rhinitis.  
h APP, Actinobacillus pleuropneumoniae. 
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DISCUSSION 
Methodology 
In intensive livestock production such as pig, veal and poultry production, antimicrobials are often 
administered on a regular basis by the farmer himself upon advice and receipt of the prescription documents 
by the herd veterinarian (Dunlop et al., 1998). Therefore, pig farmers play a crucial role in the administration 
of antimicrobials to pigs. As a result, valid data on the actual dose and treatment duration of antimicrobial 
group treatment can be obtained directly from the farmer (Chauvin et al., 2008). 
Yet, the collection of retrospective data based on an interview with the farmer may be subject to recall and 
intervention bias. Recall errors may occur when a farmer’s answers were affected by a lack of memory 
(Vrijheid et al., 2006). In this study, systematic external validation, such as prescription documents or order 
forms, were not readily available. However, in intensive pig production, group-level use of antimicrobials is the 
most important way of antimicrobial administration (Schwarz et al., 2001; Regula et al., 2009). Group level-
treatments are mostly standardized treatments, and therefore well known by the farmer and so less subject to 
recall bias. This methodology would not work for the collection of data on incidental therapeutic use of 
antimicrobials since these are likely very prone to recall biases. This is the primary reason why in this study 
data collection was restricted to (standardized) group level-treatments. If accidentally recall bias occurred, this 
most likely led to an underestimation of the group level-antimicrobial use. Intervention bias could have 
occurred if a farmer had elected to deliberately misstate treatment data. This was avoided as much as 
possible by guaranteeing confidentiality of the individual herd data. Besides, observed differences with the 
results from 2003 are likely real as the authors from 2003 had similar challenges to confront. 
A different response rate was found between 2003 and 2010 (60% and 38% respondents in 2003 and 2010 
respectively) (Timmerman et al., 2006). The higher rate of non-responders can mainly be attributed to the 
higher number of farmers which had stopped their activities since the latest update of the SANITEL database 
(25 farmers had stopped their activities in 2010 whereas only 3 in 2003). This is in agreement with a 
decreasing number of pig herds found in the national agricultural census in Belgium between 2009 and 2010 
(Landbouwtelling, 2009). A current disadvantageous economic situation could be a reason for the higher 
number of farmers which have stopped their activities. Thus this higher none response rate is not seen as an 
increased resistance of the farmers to cooperate but rather as a result of the not fully updated data in the I&R 
database. Therefore, this lower response rate is believed not to influence an adequate comparison of the 
results between 2003 and 2010. Moreover, since data collection was performed in exactly the same way, it 
can be assumed that the biases are similar. Therefore, observed differences are likely to be real. 
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In interpreting antimicrobial use data, the unit of measurement is crucial. The use of treatment incidences (TI) 
based on the Defined Daily Dose (DDD) and the animal daily dose (ADD) as described earlier for human 
(WHO, 2003) and veterinarian antimicrobial use (Jensen et al., 2004; Timmerman et al., 2006; Persoons et 
al., 2012) is an appropriate way to express the selection pressure exerted by the administered antimicrobial 
drugs for time at risk and average weight of the pigs at time of treatment. 
The repeated performance of surveillance studies are restricted in both number of times and cooperating 
herds. As a result, well established surveillance programs using sources such as feed mills, pharmacies and 
veterinarians are imperative. Yet, only few countries have well established surveillance programs (DANMAP, 
MARAN). Recently, in Belgium, the first national antimicrobial consumption report in food animals has been 
published (BelVet-Sac, 2011). The reported data consist of all veterinary antimicrobials sold to a veterinarian 
or pharmacist in Belgium for the years 2007, 2008 and 2009. Yet, the obtained results in the BelVet-Sac 
report are still crude and do not give any details on animal species, indications, correctness of dosages, 
individual herd usages, number of treatments attributed to an animal during its life span etc. In this context 
the collection of more detailed and accurate animal species-level data implies the collection of data directly on 
the end user level. Countries such as Denmark, have organized structures which facilitates the monitoring of 
antimicrobial use patterns at the individual herd level (Vieira et al., 2010). In Belgium, plans to develop a 
comparable system are currently studied, however it will probably take some more years before this system 
will be fully operational. In this understanding the current study delivered very valuable information on species 
and herd specific data. 
Antimicrobial drug consumption 
In 2003, six out of the 50 herds (12%) did not administer antimicrobials in group (Timmerman et al., 2006). In 
the present study, antimicrobials were not administered in group in only one herd (2%) (Fig. 1). As in 2003 
(Timmerman et al., 2006) large between herd variation exists which fattening pigs were treated (Fig. 1). 
These differences may be related to herd differences in disease incidence, management, husbandry, 
biosecurity as well as differences in farmer and veterinarian attitudes (Hybschmann et al., 2011). More 
thorough studies are needed to identify the influencing factors. 
The average TIADDpig and TIUDDpig in 2010 (235.8 and 200.7 respectively) were higher than those in 2003 
(178.1 and 170.3 respectively). The higher group-level use is reflected in an increased number of prophylactic 
group treatments whereas a drastic decrease of the portion of metaphylactic group treatments (7%) to the 
total number of group treatments (prophylactic and metaphylactic) is observed since 2003 (44% metaphylactic 
and 56% prophylactic) (Timmerman et al., 2006). The high number of prophylactic group treatments is not in 
agreement with the “Good Agriculture Practices” (GAP) formulated by the Food and Agriculture Organization 
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of the United Nations (FAO, 2003). GAP refer to a minimization of the non-therapeutic use of antimicrobials 
and highlight a reduction of infection and disease in terms of prevention. Yet, they refer to prevention as in 
vaccination programs, proper management and housing, good hygiene standards in housing by proper 
cleaning and disinfection, etc. Moreover, appropriate veterinary advice in order to avoid disease and health 
problems is set as an example in both the GAP principles and the Good Veterinary Principles (GVP) (FVE, 
2002). 
Taking into account the suggested guidelines by several institutions on restricted therapeutic or metaphylactic 
treatments, identifying the causal pathogen and appropriate dosing, it can be stated based on the present 
study that the guidelines for prudent use are currently not implemented in pig production in Belgium. In this 
study 93% of the group treatments were for preventive reasons and antimicrobials administered for these 
reasons often lack a precise diagnosis. Although there is no well-founded justification for the repeated use of 
prophylactic group treatments. Farmers often consider the prophylactic use of antimicrobials, in spite of the 
associated high cost, as a necessity to achieve less disease, lower mortality and better production results. 
Moreover pig production is rapidly evolving into a highly organized production system where standardized 
management procedures are used in order to prevent production losses. In this type of highly organized 
production, standard prophylactic therapies are easier and less labor intensive to implement than treatment of 
clinically diseased animals and after losses have occurred. Selected herds were on average larger than those 
in 2003 (216 and 289 sows in 2003 and 2010 respectively, 1250 and 1420 fattening pigs in 2003 and 2010 
respectively). A yearly increase in the number of pigs per herd is confirmed by the national agricultural census 
in Belgium evaluating changes in herd size (Landbouwtelling, 2009). It could be assumed that a larger herd 
size includes a greater risk of transmission of pathogens within herds resulting into a higher antimicrobial use. 
Yet, Danish and Dutch studies reported higher TI rates being associated with smaller herds (Vieira et al., 
2010; Poortwachter, 2010). On the other hand, compared with small herds, large herds might more frequently 
adopt management and housing practices decreasing this risk (Gardner et al., 2002). Therefore in Belgium, a 
non-adapted herd management for an increased number of pigs per herd could be a possible reason for an 
increased antimicrobial group-level use. Pharmaceutical companies serve more and more as advisers in 
disease management, linked to the provision of antimicrobial agents and vaccines. A recent study showed 
that in Belgium, on average, 43% of the income of pig veterinarians results from the selling of medicines, 
including vaccines, antimicrobials and other drugs (Maes et al., 2010). New active and more potent 
antimicrobial substances, like long acting critically important compounds (tulathromycin, crystallic ceftiofur), 
offer advantages to the farmer and as a result are easily introduced. These new substances could be another 
reason for an increased antimicrobial group-level use in food producing animals. Although most of the 
antimicrobials used in 2003, are currently still in use, a substantial shift in the relative importance between the 
commonly used antimicrobials and route of administration was seen. In particular the oral group treatments 
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with doxycycline and potentiated sulfonamides (trimethoprim-sulfonamides) appeared to have been replaced 
by long acting injectable group treatments. The introduction of ceftiofur in a long acting formulation since 2003 
could explain the current higher use, as farmers see practical advantage in a single administration instead of 
repeated administration of short acting formulations. The contribution of 3rd and 4th generation 
cephalosporins to the total group medication increased from 0.1% in 2003 to 5.3% in 2010. The same is seen 
for injectable amoxicillin and ampicillin. In 2003, 1.8% of all injectable amoxicillin and ampicillin was 
administered as a short acting formulation in contrast to 2010, where all use of these compounds was in long 
acting form. Similarly, the overall use of macrolides (tulathromycin, tylosin and tilmicosin) has increased 
(proportional TIUDDpig equals 5.5% and 13.4% respectively in 2003 and 2010), in particular due to the newly 
introduced long acting tulathromycin in 2004. A slight decrease in use was seen for tilmicosin whereas the 
use of tylosin, having the same spectrum as tilmicosin (Prescott, 2000), has increased. Iron supplementation 
shortly after birth is often performed in combination with tulathromycin in a single injection, mainly because of 
reduced labor. The use of fluoroquinolones was lower compared to 2003 (proportional TIUDDpig to all injectable 
antimicrobials equals 6.5% and 0.4% respectively in 2003 and 2010). The high cost of both enrofloxacin and 
marbofloxacine could interfere with the choice for this large spectrum antimicrobial. 
An indication of the appropriateness of dosing of individual antimicrobials was obtained by evaluating the 
distribution of the UDD/ADD ratios (Timmerman et al., 2006). In accordance with results from 2003, injectable 
antimicrobials were generally overdosed (UDDpig/ADDpig > 1.2), whereas orally administered group treatments 
were generally underdosed (UDDpig/ADDpig < 0.8). Sub-therapeutic doses can lead to a lack of efficiency and 
in some cases, may increase antimicrobial resistance (Regula et al., 2009). The relation between dosing and 
the selection and spread of antimicrobial resistance has been studied very often (Drusano, 2003; Olofsson 
and Cars, 2007). No general conclusion can be drawn on the impact of different dosage regimens on 
resistance selection and spread as this is complicated by different resistance mechanisms and differences in 
results between in vitro and in vivo studies (Smith et al., 2003; Roberts et al., 2008). Yet, for mutational 
stepwise resistance, seen e.g. for the fluoroquinolones, the use of antibiotic concentrations within a certain 
range has been shown to favor isolates with higher MIC’s and to cause a considerable amplification of the 
resistant subpopulation (Tam et al., 2007). The finding that many of the administered doses differ from the 
recommended dose is consistent with a study in Switzerland on prescription patterns in veterinary medicine 
(Regula et al., 2009) and a study on antimicrobials described in pig feed in Germany (Ungemach et al., 
2006). Reasons for non-compliance of prescription doses could be: misevaluation of the bodyweight at 
moment of administration (Timmerman et al., 2006), intentional overdosing to aim at less disease or lack of 
precision of dosing. 
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Another guideline suggests the selection of an appropriate antimicrobial, based on defined lists of 
antimicrobials of first, second or third choice (van Duijkeren et al., 2008b) or based on Good Veterinary 
Practices (FVE, 2002). Both refer to the choice of an antimicrobial with a spectrum as narrow as possible and 
the use of critically important antimicrobials only in single animals for a limited number of strict indications 
when other antimicrobials would fail based on susceptibility testing. Largely used broad-spectrum 
antimicrobials recorded in this study were aminopenicillins, 3rd and 4th generation cephalosporins, 
tulathromycin, trimethoprim-sulfadiazine and doxycycline. Also critically important antimicrobials were 
extensively used (β-lactam antimicrobials, 3rd and 4th generation cephalosporins and macrolides). The WHO 
classification of critically important antimicrobials serves as a factor in guiding decisions regarding risk 
management strategies for antimicrobial use in food animals and agriculture (Collignon, 2009). The high 
number of antimicrobials classified as either critically or highly important for human proves that from now on, 
the reduction of use should be emphasized and be set as the major objective, prior to a well-considered 
choice of antimicrobial agent when use is required. 
The higher use of group treatments in suckling pigs and weaners compared to growers and finishers (Fig. 2) 
has also been reported in the other studies. The MARAN report (2009) published data assuming that 83% of 
antimicrobial treatments are administered to pigs younger than 74 days of age (age at beginning of the 
fattening unit). This higher use can be explained by the application of group treatment at critical time points 
and key intervals, such as castration and weaning. At these time points, it is often expected by the farmer that 
pigs will become diseased shortly after (Schwarz et al., 2001). Besides, most of the vaccines are 
administered to prevent pigs from getting ill during fattening period and less during the stressful farrowing and 
nursery periods. 
Although the use of antimicrobial growth promoting antibiotics is banned in Europe since 2006, the use of 
antimicrobials in food producing animals is continued under the pretext of treatment, control or prevention of 
infectious diseases but may still be driven by the hope of better production results. In order to ensure the 
efficiency of antimicrobials, any prophylactic use other than in very limited, clearly defined situations, should 
be phased out. Some European countries like Denmark, Sweden and the Netherlands (Nielsen et al., 2007; 
Cogliani et al., 2011) are pioneer in the prudent use of antimicrobials as they prohibited the prophylactic use 
of antimicrobials. 
These results clearly show that the need for clear information about correct dosing and a reduction of group-
level prophylactic antimicrobial use, stated as a conclusion on the results obtained in 2003, has not been 
answered ever since. Herd veterinarians, pharmaceutical companies, farmers and other stakeholders have a 
responsibility in the prudent use of antimicrobials in pig and other animal production and should be trained on 
the implementation of the guidelines for prudent antimicrobial use. 
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CONCLUSIONS 
The guidelines for prudent use of antimicrobials are not yet implemented in Belgium. An overall higher use of 
prophylactic antimicrobial group-level therapy was recorded in 2010 compared to 2003. This shift was marked 
by a partial yet substantial replacement of older, orally administered compounds by new injectable long acting 
products. This evolution warrants an assessment of antimicrobial resistance trends in commensal and 
pathogenic bacteria. Critically important antimicrobials to human and veterinarian medicine were used on a 
regular basis and 82% of the administered doses were incorrect, with large between herd variations.  
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ABSTRACT 
Streptococcus suis (S. suis) has often been reported as an important swine pathogen and is considered as a 
new emerging zoonotic agent. Consequently, it is important to be informed on its susceptibility to antimicrobial 
agents. In the current study, the Minimum Inhibitory Concentration (MIC) population distribution of nine 
antimicrobial agents has been determined for nasal S. suis strains, isolated from healthy pigs at the end of 
the fattening period from 50 closed or semiclosed pig herds. The aim of the study was to report resistance 
based on both clinical breakpoints (clinical resistance percentage) and epidemiological cut-off values (non-wild 
type percentage). Non-wild type percentages were high for tetracycline (98%), lincomycin (92%), tilmicosin 
(72%), erythromycin (70%), tylosin (66%), and low for florfenicol (0%) and enrofloxacin (0.3%). Clinical 
resistance percentages were high for tetracycline (95%), erythromycin (66%), tylosin (66%), and low for 
florfenicol (0.3%) and enrofloxacin (0.3%). For tiamulin, for which no clinical breakpoint is available, 57% of 
the isolates did not belong to the wild type population. Clinical resistance and non-wild type percentages 
differed substantially for penicillin. Only 1% of the tested S. suis strains was considered as clinically resistant, 
whereas 47% of the strains showed acquired resistance when epidemiological cut-off values were used. In 
conclusion, MIC values for penicillin are gradually increasing, compared to previous reports, although pigs 
infected with strains showing higher MICs may still respond to treatment with penicillin. The high rate of 
acquired resistance against tiamulin has not been reported before. Results from this study clearly demonstrate 
that the use of different interpretive 
criteria contributes to the extent of differences in reported antimicrobial resistance results. The early detection 
of small changes in the MIC population distribution of isolates, while clinical failure may not yet be observed, 
provides the opportunity to implement appropriate risk management steps. 
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INTRODUCTION 
Streptococcus suis (S. suis) is an important swine pathogen affecting pigs of different ages, although 
susceptibility to the  disease decreases with age after weaning (Amass et al., 1996; Staats et al., 1997). It is 
known to cause meningitis, arthritis, septicemia, endocarditis, polyserositis, bronchopneumonia, and abortion, 
(Higgins and Gottschalk, 1990; Amass et al., 1996; Staats et al., 1997) but can also be found in the upper 
respiratory, alimentary, and urogenital tract of healthy pigs (Amass et al., 1996; Han et al., 2001). S. suis has 
also been implicated in disease in humans, especially among people in close contact with swine and pork 
(Ma et al., 2008; Gottschalk et al., 2010). Moreover, S. suis has recently been reported as an emerging 
zoonotic pathogen evidenced by a few large-scale outbreaks of severe S. suis epidemics in Asia (Ye et al., 
2006; Yu et al., 2006; Mai et al., 2008). The most frequently applied treatment for pigs with clinical signs of S. 
suis infection is feed medication with antimicrobials, particularly, broad-spectrum penicillins (Gottschalk et al., 
1991; Timmerman et al., 2006; Callens et al., 2012). Currently, no effective commercial vaccine is available. 
Prevention is based on the optimization of management, autogenous vaccines, and primarily the strategic 
administration of antimicrobial agents at periods with the highest risk, for example, weaning (Haesebrouck et 
al., 2004; Wisselink et al., 2006). High levels of resistance to tetracyclines (Kataoka et al., 2000; Martel et al., 
2001), macrolides, and lincosamides (Martel et al., 2001) have been reported. 
Different methods are often applied for interpreting the results of antimicrobial susceptibility testing. In most 
studies, clinical breakpoints have been used resulting in the categorization of the tested isolates in 
susceptible, intermediate, or resistant against the tested antimicrobials (clinical resistance) (CLSI, 2011). The 
use of clinical interpretive criteria may be sufficient from the point of view of the clinician as it predicts the 
antimicrobial effect of the drug in the patient at the prescribed dose (Dudley and Ambrose, 2000; Simjee et 
al., 2008; Turnidge and Paterson, 2008). However, these breakpoints can vary over time and between 
countries (Kahlmeter et al., 2003), making comparisons between different studies and evolution of 
antimicrobial resistance patterns in S. suis over time hard. Moreover, this categorization precludes the 
detection of small changes in the population distribution that may indicate the acquisition of new resistance 
mechanisms of which the clinical implications are not yet clear, as has been noted for fluoroquinolones and 
Gram-negative bacteria (de Jong et al., 2012). For such changes to be noticed, epidemiological cut-off values 
are very valuable. These cut-off values are based on the differentiation between the wild type and the non-
wild type population (Kahlmeter et al., 2003; EUCAST, 2015; CLSI, 2011). They enable to detect strains with 
a decreased susceptibility, which are isolates with Minimum Inhibitory Concentrations (MICs) that are non-wild 
type, but less than or equal to the susceptible clinical breakpoint (CLSI, 2011; Simjee et al, 2008). However, 
only few studies report resistance results as MIC population distributions, necessary for setting the 
epidemiological cut-off values. Finally, S. suis from diseased animals have been tested more often (Salmon et 
al., 1995; Marie et al., 2002; Wisselink et al., 2006) than S. suis from clinically healthy animals. This could 
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lead to biased results, since isolates from diseased animals may represent a different population (Allgaier et 
al., 2001) and since they have often been exposed to an antimicrobial selection pressure shortly before 
sampling (Silley et al., 2011). 
This study aimed to report the level of resistance in S. suis isolates from clinically healthy fattening pigs at 
slaughter age. Resistance percentages were calculated based on both clinical breakpoints and 
epidemiological cut-off values. 
MATERIALS AND METHODS 
Study design, sample, and data collection 
For the isolation of S. suis, nasal swabs were taken from clinically healthy fattening pigs from 50 different pig 
herds in Belgium. A list of 140 pig herds that fulfilled the selection criteria were randomly selected from the 
Belgian farm-animal identification and registration database (Sanitel-Pigs, 2005). The sampling frame 
consisted of all farrow-to-finish herds that used a closed or semi-closed production system and held at least 
150 sows and 600 fattening pigs. The sample was stratified by province (n = 5), proportional to the number of 
pig herds per province. A random selection was performed using a computer-generated list (Cameron, 1999). 
All selected herds were contacted by telephone and the first 50 herds that were willing to cooperate in the 
study were visited between January and October 2010.  
The pigs were sampled ~ 2 weeks before the slaughter age. The average age of the pigs was 182 days 
(minimum 156 days; maximum 220 days). In each herd, 20 fattening pigs were randomly sampled.  
Bacterial isolation 
Swabs were plated on Columbia agar plates with 5% defibrinated sheep blood, supplemented with colistin 
and nalidixic acid (CNA; Oxoid, Basingstoke, United Kingdom) within 24 hr after collection and cultured at 
35°C in a 5% CO2-enriched atmosphere for 24 hr. Colonies showing alpha-hemolysis were purified for further 
identification (Aarestrup et al., 1998; Lun et al., 2007). Isolates showing a positive amylase reaction, a 
negative catalase reaction, and a negative Vogues-Proskauer test were considered to be S. suis (Higgins and 
Gottschalk, 1990; Aarestrup et al., 1998; Han et al., 2001). The identity of 28 randomly chosen S. suis 
isolates was confirmed by sequencing the 16s rRNA gene as described before (Baele et al., 2003). S. suis 
isolates were stored at – 80°C until antimicrobial susceptibility testing. 
Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing was performed on all isolates using the agar dilution method according to 
the standardized methods described by the Clinical and Laboratory Standards Institute (CLSI, 2013). Inocula 
were prepared suspending colonies in sterile 0.9% NaCl to a turbidity equivalent of 0.5 Mac Farland and 
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diluted 1/10. Using a Steers inoculum applicator, the suspensions were inoculated on the Muller-Hinton II agar 
(BBL; Cockeysville, MD) supplemented with 5% sheep blood and containing doubling concentrations, ranging 
from 0.03 µg/ml to 128 µg/ml of the following antimicrobial agents: enrofloxacin, erythromycin, florfenicol, 
lincomycin, penicillin, tetracycline, tiamulin, tilmicosin, and tylosin. The plates were incubated at 35°C in 5% 
CO2-enriched atmosphere for 24 hr. The MIC was defined as the lowest concentration producing no visible 
growth. Staphylococcus aureus ATCC_29213, Enterococcus faecalis ATCC_29212, and Streptococcus 
pneumoniae ATCC_49619 were included as quality control (QC) strains. Interpretation of the MIC values was 
done using both clinical breakpoints (CLSI, 2013) and epidemiological interpretative criteria (Turnidge and 
Paterson, 2007). 
For lincomycin, tiamulin, tilmicosin, and tylosin, no clinical breakpoint for S. suis is available (CLSI, 2013). For 
florfenicol and tetracycline, the clinical breakpoint for swine respiratory disease caused by S. suis was used 
(CLSI, 2013). For erythromycin and penicillin, clinical breakpoints were used, as described by the Clinical and 
Laboratory Standards Institute (CLSI) for veterinary pathogens, but which were based on CLSI breakpoints for 
human Streptococci (CLSI, 2013). Since no epidemiological cut-off values are available for S. suis from the 
European Committee on Antimicrobial Susceptibility (EUCAST, 2015), acquired resistance was assumed 
when MIC values showed a bimodal or multimodal distribution or tailing (Butaye et al., 2003; Dung et al., 
2008). Isolates in the higher range of MICs were considered not to belong to the wild type population. For 
antimicrobials for which no clear bimodal distribution was present, ECV were used available from a previous 
study carried out in the same laboratory using identical test conditions. This was done for the following 
antimicrobials: penicillin, tilmicosin, erythromycin, lincomycin, tiamulin, and tetracycline (Martel et al., 2001). 
The MIC50 and MIC90 were calculated and presented the lowest MIC at which at least 50% and 90% of the 
isolates in a test population are inhibited, respectively. 
RESULTS 
In the current study, S. suis was recovered in 33.2% of all nasal samples (332/1000). The number of isolates 
obtained per herd was normally distributed, with on average, 6.6 isolates recovered from one herd (minimum 
number of isolates per herd equaled 5 isolates; maximum equaled 8 isolates; median equaled 7 isolates). The 
MIC values of 10 antimicrobial agents were determined for 332 S. suis isolates. Yet, a number of S. suis 
isolates showed poor growth under the prescribed conditions, as has been observed before (Wisselink et al., 
2006) and their MIC could not be determined. Therefore, in this report, MIC data have been reported for a 
variable number of S. suis isolates (Table 1). The MIC values for QC strains were within the acceptable QC 
ranges when available (CLSI, 2013). For lincomycin, QC strains S. aureus ATCC_29213 and E. faecalis 
ATCC_29212 had similar MIC values as described earlier (Salmon et al., 1995; Marie et al., 2002).  
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In table 1, the MIC distribution for all tested S. suis isolates is shown. A bimodal distribution was seen for 
enrofloxacin. A monomodal distribution was seen for florfenicol. For penicillin, a distribution with tailing toward 
higher MIC values was noted. No clear bimodal distribution was seen for erythromycin, lincomycin, tylosin, 
tilmicosin, tiamulin, and tetracycline. 
In table 2, the clinical breakpoints (CLSI, 2013) and the ECV for the different antimicrobials tested are shown. 
Based upon clinical breakpoints, percentage of susceptible, intermediate, and resistant S. suis strains are 
shown. Equally, based upon ECV, % of wild type and non-wild type strains are presented.  
No or very low percentages of clinical resistance were found against enrofloxacin (0.3%), florfenicol (0.3%), 
and penicillin (1%). High to very high-resistance percentages were observed against erythromycin (66%) and 
tetracycline (95%). 
Using the ECV, low percentages of non-wild type isolates were seen to enrofloxacin and florfenicol (0.3% and 
0%, respectively). Acquired resistance was observed for penicillin (percentage of non-wild type isolates equals 
47%), tiamulin (57%), erythromycin (70%), tylosin (66–67%), tetracycline (98%), tilmicosin (72%), and 
lincomycin (92%). 
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Table 1. Minimum Inhibitory Concentration (MIC) distribution for Streptococcus suis isolates obtained from clinically healthy fattening pigs on 50 closed or semi-closed pig 
herds.  
Antimicrobial agent 
   
Number of strains with MIC (μg/ml) 
  
Number of isolates tested 
 ≤0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128   
Erythromycin 24 40 33 8 6 8 7 16 22 9 7 2 8 136 326  
Lincomycin 2 0 3 6 3 9 24 11 10 3 7 7 7 214 306  
Tylosin 3 6 1 1 27 63 8 2 3 1 1 4 13 197 330  
Tilmicosin 6 0 0 1 2 13 15 20 9 15 9 14 10 174 288  
Tiamulin 3 1 5 9 12 25 57 30 10 16 33 34 43 54 332  
Tetracycline 0 0 4 2 4 5 9 6 19 40 115 112 14 0 330  
Penicillin 22 32 48 71 86 54 13 1 2 0 0 0 0 0 329  
Florfenicol 0 0 2 0 11 97 218 2 1 0 0 0 0 0 331  
Enrofloxacin 1 9 22 129 122 17 0 0 1 0 0 0 0 0 301  
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Table 2. Minimum Inhibitory Concentrations (MIC) clinical breakpoints (CBP) and epidemiological cut-off values (ECV) of 10 antimicrobial agents for Streptococcus suis 
isolates obtained from clinically healthy fattening pigs on 50 closed or semi-closed pig herds. The percentage of resistant (%R), intermediate (I%) and susceptible (%S) 
strains is provided based on clinical breakpoints.  
The percentage of wild type (WT) and non-wild type (non-WT) is provided based on epidemiological cut-off values.                           
Antimicrobial 
agent 
Epidemiological Interpretive 
Criteria 
Clinical Interpretive Criteria   
 ECV Wild typea 
Non-wild 
typeb 
CBPc %R %I %S MIC50
d MIC90
e 
  % % S I R      
Erythromycing 0.12 30 70 0.25 0.5 1 66 2 32 16 >128 
Lincomycinf, g 1 8 92 - - - - - - >128 >128 
Tylosinf 2-4 33-34 
66-67 
 
- - - - - - >128 >128 
Tilmicosinf, g 16 23 72 -  - - - - >128 >128 
Tiamulinf, g 4 43 57 - - - - - - 32 >128 
Tetracyclineg 0.25 2 98 0.5 1 2 95 2 3 64 128 
Penicilling 0.25 53 47 0.12 0.25-2 4 1 68 31 0.5 2 
Florfenicol 8 100 0 2 4 8 0.3 0.6 99.1 4 4 
Enrofloxacin 1 99.7 0.3 0.5 1 2 0.3 5.6 94 0.5 1 
a Wild type describes isolates with minimal inhibitory concentrations below the epidemiological cut-off value (WT ≤ X μg/ml)  
b Non-wild type describes isolates with minimal inhibitory concentrations above the epidemiological cut-off value (non-WT > X μg/ml)    
c Clinical breakpoints were obtained from Clinical and Laboratory Standards Institute standards (CLSI, 2011). S: Susceptible, I: Intermediate, R: Resistant (R ≥ Y μg/ml; Z 
μg/ml < I < Y μg/ml; S ≤ Z μg/ml) 
d, e MIC50 and MIC90 are the lowest MIC at which at least 50% and 90% of the isolates in a test population are inhibited in their growth 
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f For lincomycin, tiamulin, tilmicosin and tylosin, no clinical breakpoint is available (CLSI, 2012) 
g Epidemiological cut-off value was based on study from Martel et. al (2011) 
CLINICAL RESISTANCE AND DECREASED SUSCEPTIBILITY IN STREPTOCOCCUS SUIS CHAPTER 4 
 
122 
 
DISCUSSION 
The choice of the epidemiological cut-off value, based on the distinction between the wild type and the non-
wild type population within a bacterial population, should be fixed for one antimicrobial agent within a bacterial 
species, independent of time. Moreover, given that wild type MIC distributions of bacteria of human and 
animal origin coincide, the same epidemiological cut-off value can be used for monitoring resistance in 
humans and in different animals (Aarestrup et al., 2007). Yet, discrepancies between antimicrobial 
susceptibility test protocols may result in the establishment of a different epidemiological cut-off value between 
studies within one bacterial species for one antimicrobial agent (Butaye et al., 1998, Silley et al., 2001). 
Nevertheless, the preferred method for reporting MIC results is to present all data in a distribution table, 
containing the quantitative data (Watts and Lindeman, 2006) to allow the reader to interpret the data with 
changing interpretive criteria over time (clinically or epidemiologically).  
The high percentages of non-wild type S. suis isolates for erythromycin, lincomycin, tilmicosin, tylosin, and 
tetracycline are in accordance with other studies reporting percentages of non-wild type S. suis isolates for 
macrolides, lincosamides, and tetracyclines (Martel et al., 2001; Wisselink et al., 2006). Despite differences in 
interpretive criteria (clinical breakpoints or epidemiological cut-off values), susceptibility testing methods (disk 
diffusion, microdilution, and agar dilution), sampled animals (clinically healthy or diseased pigs, sows or 
fattening pigs), and geographical location, there seems to be a similarity concerning results on clinical 
resistance percentages, when available, and percentages of non-wild type S. suis isolates for those 
antimicrobials, which in some studies have been supported by the identification of genotypic resistance 
mechanisms (Martel et al., 2001; Princivalli et al., 2009). In the farms included in the current study, 
macrolides were frequently used during the farrowing and nursery period (Callens et al., 2012). Genes 
encoding cross resistance to macrolides, lincosamides, and streptogramin B are widespread among S. suis 
isolates (Martel et al., 2001). As a result, the administration of macrolides may select for resistance against 
these antimicrobials. Similarities between the current study results and others have equally been found for the 
low-resistance percentages against florfenicol (Wisselink et al., 2006) and enrofloxacin (Martel et al., 2001; 
Wisselink et al., 2006). 
For tiamulin, a high percentage of S. suis isolates did not belong to the wild type population, defined as 
having a MIC of ≤ 4 mg/ml, demonstrating acquired resistance in these isolates against this antibiotic. For 
tiamulin, no clinical breakpoints are available for S. suis and epidemiological cut-off values do not necessarily 
predict how a patient will respond to therapy. However, for 49% of the isolates, the MIC of tiamulin varied 
between 32 and > 128 mg/ml, being at least 8 to more than 32 times higher than for isolates belonging to the 
wild type population. Although it has not yet been tested, the likelihood that pigs infected with isolates 
demonstrating the higher MIC values of tiamulin will respond well to treatment with this antibiotic should be 
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considered to be low (Silley et al., 2011). For evaluation of tiamulin resistance in S. suis isolates, Zhang et al. 
(2008) used the clinical breakpoint reported by CLSI (2013) for Actinobacillus spp. causing respiratory tract 
disease in pigs (32 mg/ml) and reported that 34.4% of their isolates were resistant. Although this clinical 
breakpoint cannot be extrapolated as such to other bacterial species or disease conditions (Schwarz et al., 
2010), the percentage of isolates with a MIC of ≥ 32 mg/ml was clearly higher in this study. Also based on 
MIC determinations from S. suis isolates recovered between 1999 and 2000 from clinically diseased pigs, 
carried out in the same laboratory using identical test conditions (Martel et al., 2001), a clear shift towards 
higher MIC values was observed in this study. The sampled pigs from this study did not receive tiamulin for 
prophylactic or metaphylactic reasons (Callens et al., 2012). Yet, the use of tiamulin as a therapeutic 
antimicrobial agent against Brachyspira spp. and Mycoplasma hyopneumoniae infections is common and 
cannot be ruled out for this study. 
Broad-spectrum penicillins were the most frequently used antimicrobial class in pigs from this study, as 
described in a former study conducted in the same pig herds (Callens et al., 2012). Based on the clinical 
breakpoint for penicillin (CLSI, 2013) in this study, only three isolates could be categorized as resistant. Yet, 
when considering isolates with MICs beyond the wild type cut-off value, a high number of isolates showed a 
decreased susceptibility. Penicillin resistance in streptococci is the result of the acquisition of stepwise 
mutations in genes encoding penicillin binding proteins (Aarestrup et al., 2007). A single-point mutation results 
in isolates with a modest increase in MIC, and infections due to these isolates may still be treatable with 
penicillins, but they are of great concern as they represent an introductory step to full resistance (Amyes, 
2007). Isolates showing higher values of MICs are associated with additional mutations and most likely lead 
to therapy failure (Chambers, 1999). Additionally, these mutations are selected by the use of β-lactam 
antimicrobials (Chambers, 1999). As a result, reporting a decreased susceptibility based on epidemiological 
cut-off values is important as it can act as an early warning for an emerging clinical problem (Aarestrup et al., 
2007; Silley et al., 2011).  
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CONCLUSIONS 
The current study on S. suis isolates from healthy carrier pigs confirms the high level of acquired resistance to 
macrolides, lincosamides, and tetracycline. MIC values for penicillin are gradually increasing, compared to 
previous reports (Martel et al., 2001), as has been seen for S. pneumoniae in humans, although pigs infected 
with strains showing higher MICs may still respond to treatment with this antibiotic. The high rate of acquired 
resistance against tiamulin has not been reported before. 
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ABSTRACT 
Objectives: To improve antimicrobial surveillance accuracy for results obtained by the disk diffusion 
technique for porcine Escherichia coli, by comparing traditional clinical breakpoint interpretation with the 
Normalized Resistance Interpretation (NRI) method. 
Methods: The susceptibilities of 921 E. coli isolates from clinically healthy pigs at slaughter age was 
determined for 15 antimicrobials by the Kirby Bauer disk diffusion technique. NRI with previously established 
optimal controlled parameters for E. coli ATCC25922 was used to reconstruct the fully susceptible population 
of the tested E. coli isolates. Based on a lower limit for susceptibility, set at 2.5 standard deviations below the 
mean of the reconstructed susceptible population, the percentage of wild type (WT) and non-wild type isolates 
was compared with the percentage of clinical resistance as determined by traditional breakpoints to categorize 
strains as susceptible, intermediate or resistant.   
Results: The NRI method was applicable for 11 out of the 15 antimicrobials tested. Antimicrobials for which 
no normal distribution of inhibition zones for the population of susceptible isolates was seen, could not be 
used to reconstruct the susceptible population and had to be discarded from the calculations. Clinical 
breakpoints much lower than the epidemiological cut-off values (ECV) resulted into presumptively identifying 
isolates as clinically susceptible, but likely carrying acquired resistance determinants. On the other hand, 
clinical breakpoints did cut through the WT population for several antibiotics tested, categorizing isolates from 
the WT population as not susceptible. 
Conclusion: NRI was shown to be a valid method to define the WT population for disk diffusion outcomes 
provided a normal distribution of the susceptible bacterial species population is present. Until international 
harmonization of breakpoints is achieved, it might give rise to a wide application in monitoring antimicrobial 
resistance in veterinary medicine.  
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INTRODUCTION 
Escherichia coli (E. coli) is internationally used as Gram-negative indicator organism for resistance 
surveillance (Wray and Gnanou, 2000) and included in large scale monitoring studies at the national and 
supranational level (Hendriksen et al., 2008; MARAN, 2014; EFSA and ECDC, 2015). In addition, local 
microbiological laboratories often have access to a historical large databank of E. coli antimicrobial 
susceptibility test results. From the mid-2000s onwards, resistance in E. coli is increasingly reported using 
minimum inhibitory concentrations (MIC) distributions, obtained from dilution methods, to which clinical 
breakpoints and/or epidemiological cut-off values (ECV) are applied (Finnish Food Safety Authority, 2011; 
DANMAP, 2013; Chantziaras et al., 2014; CODA-CERVA, 2014; MARAN, 2014).  However, the previously 
more commonly used disk diffusion method is still generally applied as a method of antimicrobial susceptibility 
testing in routine microbiology testing (Matuschek et al., 2014). It is a fairly reproducible and accurate method, 
technically easy to perform with a relatively low cost which allows large number of isolates to be tested 
(Matuschek et al., 2014). Yet, differences in the standardization of the methodology over time and between 
laboratories, as well as differences between recommended clinical breakpoints result in a lack of comparability 
between the test results of disk diffusion assays. Potentially valuable data collected in laboratories worldwide 
is hence precluded from resistance surveillance studies (Silley et al., 2011). The variations in disk content 
potency and in clinical breakpoints over time, between countries, animals and organs can be circumvented by 
analysing the population distribution by the ECV if available. These are based on the differentiation between 
the wild type (WT) and the non-wild type (non-WT) population, are fixed for a certain bacterium- antimicrobial 
agent combination, and make the detection of even small susceptibility changes in the bacterial species 
population possible (Kahlmeter et al., 2003; EUCAST, 2015; CLSI, 2011). ECVs are established by the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) for a primary public health relevant 
selection of bacterium-antibiotic combinations (EUCAST, 2015). In the absence of an ECV, one might define 
the WT and non-WT populations based on the examination of the observed outcome distributions in the 
available study population. The emergence of resistance may evoke an unclear transition between the WT 
and non-WT populations, which makes the determination of the ECV sometimes difficult for results obtained 
by disk diffusion techniques as well as by the ‘golden standard’ dilution techniques (Turnidge and Paterson, 
2007). Whereas disk diffusion techniques rely on a concentration gradient of an antimicrobial agent 
throughout an agar medium, dilution techniques rely on defined two-fold dilutions of standard antimicrobial 
concentrations. The latter is therefore more discriminatory and reproducible.  
For disk diffusion results the normalized resistance interpretation (NRI) method has been described in human 
medicine as an objective method to define the WT population in a bacterial collection, and thereby identifies a 
subpopulation of isolates with decreased susceptibility (= subset of strains with decreased inhibition zone 
diameters) (Joneberg et al., 2003; Kronvall, 2010). The method uses the high zone side of the susceptible 
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peak in a zone diameter histogram as an internal calibrator to construct the real standard distribution of 
susceptible isolates (Kronvall et al., 2003a). Therefore, it has made comparisons possible of zone diameter 
population distributions despite discrepancies in methodology over time and between individual laboratories 
(Kronvall, 2010).  
For the first time, the NRI method was used on a dataset of animal related bacteria, i.e. E. coli isolated from 
clinically healthy pigs at slaughter age to define the WT and non-WT population and to compare the obtained 
results with the percentage of E. coli categorized as susceptible, intermediate or resistant according to 
described clinical breakpoints. 
MATERIALS AND METHODS 
Study design, sample, and data collection 
For the isolation of E. coli, fresh fecal samples were collected after rectal stimulation from clinically healthy 
fattening pigs from 50 Belgian herds. A list of 140 swine herds that fulfilled the selection criteria, mentioned 
below, were randomly selected from the Belgian farm-animal identification and registration database (Sanitel-
Pigs, 2005). The sampling frame (selection criteria) consisted of all farrow-to-finish herds that used a closed 
or semi-closed production system and held at least 150 sows and 600 fattening pigs. The sample was 
stratified by province, proportional to the number of pig herds per province, only including the 5 provinces (out 
of the 10) with a substantial pig breeding activity (covering 95% of pig breeding in Belgium). A random 
selection was performed using a computer-generated list (Cameron, 1999). All selected herds were contacted 
by telephone and the first 50 herds that were willing to cooperate in the study were visited between January 
and October 2010.  
The pigs were sampled approximately 2 weeks before the slaughter age. The average age of the pigs was 
182 days (minimum 156 days; maximum 220 days). In each herd, 20 fattening pigs were randomly sampled. 
Isolation and identification 
For the isolation of E. coli, faecal samples were inoculated on MacConkey agar plates (MacConkey Agar No. 
3; Oxoid Ltd.). Plates were incubated aerobically for 24h at 35°C ± 2°C. From each culture, one suspected E. 
coli colony was identified by means of positive glucose and lactose fermentation, gas production and absence 
of H2S production using Kligler Iron Agar (Oxoid Ltd.), indole production (Indole spot on; Becton Dickinson), 
and the absence of aesculin hydrolysis (Bile Aesculin Azide Agar; Oxoid Ltd.) (Callens et al., 2015).  
Antimicrobial susceptibility testing 
For antimicrobial resistance profiling of E. coli, the Kirby-Bauer disk diffusion method with Mueller-Hinton II 
agar was used for susceptibility testing of fifteen different antimicrobial agents. The Clinical Laboratory 
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Standards Institute (CLSI) standards were followed for inoculum standardization, incubation conditions, and 
internal quality control organisms (CLSI, 2013). Antimicrobial tablets used, including potency in µg, are 
presented in tables 1 and 2. After 18h of aerobic incubation at 35°C ± 2°C, inhibition zones were read and 
interpreted according to the manufacturer’s guidelines, based on CLSI standards (Rosco, 2007). Using these 
clinical breakpoints, shown in Table 2, the E. coli isolates were categorized as susceptible, intermediate or 
resistant (Rosco, 2007). 
Normalized Resistance Interpretation (NRI) method 
Based upon the obtained inhibition zone diameters, a population distribution was plotted for each 
antimicrobial. Visual examination of the distribution did not allow for clear distinction between isolates with 
acquired resistance (non-WT) and the WT population. Therefore, the NRI method was used to construct the 
standard distribution of susceptible isolates in the possible presence of isolates carrying resistance 
determinants as previously described in detail by Kronvall et al. (2003a).  
The method uses the upper high-zone region of the susceptible peak in an inhibition zone histogram to 
reconstruct the distribution of the fully susceptible population (Kronvall et al., 2003a). The upper high-zone 
region groups the observations with the largest (=most susceptible) inhibition zone values. Since it is 
assumed that this part of the distribution is not influenced by the presence of any acquired resistance, it is 
used to reconstruct the full susceptible population. For this, first the high-zone side of a zone histogram 
distribution is analyzed by calculating the moving averages of the number of observations per zone value 
based on a certain window of observations going from the highest zone diameter values downwards (Fig. 1). 
By applying the moving average, the ruggedness of the histogram is evened out and therefore the 
determination of the peak position is facilitated (Kronvall, 2003a). The optimal window for determination of the 
moving average has previously been investigated for (external quality) control strain E. coli ATCC25922, i.e. a 
four-zone value average (e.g. 32 mm; 31mm; 30 mm; 29 mm), and was consequently applied to E. coli in this 
study (Joneberg et al., 2003). When the moving average is starting to decrease the peak position of the 
susceptible population is reached or even passed. Subsequently, the peak position is determined by adjusting 
the observed peak (peak adjustment). For control E. coli ATCC25922 the optimal peak adjustment has been 
set at 2.5 for a four-zone value average (Joneberg et al., 2003) and was therefore used in this study (Fig. 1). 
The next step in the NRI method is to calculate the accumulated percentages of observations of the different 
zone values, from the highest zone values down to the peak position. The total number of isolates included in 
the susceptible population is defined to be twice the number of isolates for the upper half of the susceptible 
peak (Kronvall, 2003a) (Fig. 1). Given the total number, the accumulated percentage of isolates can easily be 
calculated. Assuming a normal distribution for the susceptible population in a histogram according to earlier 
studies (Kronvall et al., 1991) the probit values of the accumulated percentages will form a straight line 
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against the zone diameter values (Fig. 2). The accumulated percentages were, therefore, converted to probit 
values by using an Excel function and plotted. Subsequently the best fitting line, determined by means of the 
least-squared differences, is plotted. The slope and intercept of this line are equal to and therefore provide 
the mean and standard deviation (SD) of the ideal normal distribution of the susceptible population. The mean 
and SD have been shown earlier to describe histogram populations accurately (Kronvall et al., 1991). The 
susceptible population is thereby defined and a lower limit for susceptibility can then be set to any value of 
the SD below the mean, e.g. 2.5 SD below the mean. All isolates with zone values lower than the calculated 
lower limit can be considered different from the normally distributed susceptible isolates, i.e. non-WT. A 2.5 
SD limit will theoretically include 97.725% of the susceptible isolates. Finally, SD of the normalized NRI-
calculated distributions were used as estimates for the appropriateness of the NRI method for the observed 
disk diffusion results. Limits for SD to accept results of the NRI calculations have not yet been established 
(Smith and Kronvall, 2014). In this study, highly deviating SD within all SD calculated were taken as indicative 
for the NRI method not being applicable to the disk diffusion data.  
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Figure 1. Histogram of zone diameter values of apramycin (40 μg) disk diffusion results for 921 Escherichia 
coli isolates from healthy pigs. The moving average of the four-zone value average is shown as a line plot. 
The switch to the lower position is noticed at position 22 mm (down arrow). The strains of half the ideal peak 
are marked as grey bars. Twice these isolates will give the total number of the ideal susceptible peak, the 
denominator when calculating accumulated percent values. 
 
Figure 2. Histogram of zone diameter values of apramycin (40 μg) disk diffusion results for 921 Escherichia 
coli isolates from healthy pigs. The straight dotted line represents the correlation between probit values of the 
accumulated percentages and zone diameter values (mm). The normalized resistance interpretation (NRI)-
calculated distribution is shown as a line graph and the 2.5 SD (standard deviation) lower limit is indicated by 
the vertical arrow (21 mm). 
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RESULTS 
NRI 
E. coli isolates were obtained from 921 of the 1000 faecal samples that were collected, showing a high rate of 
isolation success (92.1%) for E. coli in this study.  
Figure 3 (a-o) represents the inhibition zone diameter distribution for 15 antimicrobials tested on these E. coli 
isolates. The normalized NRI-calculated distribution was based on an optimal peak adjustment set at 2.5, for 
a moving average based on the four-zone value, and is shown as a line curve.  
For chloramphenicol, enrofloxacin and trimethoprim, the calculations resulted in erroneously wide normalized 
distributions. SD of the normalized distributions were deviant for these antibiotics (14.1, 44.9 and 11.9 for 
chloramphenicol, enrofloxacin and trimethoprim, respectively) compared with the SD of the other antibiotics 
used in the calculations (range between 1.0 and 3.2) (Table 1). An attempt to reconstruct better fitting 
normalized distributions was done by shifting the 2.5 peak adjustment to 2. This resulted in better fitting 
distributions for chloramphenicol and trimethoprim, but provided no optimized distribution for enrofloxacin. 
Moreover, a 2.5 to 2 shift decreased the appropriateness of NRI distribution of nalidixic acid (Fig. 3i). 
Chloramphenicol, enrofloxacin, nalidixic acid and trimethoprim were consistent with each other in their 
absence of a normal distribution of the population of susceptible isolates with a steep slope on the high zone 
value side (Fig. 3e, f, j and o) and highly varying SD when switching between the 2 and the 2.5 peak 
adjustment, whereas this was not the case for the other antibiotics tested (Table 1).  
The use of the same optimal parameters through all the distributions has been emphasized, as they take into 
account the laboratory-specific methodology (Kronvall et al., 2003b).  A peak adjustment of 2.5 was therefore 
chosen and chloramphenicol, enrofloxacin, nalidixic acid and trimethoprim were discarded from the NRI 
calculations.  
 
 
 
 
 
 
CLINICAL RESISTANCE AND DECREASED SUSCEPTIBILITY IN ESCHERICHIA COLI CHAPTER 5 
 
141 
 
Table 1. Standard deviations (SD) of the normalized NRI-calculated distribution applied to a bacterial 
collection of 921 porcine commensal E. coli for a peak adjustment of 2 and 2.5 zone diameters. 
Antibiotic  
Disk 
content μg 
AMC 
30+1
5 
AM
P 
30 
APR
A 
40 
CE
F 
30 
CHLO
R 
60 
ENR
O 
10 
FLO
R 
30 
GENT
A 
40 
KAN
A 
100 
NA
L 
130 
NE
O 
120 
STRE
P 
100 
SU
L 
240 
TETR
A 
80 
TRI
M 
5.2 
Peak 
adjustmen
t = 2 
2,6 2.4 1.7 1.9 1.8 17.8 2.7 1.9 2.1 0.8 1.4 2.8 3.4 2.7 2.4 
Peak 
adjustmen
t = 2.5 
2.8 2.4 1.5 1.9 14.1 44.9 2.6 1.8 2.4 3.2 1.0 2.9 3.6 2.7 11.9 
AMC: amoxicillin/clavulanic acid; AMP: ampicillin; APRA: apramycin; CEF: ceftiofur; CHLOR: chloramphenicol; 
ENRO: enrofloxacin;  
FLOR: florfenicol; GENTA: gentamicin; KANA: kanamycine; NAL: nalidixic acid; NEO: neomycin; STREP: 
streptomycin; 
SUL: sulfadiazine; TETRA: (oxy)tetracycline; TRIM: trimethoprim 
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E. coli susceptibility based on clinical interpretive criteria and normalized interpretation 
Highest percentages of clinical resistance (R+I) were seen for streptomycin (58.5), tetracycline (57.4%), 
sulfadiazine (56.9%), and trimethoprim (49.5%). Moderate resistance was present against ampicillin (38.5%) 
and chloramphenicol (23.5%). Low levels of clinical resistance were seen for florfenicol (9.6%), nalidixic acid 
(4.9%), ceftiofur (3.1%), amoxicillin/clavulanic acid (3%), gentamicin (3%), neomycin (2.2%), apramycin (2%), 
enrofloxacin (1.7%), and kanamycin (1,2%).  
For amoxicillin/clavulanic acid, ampicillin, ceftiofur and neomycin, a gap was present between the clinical 
breakpoint for susceptibility and the epidemiological cut-off value of the reconstructed distribution of the 
susceptible population (Fig 3a, b, d, k). For neomycin, this resulted into 97.8% susceptible isolates according 
to clinical interpretive criteria and 90.7% WT using normalized interpretation (Table 2). However, for 
amoxicillin/clavulanic acid, ampicillin and ceftiofur, due to the low number of isolates within the gap, the 
difference between the percentage of susceptible isolates according to clinical interpretive criteria and WT 
using normalized interpretation was very small (between 0.3% and 0.6%; Table 2).  
For florfenicol, clinical breakpoints divided the NRI calculated WT population in a way that 7.1% and 2.5% of 
WT isolates were classified as intermediate and resistant, respectively (Fig 3g). The percentage of susceptible 
isolates was then 90.4%, whereas according to NRI and a 2.5SD limit below the mean, susceptibility of 
strains equaled 98.4% (Table 1). A similar result was seen for sulfadiazine, with 1.2% of the isolates 
interpreted as intermediate and 0.8% as resistant, whereas the NRI distribution includes these isolates as 
belonging to the WT population. Also for gentamicin, 2% of the isolates were divided as ‘intermediate’, where 
the normalized distribution indicates them as member of the WT population (Fig 3h, i). For streptomycin, 
overlapping populations were seen (Fig. 3l). Mid zone values were shared by the low zone side and the high 
zone side of both parts of the distribution.  
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Table 2. Percentages of wild type (WT) and non-wild type (non-WT) for 921 Escherichia coli isolates, from 
healthy pigs at slaughter age, based on a lower limit of 2.5 standard deviations (SD) below the mean. The 
percentage of susceptible (S), intermediate (I) and resistant (R) strains are provided based on clinical 
breakpoints (Rosco, 2007). The Clinical Laboratory Standards Institute (CLSI) standards were followed for 
inoculum standardization, incubation conditions, and internal quality control organisms (CLSI, 2013). 
 
Antibiotic  
Disk 
content μg 
AMC 
30+15 
AMP 
30 
APRA 
40 
CEF 
30 
CHLOR 
60 
ENRO 
10 
FLOR 
30 
GENTA 
40 
KANA 
100 
NAL 
130 
NEO 
120 
STREP 
100 
SUL 
240 
TETRA 
80 
TRIM 
5.2 
Clinical 
breakpoints 
R ≤ 
16 S 
≥ 19 
R ≤ 
16 S 
≥ 19 
R ≤ 
19 S 
≥ 22 
R ≤ 
19 S 
≥ 22 
R ≤ 20  
S ≥ 24 
R ≤ 
16 S 
≥ 22 
R ≤ 
18 S 
≥ 21 
R ≤ 20 
S ≥ 24 
R ≤ 
19  
S ≥ 
22 
R 
≤20 
S ≥ 
24 
R ≤ 
19 S 
≥ 22 
R ≤ 22  
S ≥ 25 
R ≤ 
19 S 
≥ 25 
R ≤ 19  
S ≥ 22 
R ≤ 
16 S 
≥ 19 
Non-WT 3.6 38.8 2,.0 3.6 - - 1.6 1.1 1.2 - 9.3 28.4 54.9 57.4 - 
WT 96.4 61.2 98.0 96.4 - - 98.4 98.9 98.8 - 90.7 71.6 45.1 42.6 - 
S 97.0 61.5 98.0 96.9 76.4 98.3 90.4 97.0 98.8 95.1 97.8 41.5 43.1 42.6 50.5 
I 1.7 0.5 1.3 0.4 1.8 0.3 7.1 2.0 0.2 0.8 1.4 8.5 1.2 0.3 0.1 
R 1.3 38.0 0.7 2.7 21.7 1.4 2.5 1.0 1.0 4.1 0.8 50.0 55.7 57.1 49.4 
R+I 3.0 38.5 2.0 3.1 23.5 1.7 9.6 3.0 1.2 4.9 2.2 58.5 56.9 57.4 49.5 
AMC: amoxicillin/clavulanic acid; AMP: ampicillin; APRA: apramycin; CEF: ceftiofur; CHLOR: chloramphenicol; 
ENRO: enrofloxacin; FLOR: florfenicol; GENTA: gentamicin; KANA: kanamycine; NAL: nalidixic acid; NEO: 
neomycin; STREP: streptomycin; SUL: sulfadiazine; TETRA: (oxy)tetracycline; TRIM: trimethoprim 
-: results were discarded  
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(d) 
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(f) 
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(h) 
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(i) 
 
(j) 
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(l) 
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(n) 
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(o) 
Figure 3 (a-o). Histogram of zone diameter values around antimicrobial disks for 921 Escherichia coli isolates 
from pigs at slaughter age (amoxicillin/clavulanic acid (30+15 μg) (a), ampicillin (30 μg) (b), apramycin (40 μg) 
(c), ceftiofur (30 μg) (d), chloramphenicol (60 μg) (e), enrofloxacin (10 μg) (f), florfenicol (30 μg) (g), 
gentamicin (40 μg) (h), kanamycin (100 μg) (i), nalidixic acid (130 μg) (j), neomycin (120 μg) (k), streptomycin 
(100 μg) (l), sulfadiazine (240 μg) (m), oxytetracycline (80 μg) (n) and trimethoprim (5.2 μg) (o)). The 
normalized resistance interpretation (NRI)-calculated distribution is based on the four-zone average parameter 
with a peak adjustment of 2.5 zone diameters, and is shown as a line curve (◊). For chloramphenicol, 
enrofloxacin, nalidixic acid and trimethoprim the NRI-calculated distribution based on the four-zone average 
parameter but with a peak adjustment of 2 zone diameters is equally presented (∆).  
Clinical breakpoints of the Neo-Sensitabs manufacturer (Rosco, Taastrup, Denmark) were used for the 
categorization of the tested isolates as susceptible (S), intermediate (I), or resistant (R) and are shown as 
vertical lines. The Clinical Laboratory Standards Institute (CLSI) standards were followed for inoculum 
standardization, incubation conditions, and internal quality control organisms (CLSI, 2013). The NRI generated 
2.5 SD (standard deviation) limit is shown as a vertical blue arrow. The 2.5 SD limit could not be generated 
for chloramphenicol, enrofloxacin, nalidixic acid and trimethoprim because of too much irregularities in the 
normal distribution of zone diameter values. 
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DISCUSSION 
EUCAST recently extended the number of antimicrobial agents for which an epidemiological cut-off value 
(ECV) is available for E. coli, based on inhibition zone diameter distributions (EUCAST, 2015). Yet, a 
difference in disk content potency for the antibiotics included in the EUCAST database (EUCAST, 2015) and 
these tested in this study excluded the EUCAST established ECV as interpretive criteria for our results. The 
Normalized Resistance Interpretation (NRI) method, described by Kronvall et al. in 2003 and applied to 
clinical human E. coli and Staphylococcus aureus isolates (Kronvall, 2010), is here for the first time being 
used for defining the wild type (WT) population of animal related bacteria, i.e. E. coli isolated from clinically 
healthy pigs at slaughter age during a cross-sectional study, after disk diffusion. The NRI method deals with 
differences in methodology, such as different disk contents, since cut off values are calculated after 
reconstructing the WT population based on the high zone side of the susceptible peak of the obtained data 
(Kronvall, 2003a). It also circumvents subjective decisions on an ECV after visual examination of a bacterial 
population which can be hampered for bacterial species-antibiotic combinations showing an unclear transition 
between WT and non-WT isolates, equally seen for the E. coli isolates from this study. 
The NRI methodology is based on the presence of a distribution of WT isolate zone diameters following 
criteria of normality to a sufficient degree (Kronvall et al., 1999; Kronvall et al., 2003a). In this study, the 
relevance/applicability/usefulness of the NRI method, using the optimal parameters for quality control strain E. 
coli ATCC 25922 (Joneberg et al., 2003), was demonstrated for several antimicrobials. The calculation of the 
standard deviations (SD) of the normalized NRI calculated distributions was demonstrated to be useful as a 
predictor of the  appropriateness of the NRI method for the observed disk diffusion results by the detection of 
outliers in the range of SD for all antibiotics tested. Antibiotics showing deviations in SD of the normalized 
NRI-calculated distribution, for the 2 and 2.5 zone diameters peak adjustment also showed a steep slope at 
the high zone value side of the histogram, resulting in non-Gaussian distributions (chloramphenicol, 
enrofloxacin, nalidixic acid and trimethoprim). For these antibiotics, the method turned out to be none 
applicable. Non-Gaussian distributions, as a result of the high number of isolates with a zone diameter of 32 
mm, e.g. enrofloxacin, can be circumvented either by the use of a lower disk content potency or by enabling 
the reading of zone diameters > 32 mm. This will allow for the plotting of a normal distribution of the observed 
zone diameter records. 
The high zone side is of particularly interest as it is used as the calibrator to construct the real standard 
distribution of susceptible isolates. Calculations which include subjectively missing records at the high zone 
value side will result in NRI distributions wrongly shifted to the left, decreasing the probability of identifying 
strains as different from the WT population of strains. Identifying the WT populations is of particular interest 
for surveillance purposes. Therefore, the proportion of isolates classified as WT, but carrying resistance 
determinants, has to be kept to a minimum. Another subjective modification that has been observed in the 
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past is the overrepresented number of even zone diameters (Kronvall et al., 2003b), also present in the data 
from this study. In general, there is a trend of rounding down or up odd numbers in the absence of automatic 
reading devices.     
When results for clinical susceptibility were analyzed and compared, there was a fairly good agreement 
between the susceptibility levels obtained by clinical interpretive criteria and the NRI calculated levels for most 
of the antibiotics. Nevertheless, marked differences were noted between clinical breakpoints and the NRI 
derived ECV for ampicillin and ceftiofur. Clinical breakpoints much lower than the ECV resulted into a gap 
including isolates categorized as clinically susceptible, but likely carrying acquired resistance determinants. 
Results based on clinical breakpoints are of significance for the clinician as isolates with decreased 
susceptibility may still be treatable (Simjee et al., 2008). Yet, as mentioned above, NRI derived ECV 
identifying them as non-WT is important as it acts as an early warning for an emerging clinical problem 
(Aarestrup et al., 2007; Silley et al., 2011).  
Clinical breakpoints cut through the WT population for several antibiotics tested, categorizing isolates from the 
WT population as not susceptible. This raises questions on the correctness of the establishment of these 
breakpoints used for E. coli and a certain antibiotic and highlights the need for validated veterinary-specific 
clinical breakpoints which are useful in the practice of veterinary medicine. 
Given the current concerns about the emergence of and trends in antimicrobial resistance in animals, there is 
an urgent need for a harmonized approach in Europe towards the susceptibility methods used in veterinary 
medicine (VetCAST, 2014). Nevertheless, until harmonization is achieved, the NRI method can be a valid 
method to circumvent the differences in the methodology of the routinely used disk diffusion test and to 
determine the ECV, making antimicrobial susceptibility data comparable. Also, historical data, for instance 
from previous prevalence studies, might be included in surveillance programs for comparative reasons, 
provided that zone diameters have been recorded.    
In conclusion, in the absence of a clear bimodal distribution of E. coli zone histograms and previously 
established ECV for E. coli-antibiotic combinations, an objective setting of ECV was necessary. NRI was 
applicable to define the wild type population for outcomes with a normal distribution of the susceptible 
population. Applying NRI in this study highlighted the need for measuring zone diameters in a non-biased 
way. The increased use of automatic reading devices in the recording of disk diffusion susceptibility test 
results in large databases which might give rise to a wide application of the NRI method in veterinary 
medicine. 
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ABSTRACT 
This study investigated whether antimicrobial resistant Escherichia coli in apparently healthy sows and 
antimicrobial administration to sows and piglets influenced antimicrobial resistance in fecal commensal E. coli 
from piglets. Sixty sows from three herds and three of their piglets were sampled at several time points. 
Antimicrobial use data during parturition and farrowing were collected. Clinical resistance was determined for 
two isolates per sampling time point for sows and piglets using disk diffusion. Only 27.4% of E. coli isolates 
from newborn piglets showed no resistance. Resistance to one or two antimicrobial classes equaled 41.2% 
and 46.8% in isolates from sows and piglets, respectively, for the overall farrowing period. Multiresistance to 
at least four classes was found as frequently in sows (15.6%) as in piglets (15.2%). Antimicrobial resistance 
in 
piglets was influenced by antimicrobial use in sows and piglets and by the sow resistance level (p < 0.05). 
Using aminopenicillins and third-generation cephalosporins in piglets affected resistance levels in piglets (odds 
ratios [OR] > 1; p <  0.05). Using enrofloxacin in piglets increased the odds for enrofloxacin resistance in 
piglets (OR = 26.78; p < 0.01) and sows at weaning (OR = 4.04; p < 0.05). For sows, antimicrobial exposure 
to lincomycin-spectinomycin around parturition increased the resistance to ampicillin, streptomycin, 
trimethoprim-sulfadiazine in sows (OR= 21.33, OR= 142.74, OR= 18.03; p < 0.05) and additionally to 
enrofloxacin in piglets (OR= 7.50; p < 0.05). This study demonstrates that antimicrobial use in sows and 
piglets is a risk factor for antimicrobial resistance in the respective animals. Moreover, resistance determinants 
in E. coli from piglets are selected by using antimicrobials in their dam around parturition. 
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INTRODUCTION 
Since their discovery, antimicrobials have been widely used in animal husbandry for growth promoting, 
prophylactic, metaphylactic, and therapeutic reasons (Aarestrup, 2005). Despite the ban on growth-promoting 
antimicrobials in Europe by 
2006, it was estimated that in 2007, still 3,500 tons of antimicrobials were used for animal health over 10 
different 
European countries (ECDC-EFSA-EMEA-SCENIHR, 2009). Antimicrobial administration to sows is common 
around parturition. Dunlop et al. reported mastitis-metritis-agalactia syndrome and off feed as the most 
common reasons for non-routine treatments around parturition (1998). Other reasons for the administration of 
antimicrobials around parturition included the prevention of bacterial diseases in sows and the reduction of 
possible pathogen transmission to the piglets. In addition, piglets often receive antimicrobials shortly after birth 
to prevent wound infections or to prevent infections with pathogens such as streptococci, Escherichia coli, 
Clostridium species, and staphylococci (Stannarius et al., 2009; Callens et al., 2012). The use of 
antimicrobials is a concern as it engenders a selection pressure for resistance selection and spread in 
pathogenic and commensal bacteria to antimicrobials (Dewulf et al., 2007). Regardless of the use of 
antibiotics, several other factors can be involved in the selection 
and spread of resistance determinants. A different type of housing has already been identified as playing a 
role in the selection and spread of resistance in pigs by Langlois et al. (1988). Exposure of animals to 
stressors at the farm may enhance the selection and dissemination of resistant determinants (Moro et al., 
2000; Mathew et al., 2003). Also, animal categories, such as fattening pigs and sows or different ages, can 
contribute to diverged resistance rates (Butaye et al., 1999; Dewulf et al., 2007). 
Resistance to antimicrobials in sows and piglets between birth and postweaning (Mathew et al., 1998; 
Stannarius et al., 2009) and the relationship with a low or high antimicrobial have been described (Mathew et 
al., 1999). Resistant E. coli are not restricted to one animal host and they can spread naturally from one 
animal host to colonize the intestinal tract of another animal host (Levy et al., 1976) or animal species 
(Marshall et al., 1990). Indeed, transmission of resistant bacteria from sows to piglets has been assumed 
(Mathew et al., 2005). Thus, one could question to what extent the presence of antimicrobial-resistant bacteria 
in sows influences the degree of antimicrobial resistance in piglets at birth and during the suckling period, 
periods with intensive contact between sows and piglets, and within the offspring, which transmission of 
bacteria is possible (Devriese et al., 1994). Furthermore, the administration of antimicrobials to sows and 
piglets during this period may increase the presence of antimicrobial resistant bacteria in both sows and 
piglets. This can be either by a direct selection pressure in the treated animals or by the exposure to 
antimicrobials due to the shedding by treated animals. The hypothesis of a selection pressure exerted by 
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antibiotic residues in fecal material and/or feed dust, or dust particles, originating from the treatment period, 
has been 
presented before (Mathew et al., 2005; Alexander et al., 2009). The information available on the interaction 
between antimicrobial use in sows and their offspring at the one hand and resistance in these animals at the 
other hand is scarce.  
Therefore, the aim of this field study was to investigate whether the presence of antimicrobial resistant E. coli 
in sows and the administration of antimicrobials to sows and piglets during farrowing influenced the 
antimicrobial resistance in fecal commensal E. coli in sows and the offspring by using multilevel models. 
MATERIALS AND METHODS 
Study population and design 
Three different Belgian pig herds were selected and visited between December 2010 and February 2011. The 
herds were farrow-to-finish herds with at least 200 sows. Piglets were weaned between 21 and 28 days of 
age. Herds were visited four times to collect samples for antimicrobial resistance profiling of fecal E. coli from 
apparently healthy sows and piglets and to register the antimicrobial drug consumption during the latest 
production cycle and the entire observation period of the sampled sows and piglets (from birth until weaning). 
Twenty sows in gestation were randomly selected from each herd. From each sow, the fecal material was 
collected after rectal stimulation 1–3 days before parturition and within 12 hr after parturition. Sows were 
sampled a third time at weaning age of their piglets. For transport to the laboratory, the fecal material was 
kept in a clean recipient for each individual sow. 
The fecal material was also collected from three randomly selected piglets from each sampled sow by means 
of a rectal swab. The selected piglets were sampled within 12 hr after birth and before any antimicrobial 
administration. Every piglet was identified by an ear tag and additional samples were taken from the same 
animal at 2 weeks of age and at weaning. The different sampling times for sows and piglets are presented in 
Table 1. 
 
 
 
 
ANTIMICROBIAL USE AND RESISTANCE IN ESCHERICHIA COLI  
FROM SOWS AND PIGLETS  CHAPTER 6 
 
165 
 
Table 1. Sampling scheme on 3 different farrow-to-finish swine herds for the isolation of faecal Escherichia 
coli. 
a Twenty sows per herd 
b Three piglets per sows 
-: faecal samples were not taken from the respective animals at this sampling moment 
Isolation and identification 
Immediately after collection, the samples were transported to the laboratory where they were processed within 
a few hours after arrival. For the isolation of E. coli, rectal swabs from the piglets were directly inoculated on 
Mac-Conkey agar plates (MacConkey Agar No. 3; Oxoid Ltd.), whereas for the sows, a swab was used to 
inoculate the fecal material from the recipient on the plates. Plates were incubated aerobically for 24 hr at 
37°C. From each culture, two suspected E. coli colonies were confirmed by means of positive glucose/lactose 
fermentation, gas production and absence of H2S production using Kligler Iron Agar (Oxoid Ltd.), indole 
production (Indole spot on; Becton Dickinson), and the absence of aesculin hydrolysis (Bile Aesculin Azide 
Agar; Oxoid Ltd.) (Catry et al., 2007).  
For antimicrobial resistance profiling, the Kirby-Bauer disk diffusion method was used for susceptibility testing 
of seven different antimicrobial agents. The Clinical Laboratory Standards Institute (CLSI) standards were 
followed for inoculum standardization, incubation conditions, and internal quality control organisms (2008). 
The following antimicrobial tablets (charge in µg) were used: amoxicillin/clavulanic acid (30 µg + 15 µg), 
ampicillin (33 µg), ceftiofur (30 µg), tetracycline (80 µg), trimethoprim–sulfadiazine (5.2 µg + 240 µg), 
enrofloxacin (10 µg), and streptomycin (100 µg). After 18 hr of incubation, inhibition zones were read and 
interpreted according to the manufacturer’s guidelines (Rosco, 2007). The following clinical breakpoints were 
used: for amoxicillin/clavulanic acid R ≤16, for ampicillin R ≤ 16, for ceftiofur R ≤ 19, for tetracycline R ≤ 19, 
for trimethoprim–sulfadiazine R ≤ 19, for enrofloxacin R ≤ 18, and for streptomycin R ≤ 22. The response 
measure for the E. coli isolates was dichotomized into resistant or susceptible according to the clinical criteria 
Type of animals (n) Prepartum Day of Parturition Postpartum Weaning 
Sows (60)a 
1-3 days before 
parturition 
Within 12h after 
delivery (D0) 
- 
D21-28 after 
delivery 
Piglets (180)b - 
Within 12h after 
delivery 
Before any 
antimicrobial 
administration (D0) 
14 days after birth 
(D14) 
D21-28 days 
after birth (D21-
28) 
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for resistance. Intermediate responses were allocated to the susceptible ones. To define resistance, the 
clinical criteria were used. Clinical resistance will be mentioned as ‘‘resistance.’’ 
Quantification of antimicrobial drug consumption 
To investigate the influence of antimicrobial drug use on the prevalence of antimicrobial resistance in fecal E. 
coli in the piglets, data concerning antimicrobial use in the sows were collected from the start from the latest 
production cycle (prepartum) until weaning (between 21 and 28 days of age) and for the piglets from birth 
until weaning.  
Antimicrobial drug consumption was quantified as treatment incidences (TI) based on the used daily dose pig 
(UDDpig). The treatment incidence (TIUDD) is defined as the number of days per 1,000 that one pig is treated 
with one UDDpig. The UDDpig is defined as the administered dose of a drug per day per kilogram pig. For each 
of the herds, a standardized growth table was used to estimate the body weight at the time of antimicrobial 
administration. This estimated body weight was used to calculate the UDDpig. For the sows, per herd, one out 
of the 20 selected sows was weighed. The body weight of the particular sow was used as the standard 
weight for all selected sows in one herd. Treatment incidences based on the UDDpig (TIUDD) were calculated 
by means of the following formula, described by Timmerman et al (2006). 
 
 
For sows, the number of days at risk was taken for three time periods. The number of days at risk was taken 
(1) from day of insemination until 1–3 days before parturition (112–114 days), (2) from insemination until 
parturition (115 days), and (3) from insemination until weaning (136–143 days). For piglets, the number of 
days at risk was taken from birth until weaning (21–28 days). 
Statistical model 
The proportion of resistance (PR) was defined for each individual antimicrobial agent as the number of 
isolates to which resistance against this specific antimicrobial was measured as compared to the total number 
of isolates tested. In this study, multiresistance was defined as resistance to three or more antimicrobials.  
Statistical models were built in SAS® 9.4 and used to estimate the PR for each individual antimicrobial agent. 
Let Yijt be the number of isolates to which resistance was found for animal j in nest i at measurement t, and 
nijt the corresponding number of isolates being tested. In this study, a total of 60 nests were available (i = 
1,.,60), and the number of animals per nest was 4, with j = 1,2,3 corresponding to the piglets and j = 4 
corresponding to the sow. From every nest, 6 measurements were taken, as summarized in Table 1 (t = 1, 2, 
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3 correspond to the subsequent measurements taken from the piglets, t = 4, 5, 6 correspond to the 
measurements from the sows). Note that measurements are possibly associated because (1) measurements 
were taken at different time points from the same animals and (2) measurements are taken from animals in 
the same nest. To model the possible association between the resistance profiles of piglets and their sows, 
as well as the association of the resistance outcomes of the same animals at different measurements, a 
generalized linear mixed model was used. More specifically, 
it was assumed that Yijt is given by a binomial process with nijt the number of trials and pijt the PR for animal j 
in nest i at time point t. The probability pijt was modeled as follows:  
𝑙𝑛 (
𝑝𝑖𝑗𝑡
1−𝑝𝑖𝑗𝑡
) = 𝜁𝑋𝑖𝑗𝑡 + 𝑢𝑖 + 𝑣𝑗(𝑖) + εij 
where 𝜁 is the vector of unknown fixed effect (regression parameters) and 𝑢𝑖 and 𝑣𝑗(𝑖) are normally 
distributed random effects with mean 0 and variances 𝜎2 and 𝜏2, respectively. The parameters 𝑢𝑖 are nest-
specific intercepts, measuring the deviation of the resistance-profile of each nest from the average resistance-
profile. In a similar way, the parameters 𝑣𝑗(𝑖) are animal-specific parameters, measuring the deviation of the 
resistance-profile of each animal from the average. By the use of nest- and animal-specific parameters, 
associations of the outcomes within nests and within animals were taken into account. In the fixed effects 
structure, differences with respect to measurements, herd and the extent of exposure to antimicrobials were 
taken into account. The fixed effects structure can be written as: 
𝜁𝑋𝑖𝑗𝑡 = 𝛼0 +  ∑ 𝛼𝑘
2
𝑘
𝐼(ℎ𝑒𝑟𝑑 = 𝑘) + ∑ 𝛽𝑘𝐼(𝑡 = 𝑘)
5
𝑘=1
 
+ (∑ 𝛾𝑘𝑈𝐷𝐷𝑘𝑖𝑗𝑡  
5
𝑘
) 𝐼(𝑝𝑖𝑔𝑙𝑒𝑡) 
+(∑ 𝛿𝑘𝑈𝐷𝐷𝑘𝑖𝑗𝑡
5
𝑘 )𝐼(𝑠𝑜𝑤) + ε 
where I(.) is an indicator function taking the value 1 if the expression within the brackets is correct and 0 
otherwise. The function I(piglet) indicates whether animal j in nest i is a piglet or not, and a similar definition is 
used for I(sow). The 𝛼-parameters correspond with the differences amongst 3 herds, the 𝛽-parameters model 
the 6 time effects, the 𝛾-parameters measure the effect of the extent of antimicrobial exposure on the 
resistance of the piglet, and the 𝛿-parameters measure the effect of the extent of antimicrobial exposure on 
the resistance of the sow. The model was simplified in a stepwise way, keeping only the significant terms in 
the model (using Akaike’s Information Criterion). A correction for multiple testing was inserted for the fixed 
effect time. For every resistance outcome in an animal at one of the sampling time points, the model was run 
with the accordingly effect of the extent of antimicrobial exposure of the piglet and the sow for the time period 
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preceding the sampling. Thus, the model was rerun for every time point a resistance outcome was obtained 
to link the outcome with the preceding antimicrobial exposure.  
To study whether the resistance of the sow has an impact on the resistance of the piglets, a similar model 
has been used. More specifically, the same generalized linear mixed model was used, but where now pijt 
denotes the PR for piglet j in nest i at time t and the fixed effects structure was specified as  
𝜁𝑋𝑖𝑗𝑡 = 𝛼0 + ∑ 𝛼𝑘
2
𝑘
𝐼(ℎ𝑒𝑟𝑑 = 𝑘) + ∑(𝛽𝑘 + 𝛾𝑘  𝑌𝑖4𝑡)𝐼 (𝑡 = 𝑘)
3
𝑘=1
 
 
where 𝛾𝑘 represents the effect of the resistance of the sow at time 𝑡′ on the resistance of the piglets at time 
𝑘. This analysis is performed for each antibiotic and each time point 𝑡′ of measurement in the sow, 
separately. 
RESULTS 
Descriptive statistics 
E. coli antimicrobial resistance profile.  
Susceptibility testing was performed on 294 and 863 E. coli isolates from sows and piglets, respectively. 
Overall, 23.5% of the isolates from sows and 26.3% of the isolates from piglets were susceptible to all 
antimicrobials tested. Resistance to one or 
two antimicrobials was reported for 41.2% of the isolates in sows and 46.8% of the isolates in piglets. 
Resistance to at least three antimicrobials was found more frequently in isolates from sows (35.4%) than from 
piglets (26.9%) (p < 0.05). Resistance to all of the seven antimicrobials tested appeared in piglets for 2 
isolates (total of 863 isolates), whereas in sows, the highest number of antimicrobials to which resistance was 
found in the same isolate was 6 (2 isolates of a total of 294 isolates tested) (Fig. 1). Herd 1, 2, and 3 differed 
significantly for the level of resistance to ampicillin, ceftiofur, enrofloxacin, streptomycin, trimethoprim-
sulfadiazine, and tetracycline (p < 0.05) (Table 2). 
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Figure 2. Resistance results for 294 and 863 Escherichia coli isolates from sows and piglets in three pig 
herds.
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Table 2. Results of the generalized linear mixed model for the identification of the risk of antimicrobial 
exposure for the prevalence of antimicrobial resistant faecal Escherichia coli isolates in sows and piglets 
during farrowing (total of 294 and 863 isolates for sows and piglets respectively). 
Antimicrobial agent 
tested 
Risk factor  Category n 
Resistance 
prevalence 
% 
OR 
95% 
CI 
P-value 
Amoxicillin/clavulan
ic acid 
Herd 
 
 
1 1 3.0 >999 
<0.01-
>999 
0.96 
2 1 2.5 >999 
<0.01-
>999 
0.96 
3 1 0 1 Ref - 
Antimicrobi
al use 
Effec
t on 
sow 
No sign. 
effects 
     
Effec
t on 
piglet 
No sign. 
effects 
     
         
Ampicillin 
Herd 
 
 
1 1 68.6 14.39 
4.36-
47.56 
<0.000
1 
2 1 29.6 0.96 
0.29-
3.21 
0.94 
3 1 55.0 1 Ref - 
Antimicrobi
al use 
Effec
t on 
sow 
No use 
26
4 
48.1 1 Ref. - 
Lincomycin-
spectinomycin
in sow 
30 80 21.33 
5.42-
83.85 
<0.000
1 
Effec
t on 
piglet 
No use 
85
6 
49.3 1 Ref. - 
Amoxicillinin 
piglet 
7 100 6.55 
2.58-
16.64 
<0.000
1 
No use 65 33.6 1 Ref. - 
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5 
Ceftiofurin piglet 
29
8 
52.4 4.15 
2.16-
7.97 
<0.000
1 
No use 
82
1 
48.5 1 Ref. - 
Enrofloxacinin 
piglet 
42 73.8 5.42 
2.63-
11.14 
<0.000
1 
No use 
75
0 
48.7 1 Ref. - 
Lincomycin-
spectinomycin
in sow 
11
3 
56.6 8.12 
2.40-
27.47 
<0.01 
         
Ceftiofur 
Herd 
 
 
1 1 3.2 23.20 
1.09-
492.2
3 
<0.05 
2 1 2.4 4.32 
0.16-
113.1
5 
0.38 
3 1 0.2 1 Ref. - 
Antimicrobi
al use 
Effec
t on 
sow 
No sign. 
effects 
     
Effec
t on 
piglet 
No use 
56
5 
0.2 1 Ref. - 
Ceftiofurin piglet 
29
8 
4.4 >999 
10.34-
>999 
<0.01 
No use 
82
1 
0 1 Ref. - 
Enrofloxacinin 
piglet 
42 1.7 
702.3
4 
39.63-
>999 
<0.000
1 
         
Enrofloxacin Herd  1 1 15.0 12.67 1.80- <0.05 
ANTIMICROBIAL USE AND RESISTANCE IN ESCHERICHIA COLI  
FROM SOWS AND PIGLETS  CHAPTER 6 
 
172 
 
 89.36 
2 1 5.9 0.36 
0.03-
4.69 
0.44 
3 1 10.1 1 Ref - 
Antimicrobi
al use 
Effec
t on 
sow 
No use 
28
6 
6.3 1 Ref. - 
Enrofloxacinin 
piglet 
8 25 4.04 
1.34-
12.20 
<0.05 
Effec
t on 
piglet 
No use  3.2 1 Ref. - 
Ceftiofurin piglet  25.2 31.08 
4.78-
202.2
7 
<0.01 
No use 
82
1 
7.1 1 Ref. - 
Enrofloxacinin 
piglet 
42 47.6 26.78 
8.12-
88.29 
<0.000
1 
No use 
75
0 
7.5 1 Ref. - 
Lincomycin-
spectinomycin
in sow 
11
3 
19.5 7.50 
1.13-
49.87 
<0.05 
         
Streptomycin 
Herd 
 
 
1 1 76.0 24.29 
7.19-
82.06 
<0.000
1 
2 1 62.8 3.97 
1.23-
12.78 
<0.05 
3 1 31.3 1 Ref - 
Antimicrobi
al use 
Effec
t on 
sow 
No use 
23
4 
62.1 1 Ref. - 
Lincomycin-
spectinomycin
in sow 
60 90 
142.7
4 
31.78-
641.1
3 
<0.000
1 
Effec No use 56 18.6 1 Ref. - 
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t on 
piglet 
5 
Ceftiofurin piglet 
29
8 
27.9 2.08 
1.07-
4.02 
<0.05 
No use 
75
0 
49.7 1 Ref. - 
Lincomycin-
spectinomycin
in sow 
11
3 
79.6 56.98 
16.13-
201.3
0 
<0.000
1 
         
Trimethoprim-
sulfadiazine 
Herd 
 
 
1 1 25.4 13.14 
1.48-
116.7
8 
<0.05 
2 1 22.4 6.90 
0.77-
61.88 
0.08 
3 1 18.2 1 Ref - 
Antimicrobi
al use 
Effec
t on 
sow 
No use 
23
4 
18.9 1 Ref. - 
Lincomycin-
spectinomycin
in sow 
60 26.7 18.03 
1.91-
170.2
0 
<0.05 
Effec
t on 
piglet 
No use 
56
5 
12.4 1 Ref. - 
Ceftiofurin piglet 
29
8 
26.8 4.72 
2.27-
9.83 
<0.000
1 
No use 
82
1 
22.5 1 Ref. - 
Enrofloxacinin 
piglet 
42 40.5 3.07 
1.46-
6.43 
<0.01 
No use 
75
0 
22.5 1 Ref. - 
Lincomycin-
spectinomycin
in sow 
11
3 
29.2 16.17 
1.88-
139.2
1 
<0.05 
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Antimicrobial use data in sows and piglets.  
Table 3 shows the TIUDD for the three herds at individual animal level (sows and piglets) during the prepartum 
period (from insemination until 1–3 days before parturition), within 24 hr after birth and at weaning (21–28 
days after parturition). No antimicrobials at all were used in sows at herd 2 during gestation (prepartum) or 
lactation (postpartum). Herds 1 and 
3 used antimicrobials in sows within 24 hr after birth. The highest use was reported in herd 3, where all of the 
20 sows were treated with lincomycin-spectinomycin in the feed. All of the three herds used antimicrobials in 
piglets between birth and weaning age (21 or 28 days). For piglets, the highest use was reported at herd 2. 
No use in piglets was registered between 14 days of age and weaning.  
 
Tetracycline 
Herd 
 
 
1 1 45.8   <0.05 
2 1 31.5   0.06 
3 1 34.9 1 Ref - 
Antimicrobi
al use 
Effec
t on 
sow 
No sign. 
effects 
     
Effec
t on 
piglet 
No use 
85
6 
36.0 1 Ref. - 
Amoxicillinin 
piglet 
7 42.9 2.49 
1.20-
5.18 
<0.05 
No use 
56
5 
28.9 1 Ref. - 
Ceftiofurin piglet 
29
8 
34.2 2.11 
1.17-
3.79 
0.01 
No use 
82
1 
35 1 Ref. - 
Enrofloxacinin 
piglet 
42 57.1 2.72 
1.45-
5.10 
<0.01 
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Table 3. Treatment incidences (TI) at animal level (sows and piglets) prepartum, at birth and at weaning for 
the three sampled herds. 
Treatment at sow level Treatment at piglet level 
Herd Time point 
Number 
of sows 
treateda 
Antimicrobial 
used 
TIUDD
b Herd 
Time 
point 
Number 
of 
piglets 
treated 
Antimicrobial 
used 
TIUDD
b 
1 
Prepartumc 0 - 0 
1 
Birthd 0 - 0 
Parturitiond 5 Marbofloxacin 8.7 
Weaning 
     1 
1 
2 
6 
 
Amoxicillin 
Amoxicillin 
Amoxicillin 
Enrofloxacin 
142.9 
107.1 
71.4 
35.7 
Weaninge 5 Marbofloxacin 7.0 
2 
Prepartum 0 - 0 
2 
Birth 0 - 0 
Parturition 0 - 0 
Weaning 
11 
60 
Enrofloxacin 
Ceftiofur LA 
35.7 
178.6 Weaning 0 - 0 
3 
Prepartum 0 - 0 
3 
Birth 0 - 0 
Parturition 20 
Lincomycin-
spectinomycin 
52.2 
Weaning 
6 
6 
 
Enrofloxacin 
Enrofloxacin 
95.2 
142.9 
Weaning 20 
Lincomycin-
spectinomycin 
44.1 
a Total number of sows per herd = 20; total numbers of piglets per herd = 60. 
b TIUDD = Treatment Incidence at the individual animal level (sow or piglet). The treatment incidence is defined 
as the number of days per 1,000 that one pig is treated with one UDDpig. The UDDpig is the administered dose 
of a drug per day per kilogram pig. 
c The number of days at risk = from day of insemination until 1–3 days before parturition (112–114 days). 
d The number of days at risk = from insemination until parturition (115 days). 
e The number of days at risk = from insemination until weaning (136–143 days). 
f The number of days at risk = not applicable. 
g The number of days at risk = from birth until weaning (21–28 days). 
TI, treatment incidences; UDDpig, used daily dose pig. 
–, no antimicrobials were used. 
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Fixed effects  
Differences in resistance prevalence were observed between herds for all tested antimicrobials, except for 
amoxicillin/clavulanic acid. Herd 1 showed the highest levels of antimicrobial resistance for all animals tested 
(p < 0.05) (Table 2).  
For amoxicillin/clavulanic acid, where only very low levels of resistance were observed, no effect was seen on 
the resistance outcome after antimicrobial exposure in sows and piglets. In general, antimicrobial exposure to 
the piglets solely resulted in higher odds for a positive resistance outcome in the piglets themselves (higher 
odds for ampicillin, ceftiofur, enrofloxacin, streptomycin, trimethoprim-sulfadiazine, and tetracycline; p < 0.05; 
Table 2) and did not result in higher odds for a positive resistance outcome in their dam at weaning, except 
for the administration of enrofloxacin to the piglets (enrofloxacin use in piglets versus no enrofloxacin use in 
piglets resulted in odds ratio for enrofloxacin resistance in sows = 4.04, p < 0.05). Furthermore, antimicrobial 
exposure to lincomycin-spectinomycin in sows resulted in higher odds for a positive resistance result in the 
sows themselves (for ampicillin, streptomycin, and trimethoprim–sulfadiazine; p < 0.05; Table 2) and in their 
piglets (for ampicillin, enrofloxacin, streptomycin, trimethoprim–sulfadiazine, and tetracycline; p < 0.05; Table 
2). In contrast, no effect at all was seen for the administration of marbofloxacin to the sows, neither for sows 
nor for piglets, however, only five sows were treated with this antimicrobial agent.  
A positive resistance outcome for streptomycin and ampicillin in sows before parturition and at parturition, 
respectively, resulted in higher odds for resistance to the respective antimicrobials in their piglets at birth (p < 
0.05). Positive resistance outcomes for tetracycline in sows at parturition resulted in higher odds for resistance 
to tetracycline in their piglets at 14 days after birth (p < 0.05).  
 
Random effects  
The chance on a positive resistance outcome significantly (p < 0.05) differed between nests (sow with three 
piglets) for ampicillin, enrofloxacin, trimethoprim-sulfadiazine, and tetracycline. The correlation of the 
resistance outcome between animals within a nest was 4.6%, 38.9%, 14.4%, and 6.8% for ampicillin, 
enrofloxacin, trimethoprim-sulfadiazine, and tetracycline, respectively. Furthermore, individual animal variances 
of outcomes measured at different time points were seen for ampicillin, enrofloxacin, streptomycin, 
trimethoprim–sulfadiazine, and tetracycline (significant random intercept on the individual animal level p < 
0.05). The correlation of the resistance within an animal was 7.7%, 5.6%, 15.3%, 9.1%, and 10.9%, 
respectively, for ampicillin, enrofloxacin, streptomycin, trimethoprim–sulfadiazine, and tetracycline. 
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DISCUSSION 
The occurrence of clinically resistant E. coli isolates in piglets between birth and weaning may be called 
substantial with almost half of the isolates being resistant to one or two antimicrobials and more than a 
quarter of them being resistant to at least three antimicrobials.  
During farrowing, E. coli isolates from sows were found more often resistant to at least three antimicrobials 
compared with piglet isolates. However, resistance to at least four antimicrobials was found as frequently in 
sows as in piglets (15.6% and 15.2% of the isolates in sows and piglets, respectively). High levels of 
antimicrobial resistance in young animals have been reported before (Langlois et al., 1988; Mathew et al., 
2003; Dewulf et al., 2007; Stannarius et al., 2009). The presence of resistant E. coli strains in newly born 
piglets before any direct selection pressure, might put the sow forward as a resistance reservoir for her 
offspring, since young piglets are continuously exposed to the sow’s microflora. Similarly, resistant E. coli 
have been found in young calves not previously exposed to antimicrobials (Berge et al., 2005). The individual 
treatment of the dam has been proposed as a risk for the persistence of a resistant microflora, acting as a 
commensal resistance pool for the offspring.  
Results from this research show a higher resistance frequency in isolates from pigs suckling sows with 
exposure to in-feed lincomycin-spectinomycin, although only used in one herd. Again, this might be the result 
of the transfer of resistant bacteria from the dam to her offspring. However, also, as the majority of orally 
administered spectinomycin is excreted unchanged in the feces (Giguère, 2006), this might form a direct 
selection pressure for suckling piglets. Treating sows and/or piglets involves a disturbance of the E. coli 
population, without inventing de novo or changing the presence of the antimicrobial resistance determinants 
itself, but by the selection of the less susceptible subpopulation.  
The use of intramuscular marbofloxacin in the sow did not appear to affect resistance in E. coli isolates in 
piglets or in E. coli isolated from the sows themselves. Marbofloxacin is mainly excreted in the urine and the 
excreted residues are in an active form (Walker and Dowling, 2006). As a result, the residues might engender 
a selection pressure on the bacteria of animals in the surroundings. Yet, no link was found between the 
administration of marbofloxacin in sows and resistance in either the 
treated sows or in their piglets. This might be because of the treatment of too little sows (n = 5), which lowers 
the power 
for detection of any trend.  
The use of antimicrobials in piglets increased the prevalence of resistance in the piglets themselves. In this 
study, no effect of use in piglets (amoxicillin and ceftiofur) on the presence of resistance in their dam was 
seen, except for enrofloxacin use in piglets toward enrofloxacin resistance in the sows. Resistance to 
quinolones is mainly determined by a mutation process, which is enhanced by antibiotic concentrations within 
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the mutant selection window (Smith et al., 2003). Small amounts of excreted enrofloxacin in urine from piglets 
might engender a selection pressure and select for mutants less susceptible to enrofloxacin. Resistance to 
amoxicillin and cephalosporins, antimicrobials which are equally excreted in urine (Prescott, 2006), have other 
resistance mechanisms, for which the mutant selection window is less appropriate (Smith et al., 2003).  
One of the herds showed significantly higher resistance outcomes compared with the other herds, whereas 
the extent to which antimicrobials were used in the currently observed sows in the current production cycle 
was not proportionally higher in comparison to the other herds. Yet, also the antimicrobial use in the other 
age categories and in the previous production rounds is likely to influence the resistance levels, as it 
maintains a commensal resistance pool, as previously described. In this study, no other herd-related factors 
than antimicrobial use, which also might influence the selection and spread of resistance determinants, were 
investigated. 
For most antimicrobials, a significant correlation between the occurrences of resistance in animals in one nest 
was observed, indicating that the resistance level in animals within a nest is more alike than from animals in 
different nests. Only amoxicillin/clavulanic acid and ceftiofur were not consistent with these results. Yet, the 
low resistance percentages noticed for these antimicrobials may partly explain this divergence. Although the 
observed correlations are significant for most antimicrobials, they are not always very high, illustrating that 
substantial different results can be found between animals in the same nest. This is likely the result of the fact 
that only two isolates are tested per animal, whereas a variation of E. coli populations is expected to be 
present within the gut of each animal. 
CONCLUSION 
In conclusion, the current results suggest that sows act as a reservoir for their newborns and that the 
administration of antimicrobial agents to sows during lactation is a risk factor for the persistence of resistant 
E. coli not solely for themselves, both also for their newborn offspring. Also, the administration of 
antimicrobials in the piglets exerts a direct selection pressure in the piglets themselves during lactation. 
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MONITORING ANTIMICROBIAL USE AND RESISTANCE 
The emergence of antimicrobial resistance in commensal, zoonotic, and pathogenic bacteria from pigs, mainly 
as a result of antimicrobial consumption, and potentially threatening treatment options in both human and 
veterinary medicine, is worrisome. Closely monitoring antimicrobial use and antimicrobial resistance levels are 
both important first steps in strategies aiming to contain antimicrobial resistance. Commensal bacteria, 
commonly present in animals, are exposed to any antimicrobial administration and therefore good indicators 
for antimicrobial resistance. The first aim of this thesis was to quantify group use of antimicrobial agents in 
Belgian pig herds. 
ANTIMICROBIAL USE IN BELGIAN PIG PRODUCTION 
WHAT HAS (NOT) CHANGED SINCE 2003 AND WHAT HAS TO BE DONE?   
A first estimation on the use of antimicrobials in Belgian swine production was made in 2003. Since then, no 
antimicrobial use data have been collected through single monitoring studies or on a continued basis. 
Therefore, at the onset of this thesis in 2009, it was questioned how this situation did evolve. The objective of 
the study on antimicrobial use in the Belgian pig production was to determine the quantitative and qualitative 
group use at herd level for pigs between birth and slaughter for a representative number of herds of the 
national population (Chapter 3). These data were preferably compared to the 2003 antimicrobial use data on 
a similar study population, including equal sample size. Currently, there is no consensus on the best indicator 
to be selected to quantify antimicrobial consumption in animals (OIE, 2014a). Treatment incidences (TI) based 
on the defined daily dose animal (DDDApig) and on the used daily dose animal (UDDApig), used in the former 
Belgian study on antimicrobial usage, allowed for the quantification of the number of animals being treated in 
a herd and for a trend analysis of antimicrobial consumption over time. TI based upon DDDApig take into 
account variation in potencies (e.g. higher in frequently used 3th and 4th generation cephalosporins) and were 
thus more suitable as a technical unit of measurement than weighing active substances used relative to the 
animal population at risk (Jensen et al., 2004). Information on indications, correctness of dosing, prophylactic 
or metaphylactic use, active substances and administration routes applied, were all part of the primary 
objective of this study. In order to quantify the truly administered doses, i.e. UDDApig, detailed data such as 
the numbers of pigs at risk of being treated, the weight at treatment and the treatment length were needed. 
This required direct access to the herd data. Since at that time no organized structures were present that 
facilitated the monitoring of antimicrobial usage patterns at the individual herd level, a questionnaire during a 
face-to-face on site interview with the farmer was performed.  
Conclusions of the report on antimicrobial use data collection in 2003 included a high prophylactic group level 
use and incorrect dosing of most treatments (Timmerman et al., 2006). In the beginning of the 2000s, first 
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available antimicrobial usage data for pigs equally showed a high antimicrobial use in the Netherlands and 
Denmark, as Belgium, countries with substantial levels of pork production (LEI, 2011; DANMAP, 2013). 
Concerns about the risk for antimicrobial resistance selection and spread related to the use of antimicrobials 
in pigs, as well as other food animals have prompted several institutions, including veterinary specialty 
practice organizations, to develop and publish judicious use guidelines (RUMA, 2013; EPRUMA, 2015; FVE, 
2015). Every use of antimicrobials should be preceded by a proper clinical examination of the animal. Both 
clinical experience of the veterinarian and diagnostic laboratory information (pathogen isolation and 
identification) should be part of the final diagnosis. The above excludes the use of antimicrobials as 
prophylaxis, as animals are then treated at times, it is expected that they will become affected but do not (yet) 
exhibit symptoms of a disease. Laboratory confirmation of the bacterial pathogen as well as an accurate 
assessment of its in vitro antimicrobial susceptibility form the ideal basis for choosing the most appropriate 
antimicrobial agent (as narrow as possible). Also, clinical experience of the veterinarian will determine the 
expected efficacy of the treatment, if this treatment is initiated before the results of laboratory testing are 
available. For this, the herd veterinarian should be guided by the epidemiological history of the pig herd, 
particularly in relation to the antimicrobial resistance profiles of the pathogens involved. Regarding this 
antimicrobial choice, special attention has to be paid to the OIE and WHO list of antimicrobial agents of 
veterinary and human importance, which both indicate quinolones and 3rd/4th generation cephalosporins as 
critically important (WHO, 2011; OIE, 2014b). Their use should be restricted to final resort and after 
susceptibility testing. Finally, the appropriate dosage/duration regimen, as mentioned on the prescription 
leaflet, should be followed. 
Compliance between results from chapter 3 and the above described guidelines, can be assessed in order to 
verify to what extend these guidelines were implemented in Belgian pig production. 
Usage data collected in 2010 (Chapter 3) revealed an average TI, based on the DDDApig and on the 
UDDApig, equal to 235.8 and 200.7, respectively. These numbers indicate that Belgian pigs were being 
administered antimicrobials (for preventive or metaphylactic reasons) on average during 20% of their life time. 
Numbers for 2010 were substantially higher than what was found in 2003 (TIDDDApig and TIUDDApig equaled 
178.1 and 170.3 respectively) suggesting that, in between, there was a clear rise in the average antimicrobial 
usage in pigs. Moreover, results for 2010 showed that only one out of the 50 questioned herds (2%) did not 
administer antimicrobials in group (Chapter 3), where six out of the 50 herds (12%) did not use group 
treatments in the 2003 study (Timmerman et al., 2006). A random sampling of the population may suffer from 
the willingness for farmers to participate, which likely results in a selection bias. Yet, since data collection and 
quantification of drug consumption was performed in a comparable manner in 2003 and 2010, observed 
differences are believed to be a true representation of the evolution over these years. Based on these results 
it became clear that preventive group treatments have become, although not compliant with guidelines on no 
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preventive antimicrobial use, more than ever, a habit in the daily management of raising pigs. This illustrates 
that antimicrobials are often considered as a management tool administered for prophylactic reasons to entire 
groups of animals. Data from our study did not include any antimicrobial administration for curative reasons. 
Given that pig farmers in Belgium were only required to keep records of antimicrobial treatments for 2 months 
prior to the slaughter of animals, it was very difficult to obtain reliable retrospective information on the 
therapeutic use of antimicrobials throughout the production cycle. In a recent study of Postma et al. (2014), 
also large between herd variation in curative treatments has been observed, indicating that also this curative 
use may still contribute substantially to the total amount of antimicrobials administered in a herd. Furthermore, 
no data on antimicrobial usage in breeding animals were included. Recently, for Belgian pig herds, it has 
been estimated that sows are treated for prophylactic and curative reasons during 7% of the time of one 
breeding cycle (Postma et al., 2014). Usage in sows is therefore estimated to be much lower than in fattening 
pigs. Yet, results from Chapter 6 indicate that antimicrobial exposure of sows prior to farrowing and during 
lactation can increase antimicrobial resistance in the bacteria of their offspring. Although the prevalence of 
resistant E. coli is decreased in elderly pigs, sows can still act as a reservoir for resistant bacteria to their 
newborns (Chapter 6).  
From the above, it is clear that antimicrobial usage in pig production is very high and that the reported data 
from this study (prophylactic and methaphylactic group level use for fattening pigs between birth and 
slaughter) are still an underestimation of what is truly administered to all pigs on a herd. Therefore, a more 
precise estimation requires collection of antimicrobial usage data for all reasons via the different 
administration routes (preventive, metaphylactic and curative treatments via feed and water, parenteral and 
local) and for all categories on a farm (nursery pigs, weaned pigs, fattening pigs and sows) on a continued 
basis by a well-established data collection system.  
The frequent incorrect dosing reported by Timmerman et al. (2006) was reaffirmed by the fact that 82% of the 
administered doses in our study were incorrect (79.5% overdosed and 47.3% underdosed for injectable and 
oral products respectively) and reflects the negligent handling when it comes to antimicrobial drug 
administration to pigs (Chapter 6).  
The increased portion of long acting injectable antimicrobial formulations (long acting amoxicillin, ceftiofur and 
tulathromycin) as well as broad spectrum substances (3rd and 4th generation cephalosporins) in the number of 
treatments compared to 2003 clearly shows that farmers intend to choose for new and easy-to-use 
formulations instead of substances who have been licensed for a longer period, as doxycycline and 
potentiated sulfonamides (trimethoprim-sulfonamides). 
Third and 4th generation cephalosporins have antibacterial activity against Gram-positive (aerobic and 
anaerobic), Gram-negative aerobic and to a lesser extent Gram-negative anaerobic bacteria (Giguère, 2013). 
Therefore, they belong to the antimicrobial classes with the broadest spectrum. A bacterial diagnosis can be 
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considered irrelevant, since their use covers almost the entire spectrum of routinely cultured bacteria. 
However, their use also results in a broad antimicrobial resistance selection pressure on both pathogenic and 
commensal bacteria. Therefore, the majority of the use of these broad spectrum substances is not in 
agreement with the concepts of responsible antimicrobial use. It is highly questionable whether they are 
necessary to control animal disease problems. The tendency towards the use of new, long acting substances 
should be stopped in order to minimize antimicrobial selection pressure. While old substances, such as 
tetracyclines, trimethoprim and penicillin have a more narrow spectrum, their use should equally be reserved 
as they might act as (co-)selectors for LA-MRSA (Kadlec et al., 2012). A restricted use of critically important 
3rd and 4th generation cephalosporins and quinolones should result from the implementation of specific 
recommendations on antimicrobial use for animal species per indication, developed in Belgium by AMCRA, 
Centre of Expertise on Antimicrobial Use and Resistance in Animals. Active substances within these classes 
are assigned a red colour code and are always placed as the final choice option for any bacterial infection in 
all animal species. Substances with a red colour code must only be used when results of the antimicrobial 
susceptibility testing clearly show that the bacterial isolate is not susceptible to compounds with a spectrum 
less broad than the one of 3rd and 4th generation cephalosporins and quinolones. From this, it can be 
concluded that these red molecules are identified ‘the last remaining resort’, and awareness among users is 
stimulated. When strictly applying such an approach, the use of the red molecules is expected to be reduced 
substantially, as examples in other countries have demonstrated (MARAN, 2014). 
Results in chapter 3 show that pigs are more often exposed to oral antimicrobial therapy (TIDDDDDDA, oral = 
183.5 and TIUDDA, oral = 176.5) than injectable administrations (TIDDDA, injectable = 52.3 and TIUDDA, injectable 
= 24.2). Moreover, 75 % of the oral administrations are in-feed. BelVet-SAC confirms the high use of 
medicated feed in pigs by reporting 59.74 tons of antibacterial premixes being used in 2010 in veterinary 
medicine, of which more than 99% is intended for the pig sector (BelVet-SAC, 2015). As a result, as part of 
the achievement of a substantial antimicrobial use reduction target in pigs, particular attention should be given 
to the use of antimicrobials in medicated feed. The in feed mixing in the compound feed company is highly 
controlled, offering advantages regarding the homogeneity and dosing of the antimicrobial substance. The 
threshold for use of medicated feed is low and one might question whether this is still acceptable in the 
current climate of sustainable antimicrobial usage, as was discussed in the recent report of the Scientific 
Committee of the Federal Agency for the Safety of the Food Chain (2013). Between 2011 and 2013, a 10.2% 
decrease in medicated feed use has been realized, although in 2014, an increase of 0.2% was seen again 
(BelVet-SAC, 2015). A continuation and solidification of the decrease will be needed to achieve the 50% 
reduction in 2017 compared to what was used in 2011. The latter is set as an objective in the vision 
statement, developed by all member sectors of AMCRA in 2014, defining the guidelines of the antimicrobial 
use and resistance policy among animals in Belgium (AMCRA, 2014). The authorization to prescribe 
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medicated feed only by the veterinarian responsible for guidance might substantially contribute to this 
reduction.  
In 2003, in Belgium, data on antimicrobial use from other intensive animal production systems were not yet 
available. Meanwhile, TI have also been reported for the broiler and veal calf production (Pardon et al., 2012; 
Persoons et al., 2012). Based upon these results it has become clear that the pig production is the second 
highest user per produced animal, preceded by the veal calf production (TIUDDA equaled 416.8) and followed 
by broiler chicken production (TIUDDA equaled 121.4). Recently, an attempt to estimate the proportion of use in 
tons in the whole population of these different species in Belgium was made taking into account the different 
size of the production sectors (Filippitzi et al., 2014). Based upon this rough estimate it was concluded that 
the vast majority of antimicrobials used in Belgium were administered to pigs (159.4 tons), followed by broilers 
and veal calves (26.5 tons and 25.2 tons respectively) (Filippitzi et al., 2014). This clearly suggests that the 
pig sector can make a significant contribution to the required decline in the tons of antimicrobials used in the 
veterinary sector and therefore carries a large responsibility.  
Data on antimicrobial use from 2010 reinforced the concerns already expressed in 2006 by Timmerman et al. 
(2006). Previously formulated guidelines and recommendations did not result in action towards a reduced and 
responsible use. 
COLISTIN USE IN ANIMALS 
In Belgian pigs, intervening with post-weaning Escherichia coli diarrhea and edema disease is one of the main 
reasons for prophylactic and metaphylactic group treatments during the stressful nursery period (Chapter 3). 
Before the introduction of zinc oxide (ZnO) at pharmacological doses in 2013, E. coli diarrhea in nursery pigs 
in Belgium has been prevented and controlled mainly via the administration of colistin in-feed and to a lesser 
extent in water (+/-75% and 25% of the administrations respectively) (Chapter 3). In 2012, the total colistin 
consumption in medicated feed for pigs in Belgium was approximately 2500 kg active substance on a total of 
55 000 kg active substance used in medicated feed (4,5%) (BelVet-SAC, 2013). The contribution of colistin in 
the total antimicrobial use for the control of enteric diseases (prophylactic and metaphylactic) in pigs has been 
estimated at 55% (Chapter 3). The high intrinsic susceptibility of E. coli and the poor absorption of colistin in 
the intestine are important criteria to select colistin in the treatment of neonatal or post-weaning E. coli 
infections in food producing animals (Landman et al., 2008). Also, colistin has high stability, relative low 
toxicity via oral administration, no cross-resistance with other antimicrobials, and slow and unstable 
emergence of resistance (Dowling, 2013b).   
Consequentially, the extended oral use of colistin in pigs and other animals, targeting intestinal pathogens 
such as E. coli and Salmonella enterica (Koyama et al., 1950; Timmerman et al., 2006; Chapter 3), requests 
stringent monitoring of colistin susceptibility, including molecular identification of resistance determinants.   
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Increasing occurrence of colistin resistance in veterinary important bacteria has only recently been reported 
(Harada et al., 2005; Boyen et al., 2010; de Jong et al., 2012). This might partially be due to relatively recent 
attention combined with the poor disk diffusion of colistin in agar. The frequently used disk diffusion technique 
is thus less appropriate for this antimicrobial agent. More appropriate phenotypic susceptibility tests, such as 
dilution techniques or disk prediffusion are necessary for proper detection (Boyen et al., 2010). 
In Belgium, a trend analysis of the colistin susceptibility test results of national monitoring studies in 2011, 
2012 and 2013 has been made for commensal E. coli isolates, obtained from healthy animals, including pigs 
(CODA-CERVA, 2014a). Colistin resistance increased slightly in E. coli from pigs (0.64%, 0.92% and 2.43% 
non-wild type strains in 2011, 2012 and 2013 respectively) and fluctuated in E. coli from broilers (0.48%, 
4.69% and 1.71% non-wild type strains in 2011, 2012 and 2013 respectively). Colistin resistance has equally 
emerged in beef cattle, but remains at acceptable low levels (CODA-CERVA, 2014a). In veal calves, the % of 
non-wild type strains was high in 2011 (14.71%), but decreased in 2012 and 2013 (6.08% and 5.94% 
respectively) (CODA-CERVA, 2014a). Although not statistically significant, the increasing trend in pigs 
warrants for further monitoring. Compared to E. coli from clinically healthy pigs, a higher percentage of colistin 
resistance (9.6%) was observed for E. coli, isolated from clinically affected pigs in Belgium, using the same 
epidemiological cut-off value (MIC > 2 μg/ml) (Boyen et al., 2010). A pan-European survey across 8 EU 
countries, including Belgium, during 2009-2012, showed a growth inhibition of at least 90% of the E. coli 
isolates from animals with clinical signs, at a concentration of 4 μg/ml (MIC90 value of 4 μg/ml) (Klein et al., 
2015).  
In the scope of the high colistin use in Belgian pigs (Chapter 3), Moore and Elborn (2012) expressed their 
concerns on the emergence of colistin resistance in E. coli in animals and the possible linked failure of colistin 
therapy in humans, for instance in the treatment of cystic fibrosis infections in humans, mainly caused by 
Pseudomonas aeruginosa. In human medicine, colistin has reemerged as a last resort therapeutic option to 
treat infections due to multi-resistant bacteria, including non-fermenting Gram-negative pathogens (e.g. 
Pseudomonas aeruginosa and Acinetobacter baumannii) and for carbapenemase producing 
Enterobacteriaceae (e.g. Klebsiella pneumoniae and E. coli) (Li et al., 2006). Therefore it can be questioned 
whether the use of colistin in the treatment of infections with these multi-resistant P. aeruginosa, A. 
baumannii, K. pneumoniae and E. coli might be jeopardized by the extended colistin use in veterinary 
medicine (Moore and Elborn, 2012).  
Therapeutic failure of a bacterial infection with an antimicrobial in humans, due to the selection of resistant 
bacteria in the animal microbiota by this same antimicrobial, supposes the spread of the animal-related 
resistant bacteria to humans, the colonization with resistant bacteria (same clone) or horizontal transfer of 
resistance genes to other bacteria in the human microbiota. For colistin resistance, one must bear in mind 
that the resistance mechanisms are defined by chromosomal mutations and until now, horizontal gene 
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transfer of colistin resistance has not yet been demonstrated (Landman et al., 2008). Thus, there is no 
evidence that colistin resistant bacteria transfer their resistance genes from animals to human pathogens or 
vice versa. Also, with the exception of some well-examined clinical strains, many of the mutation mechanisms 
are not stable after several passages in vitro (Moskowitz et al., 2012). Therefore, a potential hazard of colistin 
resistance in bacteria associated with animals is estimated to be limited and probably only involves 
zoonotically important bacteria, such as S. enterica. As far as we know, there are at present no indications 
that animal associated bacterial strains are involved in cystic fibrosis in humans. Nevertheless, based on 
current data, transmission of such resistance cannot be absolutely excluded. For other antimicrobial drug 
resistant organisms including E. coli, the emergence and transfer of resistant bacteria via direct animal contact 
or via food has been documented (Angulo et al., 2004). Further research on the potential transfer of 
resistance in which human and animal derived P. aeruginosa and A. baumannii strains are compared between 
animal related bacteria and Gram-negative bacteria from humans is warranted. In addition to the use of 
colistin, other antibiotic classes (e.g. glycylcyclines (tigecycline) and phosphonic acid derivates (e.g. 
fosfomycin)) can be used to combat infections caused by multi-resistant Gram-negative bacteria and have 
been reclassified as critically important antibiotics (WHO, 2011). Fosfomycin is active in vitro against multi-
resistant Enterobacteriaceae, including a high proportion of P. aeruginosa. However, clinical studies on 
parenteral formulation are limited (Falagas et al., 2008; Reffert and Smith, 2014). Tigecycline, which is active 
against multi-resistant Enterobacteriaceae and A. baumannii, has shown satisfactory clinical experience 
(Giamarellou, 2010). Recently, a novel aminoglycoside, ACHN-490, has shown to have in vitro activity against 
multidrug-resistant K. pneumoniae isolates (Endimiani et al., 2009).  
The veterinary community should be aware that limited options of antibiotics (including colistin) are available 
to treat multi-resistant Gram-negative infections in human medicine and that at the same time resistance to 
these agents might be on the rise. As soon as colistin resistance determinants are found on mobile genetic 
elements in the bacteria of concern from human or animal origin, or a clonal explosion of virulent bacteria 
takes place, a new risk assessment would be required (EMA, 2013).   
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MEASURES TO MANAGE 
There is an increased societal demand for sustainable animal production and intensive antimicrobial use is 
negatively perceived by the general public which might hamper pork consumption. Moreover, pig production 
represents 83% of animal meat production in Belgium and is the main part of the human meat supply inside 
Belgium (VLAM, 2014). In order to safeguard animal and human health and to maintain its market position, 
the pig production will need to invest in a more sustainable pork production including, amongst others, using 
less antimicrobials. A continued high antimicrobial usage jeopardizes both animal and public health through 
the emergence of resistant bacteria. Action must be undertaken at this level by defining an antimicrobial use 
policy which includes regulation of and control on implementation of responsible use guidelines. Though in 
order to succeed, several other factors must accompany this reduced usage. Antimicrobial stewardship is the 
term increasingly used in acute care medicine to describe the multifaceted approaches required to reduce 
usage and avoid resistance selection to sustain the efficacy of antimicrobials in the long run. Below, 
measures to manage antimicrobial use in swine husbandry are discussed.  
A CONTROLLED ANTIMICROBIAL USAGE  
Monitoring studies from 2003 (Timmerman et al., 2006) and 2010 (Chapter 3) on antimicrobial use, along 
with the estimations of the tons used in the pig sector (Filippitzi et al., 2014) provide insights in the extent to 
which intensive pig production in Belgium consumes antimicrobials. Yet, the establishment of a data collection 
system (DCS), providing usage data at herd level on a continues basis, is needed to make further actions 
possible. This DCS - at the end-user level - enables mapping of antimicrobial use per animal species and 
production category (nursery pigs, weaned pigs, fattening pigs and sows), the follow-up of evolutions in time 
on a herd and within an animal category and the benchmarking towards fellow-herds. The collection at the 
end-user level enables to identify ‘outliers’ for high and/or irresponsible use, and thus takes a central role in 
tackling undesired quantitative and qualitative aspects of use. The threshold set for defining outliers can be 
defined as the 5, 10, 15,… % highest users. As the identification of outliers is based on benchmarking, 
ideally, all pig herds should be included. In Belgium, a first initiative for data collection at the herd level has 
been taken by the pig private sector, namely the quality label Certus, managed by Belpork vzw. In the 
framework of this initiative, approximately 60% of the pig herds in Belgium, collection of data on antimicrobial 
consumption at herd level is mandatory from January 2014 onwards. It is aimed for that other pig holders will 
adhere voluntarily and that the system grows to a coverage of the whole sector. Identification of herds with a 
high antimicrobial use based on benchmarking is reliable only when data collection is mandatory for all pig 
farmers. 
The establishment of a data collection system must be well-considered both to assure clear and correct feed-
back to farmers and veterinarians in order to increase awareness on usage patterns and to assure a 
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comparability of the collected data between countries. For these farms with an antimicrobial use above the 
thresholds, adaptations of the management will be required. These can either be voluntary implemented or 
might be reinforced through legislative actions. 
Communicating precise data on antimicrobial use and if deemed necessary, followed by restrictions imposed 
by law, should guarantee the current armory of antimicrobials to be sufficient for the foreseeable future. 
Questions on the development of new antimicrobials have been put forward worldwide. Yet, it must be 
remembered that most of the antimicrobials used in pigs are already over thirty years old and that the majority 
of them are still working. Even the more modern antimicrobials such as 3rd and 4th generation cephalosporins, 
if used carefully and not for widespread prophylaxis, should maintain their efficacy. Furthermore, one must not 
forget that resistance determinants are naturally present and that they benefit from the use of antimicrobials 
for their spread in the ecosystem. As a result, the development of new antimicrobials is a ‘self-sustaining 
process’ with a high cost and a low rate of return on investment compared with drugs for the treatment of 
chronic conditions. Focus should be on research in porcine health, increasing the possibilities for new, 
innovative solutions, such as vaccines, which could have a large potential. Also, better evidence based 
treatment and improved treatment strategies with less impact on problematic resistance are important 
objectives. Effective dosing should be seen as targeting bacterial cure rather than clinical cure (Pankey and 
Sabath, 2004).  
More action can be taken in controlling antimicrobial use. The Summary of Product Characteristics (SPC) for 
currently authorized products should be reviewed to ensure consistency for measures to ensure responsible 
use. For instance, it is considered appropriate to remove all indications for prophylactic use in order to 
minimize any potential risk associated with a broader use. Yet, from our results (Chapter 3), it appears that in 
practice, the distinction between prevention and treatment is vague. In fact, much of the use of antimicrobials 
that is claimed to be therapeutic is intended to control disease and often involves mass medication. 
Furthermore, the inclusion of new indications, formulations or species on the prescription leaflet of currently 
authorized products should be subject to full antimicrobial resistance risk assessment before approval.  
DRIVERS FOR IMPROVED HEALTH 
Large between herd variations in antimicrobial use have been reported (Chapter 3, Timmerman et al., 2006). 
Understanding differences in disease incidence, management, husbandry, biosecurity, hygiene, feed, genetics 
as well as in farmer and veterinarian attitudes at the farm level might help to explain the observed differences 
in treatment incidences (Hybschmann et al., 2011; Laanen et al., 2013; Visschers et al., 2015). First attempts 
on quantifying the effect of biosecurity on production results and antimicrobial treatment incidence in breeder-
finisher pig herds through a risk-based weighted biosecurity scoring system showed that herds scoring higher 
in biosecurity equally had a more efficient production (Laanen et al., 2013; Postma et al., 2014; Backhans et 
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al., 2015). Moreover, higher biosecurity has been shown to be negatively associated with disease treatment 
incidence (Laanen et al., 2013; Postma et al., 2014). This suggests that improved biosecurity might help in 
reducing the amount of antimicrobials used prophylactically. In order to reduce antimicrobial resistance in 
piglets, control measures should be implemented, at first, at the sow level, involving minimal antimicrobial use 
and high hygienic standards (Chapter 6). Given the fact that the youngest animals are the most susceptible 
for infectious diseases and thus that the majority of strategic group treatments in pigs are given during the 
farrowing/battery phase (Chapter 3), the greatest factor impacting on the frequency of antimicrobial usage is 
to be expected in this part of the production cycle. In some European countries, ZnO at pharmacological 
doses has been introduced to control post-weaning E. coli infections (FCEC, 2010). Since August-September 
2013, Belgium is the 11th country in the EU with a (temporary) approval for the use of pharmacological doses 
of ZnO. The use of ZnO might have contributed to the decrease in colistin use in medicated feed between 
2012 and 2013 (23%). Questions raise about the long term use of ZnO in the field. Although it promotes 
health and performance in piglets, ZnO also has antibacterial properties and is a heavy metal with a potential 
environmental burden. In order to control the emission in the environment, an agreement has been reached 
between the Belgian government, compound feed manufacturers and feeding companies to reduce the 
amount of zinc used as a feed additive from 150 ppm to 110 ppm in the fattening phase in order to 
compensate for the high dosage of Zn (2500 ppm) given for maximal 14 days after weaning. Even though the 
dosing schedule during fattening leads to a total decrease of 4.5% of the environmental Zn burden, the 
search for alternatives to both antimicrobials and heavy metals should be continued. Resistance to Zn does 
occur in bacteria. Moreover resistance against this metal may co-select for antimicrobial resistance, as has 
been described for livestock-associated methicillin-resistant Staphylococcus aureus (LA-MRSA) (Cavaco et al., 
2011). Consequently, ZnO might not to be the best alternative. Ideally, as for any compound with antibacterial 
effects, the use of ZnO at the farm level should be nationally monitored. In the presence of antimicrobial 
resistance data, a potential link between ZnO use and antimicrobial resistance might then be detected in an 
early stage. Also, links between ZnO used at pharmaceutical doses and the use of other veterinary medicines 
might then be analyzed. In conclusion, one might wonder to which extent the replacement of colistin by 
pharmacological doses of ZnO will contribute to a decreased antimicrobial resistance, the ultimate goal of a 
reduced antimicrobial use. Its use might in contradiction result in an undesired increased selection pressure 
on resistance determinants. This might include the risk of compromising porcine health and welfare. 
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ANTIMICROBIAL RESISTANCE IN BELGIAN PIG PRODUCTION 
To assess the impact of the antimicrobial usage, described in chapter 3, on antimicrobial resistance trends in 
commensal and pathogenic bacteria of pigs the susceptibility of Streptococcus suis and Escherichia coli of 
clinically healthy pigs at the end of the fattening period was tested (Chapter 4, Chapter 5, Chapter 6).   
ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS SUIS STRAINS FROM BELGIAN PIGS 
S. suis, mainly associated with meningitis, affecting piglets principally between 6 and 10 weeks old, is one of 
the most important swine pathogens worldwide (Gottschalk et al., 2000). In the two monitoring studies on 
antimicrobial use in Belgium (Timmerman et al., 2003; Chapter 3), it was observed that S. suis infections are 
mentioned as one of the predominating reasons for antimicrobial treatment. This is in agreement with 
antimicrobial administration as currently being the most widespread preventive measure for S. suis infections 
(Staats et al., 1997; Prescott, 2013). S. suis can be isolated from diseased as well as from healthy carrier pigs 
as they can colonize the tonsils, the nasal cavity, the intestines and the reproductive tract of sows without 
causing clinical disease (Staats et al., 1997). In this respect, S. suis is, as colonizing bacterium, subject to any 
antimicrobial selection pressure from systemically administered antimicrobials. Results from chapter 4 on S. 
suis susceptibility levels based on clinical interpretive criteria could only be documented for erythromycin, 
tetracycline, penicillin and florfenicol, as no clinical breakpoints are available for the other antimicrobials tested 
(CLSI, 2013). S. suis was shown to be almost entirely susceptible to florfenicol and penicillin (clinical 
resistance equaled 0.3% and 1%), whereas high levels of resistance to erythromycin and tetracycline were 
seen (66% and 95% respectively). Genes encoding resistance to macrolides are widespread among S. suis 
isolates (Wisselink et al., 2006; Zhang et al., 2008; Princivalli et al., 2009) and the high-level resistance to 14-
, 15-, and 16-membered macrolides is mainly caused by the constitutive expression of the erm(B) gene 
(Martel et al., 2001; Tian et al., 2004). This gene refers equally resistance to lincosamides and 
streptogramins, due to methylation of the 50S ribosomal subunit, the common target of action for these 
classes (Martel et al., 2001). In accordance with the widespread resistance to these antimicrobials, in our 
study, a non-wild type population was observed for all macrolides and lincosamides tested. Currently, the 
clinical breakpoint used for tetracycline is only available for S. suis isolated from swine respiratory disease 
(CLSI, 2013). However, the high percentage of non-wild type strains (98%) confirmed earlier information on 
the widespread tetracycline resistance amongst S. suis isolates (Wisselink et al., 2006; Zhang et al., 2008; 
Princivalli et al., 2009). Tetracycline resistance is mainly encoded by the genes tet(M) and tet(O), but an 
increasing number of tet genes has been discovered in the past few years (Palmieri et al., 2011). Resistance 
genes to tetracycline (tet(M) and tet(O/W/32/O)) and macrolides (erm(B)) are often found in common mobile 
elements, such as transposons (Tn1545) (Seral et al., 2001; de Leener et al., 2004) and integrative and 
conjugative elements (ICESsu32457) (Palmieri et al., 2012). Tn1545 has a wide host range and it has been 
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found for instance in streptococci and enterococci from humans, pigs and poultry (Seral et al., 2001; de 
Leener et al., 2004; Cauwerts et al., 2007). Furthermore, it can be transferred by conjugation to several 
bacterial species and is therefore probably responsible for a large part of the tetracycline and macrolide 
resistance observed in streptococci from several hosts (Aarestrup and Schwarz, 2006). Also the ICESsu32457 
may be, amongst other, an important genetic vehicle for the spread of tet(O/W/32/O) and erm(B), as it is 
transferable between pathogenic Streptococcus species, such as S. suis, S. pyogenes, S. pneumonia and S. 
agalactiae (Palmieri et al., 2012). As in pig streptococci, erm(B)-encoded resistance is the most important 
mechanism in human streptococci S. pneumoniae and S. pyogenes in Belgium (Descheemaeker et al., 2000; 
Lagrou et al., 2000). Moreover, homologous sequences of the erm(B) gene from porcine S. suis and human 
streptococci (S. pneumonia and S. pyogenes) indicate possible exchange of resistance genes between human 
and porcine streptococcal strains (Martel et al., 2001). The spread of resistance determinants between 
streptococcal populations of humans and pigs is of particular interest as S. suis is considered as an emerging 
zoonotic pathogen responsible for septicemia with or without septic shock, meningitis, endocarditis, arthritis, 
hearing loss and skin lesions in humans (Goyette-Desjardins et al., 2014). S. suis infection is acquired from 
pigs, either during slaughtering or by handling and eating undercooked pork products. Intensive contact 
between animals and humans, such as for pig farmers and slaughter house workers, might predispose the 
spread of resistance determinants between bacterial populations of pigs and humans. Currently, the majority 
of S. suis cases in humans occur in South-East Asia (Goyette-Desjardins et al., 2014). Yet, from 2005 
onward, an increasing number of S. suis infections in humans has been reported worldwide, also in countries 
where the infection had been rarely or never reported before (Zalas-Wiecek, 2013; Gómez-Zorrilla et al., 
2014). The available information on the resistance determinants strongly suggests that S. suis is an important 
antimicrobial resistance reservoir (Palmieri et al., 2011). Therefore, they can contribute to the spread of 
resistance genes to other, pathogenic, bacterial populations from humans and animals. In order to find 
possible exchanges of resistance genes, there is an urge for more knowledge on the resistome of S. suis. S. 
suis isolates from pigs with pleuritis have previously been used for the continuous monitoring of antimicrobial 
susceptibility (Hendriksen et al., 2008). Because they are subject to any antimicrobial selection pressure from 
systemically, both parenteral and oral, administered antimicrobials, S. suis from healthy animals may act as a 
Gram-positive indicator bacterium when monitoring resistance over time.  
The preventive or curative use of macrolides and tetracyclines to combat streptococcal infections has been 
almost entirely excluded due to the wide spread of resistance determinants against these antimicrobials. 
Belgian therapeutic recommendations, including a wide range of antimicrobials potentially useful for 
counteracting streptococcal infections, have placed tetracyclines as third and last treatment option in 
counteracting S. suis infections (AMCRA, 2013). Dutch antimicrobial use guidelines report S. suis as highly 
resistant to macrolides and tetracyclines (KNMVD, 2014). Yet, macrolide or tetracycline administration for any 
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other indication might (co-) select for resistance determinants conferring resistance to the respective 
antimicrobials, and engender their spread between bacterial populations within and between the host animals 
and humans. In chapter 3, it has clearly been described that these molecules are still widely used in the 
Belgian pig production. In the BelVet-SAC report these molecules are presented as 3rd and 4th most frequently 
used substances in antibacterial premixes, which are designated for more than 99% to the pig sector (BelVet-
SAC, 2015). Therefore, a continuous selective pressure is and will be present in the future as long as these 
substances are used.  
Amoxicillin in feed is currently the most frequently administered antimicrobial for the treatment, prevention and 
control of S. suis infections in weaned piglets in Belgian pig production (Chapter 3). This is in line with the 
worldwide suggestion of β-lactams as the primary antimicrobials to treat streptococcal infections (Zhang et al., 
2014). Yet, several reasons can be quoted to restrict the use of broad-spectrum aminobenzyl penicillins, a 
group within the β-lactams, for instance amoxicillin, to a minimum. Its broad spectrum exerts a selection 
pressure on commonly acquired resistance determinants in Gram-negative bacteria, such as in E. coli 
(Chapter 5) or Salmonella spp. (EFSA and ECDC, 2014), bacteria commonly colonizing pigs as both 
commensal and pathogen. More precisely, its use has been shown to select for extended-spectrum-beta-
lactamase producing E. coli (ESBL) in the intestinal microbiota of pigs (Cavaco et al., 2008). Therefore, 
Belgian guidelines restrict the use of aminobenzyl penicillins by proposing the implementation of specific 
conditions for use (AMCRA, 2013).  
Instead, parenteral administered procaine benzyl penicillin (penicillin G) and orally administered benzyl 
penicillin (phenoxymethyl penicillin or penicillin V) have narrow spectrum activity, i.e. against many Gram-
positive bacteria, including beta-hemolytic streptococci, but only to a limited number of Gram-negative 
bacterial species (Prescott, 2013). Narrow spectrum use is in agreement with prudent use recommendations 
(Staats et al., 1997, AMCRA, 2013; KNMVD, 2014). Nevertheless, in Belgium, the practical implication 
interferes with these recommendations as currently no orally administered penicillin (penicillin V) is licensed 
and S. suis infections are generally controlled by group administration, for which oral substances are highly 
time efficient, and therefore preferred by the farmer.  
Furthermore, the results on penicillin susceptibility of S. suis based on clinical breakpoints differ from the 
results of the epidemiological interpretive criterion (Chapter 4). The Minimum Inhibition Concentration (MIC) 
population distribution reveals tailing toward higher MIC values (percentage of non-wild-type isolates equaled 
47% based on epidemiological cut-off value of 0.25 µg/ml). This reduced susceptibility is the result of the 
acquisition of stepwise mutations in genes encoding penicillin binding proteins (Aarestrup et al., 2007). A 
single-point mutation results in isolates with a modest increase in MIC, and infections due to these isolates 
may still be treatable with penicillins, but they are of great concern as they represent an introductory step to 
full resistance (Amyes, 2007). Isolates showing higher values of MICs are associated with additional 
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mutations and most likely lead to therapy failure (Chambers, 1999). As a result, shifts in the MIC population 
distributions may predict future evolutions in the clinical efficacy of antimicrobials used to counteract bacterial 
infections.  
Mutations resulting in a decreased susceptibility to penicillin are selected by β-lactam use (Chambers, 1999), 
commonly used in Belgian pig farms (Chapter 3). This raises questions on their future clinical use as primary 
antimicrobials for streptococcal infections. The use of narrow spectrum molecules (penicillin) should always be 
preferred above broad-spectrum aminopenicillins and the potential selection of mutant strains should be 
minimized by the implementation of specific conditions for use. The veterinary diagnostic laboratory should not 
report the full result of the susceptibility testing. It might be beneficial to report a limited number of 
antimicrobial substances, primarily first-line/small spectrum before second-and third-line/broad spectrum 
substances, in order to decrease the risk of unnecessary use of these agents. For instance, if S. suis shows 
clinical susceptibility towards broad spectrum 3th and 4th generation cephalosporins, critically important 
antimicrobials according WHO and OIE (WHO, 2011; OIE, 2014b), as well as towards small spectrum 
penicillins or potentiated sulfonamides (trimethoprim-sulfonamide), only these latter substances should be 
reported. In this respect, for veterinary diagnostic laboratories, there is an urgent need for agreements on 
what antimicrobials should be tested for certain bacteria and how results should be reported.  
COMPARING ANTIMICROBIAL SUSCEPTIBILITY OF BELGIAN AND OTHER STREPTOCOCCUS SUIS 
STRAINS – A CHALLENGE   
Interpreting susceptibility testing results of bacterial species, including S. suis, can be most challenging. 
Variations in interpretive criteria (different clinical breakpoints, clinical versus epidemiological criterion), as well 
as differences in susceptibility testing methodology (diffusion or dilution testing), animal health status 
(diseased or healthy), or differences in serotypes tested may contribute to apparent differences in 
antimicrobial susceptibility of bacterial isolates from different studies. These apparent differences hinder the 
detection of true differences, mainly caused by different selection pressures such as antimicrobial usage. 
Furthermore, they might result in different interpretations regarding the usage-resistance link. In our study, 
clinical breakpoints were consulted from the Clinical and Laboratory Standards Institute document VET01-S2 
(CLSI, 2013). This document includes the largest collection of internationally recognized clinical breakpoints 
for bacteria of animal origin currently available, a considerable number of which represent veterinary-specific 
breakpoints. These breakpoints are mainly based on the pharmacological and clinical criterion and depend on 
animal species, disease, pathogen, antimicrobial compound and treatment regimen (dose, route, duration, 
frequency). For S. suis, in the VET01-S2 no clinical breakpoints were available for lincomycin, tiamulin, 
tilmicosin and tylosin. In the absence of the appropriate breakpoint, many studies use breakpoints for bovine 
or swine respiratory pathogens different from S. suis (Wisselink et al., 2006; Zhang et al., 2008) or from 
human streptococci (Marie et al., 2002; Wisselink et al., 2006; Zhang et al., 2008). Some susceptibility studies 
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used the CLSI clinical breakpoint for Actinobacillus spp. (32 μg/ml), causing respiratory tract disease in pigs, 
for evaluating tiamulin and tilmicosin resistance in S. suis (Wisselink et al., 2006; Zhang et al., 2008). This 
resulted in respectively 34.4% and 66.7% of the S. suis isolates being clinically resistant. When changing one 
of the regimen specifics related to the approved interpretive criterion, such as a different pathogen as well as 
a different population of animals or a different disease process, the approved breakpoint may no longer be 
entirely valid for predicting clinical success after the administration of an antimicrobial compound. As a result, 
the Actinobacillus spp. clinical breakpoint cannot be extrapolated as such to S. suis (Schwarz et al., 2010). 
Hence, clinical resistance in Belgian S. suis isolates was not determined for these antimicrobials without the 
appropriate clinical breakpoint, i.e. lincomycin, tiamulin, tilmicosin and tylosin (Chapter 4). For enrofloxacin, 
florfenicol and tetracycline, the clinical breakpoint was only available for S. suis involved in swine respiratory 
disease (2 μg/ml, 8 μg/ml and 2 μg/ml respectively) and implemented as such in our study (Chapter 4). In 
2006, Wisselink et al. (2006) used breakpoints for enrofloxacin and florfenicol based on CLSI data of bovine 
respiratory Gram-negatives (2 μg/ml and 8 μg/ml respectively). Despite different pathogens or animal species, 
breakpoints equaled with the ones for S. suis involved in swine respiratory disease. For tetracycline, the 
authors used CLSI data for veterinary pathogens, but which were at that time taken by CLSI from data for 
human streptococci (8 μg/ml). This resulted in a different tetracycline breakpoint and a considerable higher 
outcome for clinical resistance in our study (95% based on a clinical breakpoint of 2 μg/ml) compared to the 
study of Wisselink et al. (2006) (75% based on a clinical breakpoint of 8 μg/ml). Also, nowadays, the CLSI-
approved clinical breakpoints in document VET01-S2 for erythromycin and penicillin are based on human 
pharmacokinetics and treatment regimens for human streptococci. These breakpoints are formulated in order 
to provide clinical breakpoints for veterinary medicine, suggesting that the application of these breakpoints for 
animal associated bacteria, e.g. S. suis, might be justified in our study as well as in other studies as long as 
no veterinary-specific breakpoints are available (Wisselink et al., 2006; Zhang et al., 2008). Clinical resistance 
to penicillin in our study was low (1% based on the 2 μg/ml breakpoint) (Chapter 4), whereas higher 
percentages have been reported in the nineties, even using a higher breakpoint (4 μg/ml) (Turgeon et al., 
1994). More recently, in Spain, 7% of the isolated strains of diseased pigs showed clinical resistance to 
penicillin, using the same breakpoint as in our study (2 μg/ml) (Vela et al., 2005). In China, higher resistance 
levels were reported for penicillin (9.5%, based on the 4 μg/ml breakpoint), meaning that the use of the 2 
μg/ml breakpoint might reveal even higher percentages of clinical resistance.  
From the above, it is clear that the lack of validated veterinary-specific resistance breakpoints is an important 
limitation for veterinarians trying to practice evidence-based medicine. Moreover, due to its variability, it often 
does not allow for proper comparisons between studies. In Europe, the Veterinary Committee on Antimicrobial 
Susceptibility Testing (VetCAST) has been recently installed by a group of veterinary microbiologists and 
pharmacologists, as a subcommittee of EUCAST, that aims at defining and approving clinical breakpoints 
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specific to the veterinary field (VetCAST, 2014). Hereby, the predictive value of susceptibility data for clinical 
purposes will hopefully improve in veterinary diagnostics.  
In the absence of clinical interpretive criteria for pathogens isolated from pigs, isolates should not be classified 
as susceptible or resistant for the concerned antimicrobial agents tested, and only MIC data should be 
presented. Unfortunately, only few studies provide MIC distributions (Martel et al., 2001; Vela et al., 2005; 
Wisselink et al., 2006). Their use ensures the comparability of data over time at country level and also 
facilitate the comparison of the occurrence of resistance between countries. Increased MICs of S. suis for 
penicillin in our study (Chapter 4) underlined the importance of reporting antimicrobial susceptibility testing 
results based on epidemiological interpretive criteria, as it can act as an early warning for an emerging clinical 
problem. Also for tiamulin, results from the S. suis MIC population distribution, showed a clear shift towards 
higher MIC values. Unfortunately, today, epidemiological cut-off values, in order to distinguish between the 
wild-type and the non-wild-type population within a bacterial population, are not available for S. suis from 
EUCAST (EUCAST, 2015). In this study, MIC values without a clear bimodal distribution, seen for some of 
the antimicrobials tested (penicillin, tilmicosin, erythromycin, lincomycin, tiamulin and tetracycline), made the 
setting of an epidemiological cut-off value harsh. Several explanations for subpopulations showing differences 
in susceptibility can be suggested. In our study, a true resistance difference within the S. suis population can 
result from animals being differently treated. Another explanation might be the presence of different serotypes 
or bacterial strains with different acquired resistance mechanisms within one S. suis population. A continued 
reporting of serotypes or genotypes is currently lacking for many countries, including Belgium, even though, 
differences in serotype susceptibility of S. suis have been described (Aarestrup et al., 1998; Marie et al., 
2002; Vela et al., 2005; Wisselink et al., 2006). Therefore, serotype specific data on susceptibility might be an 
interesting path to investigate, as it can provide valuable information on the activity of antimicrobial agents 
against the major serotypes associated with disease in pigs.  
ANTIMICROBIAL SUSCEPTIBILITY OF ESCHERICHIA COLI STRAINS FROM BELGIAN PIGS 
Antimicrobial susceptibility of commensal E. coli may provide an indication of the magnitude of the selective 
pressure from the use of antimicrobials in an animal population. Commensal E. coli are therefore often 
included as Gram-negative indicator bacteria for resistance in national and international monitoring studies (de 
Jong et al., 2009; FINRES, 2011; DANMAP, 2013; MARAN, 2014, EFSA and ECDC, 2015).  
High clinical resistance prevalence in commensal E. coli from the antimicrobial susceptibility prevalence study 
in pigs is not surprising, in view of the high antimicrobial use in Belgian pig production (Chapter 3, Chapter 
5). Results from different studies investigating antimicrobial resistance in porcine E. coli strains are often 
difficult to compare due to differences in study design, particularly the population of swine sampled as well as 
sampling, testing protocols and interpretive criteria used. Nevertheless, Chantziaras et al. (2014) 
demonstrated a high level of comparability in clinical resistance results of commensal swine E. coli between 
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the prevalence study of this thesis (Chapter 5) and the Belgian national monitoring study, despite a different 
sampling and susceptibility testing methodology. The high prevalence of resistance against streptomycin, 
tetracycline, sulfadiazine, trimethoprim and ampicillin (Chapter 5) has also been reported frequently in other 
countries (Boerlin et al., 2005; Varga et al., 2008; EFSA and ECDC, 2015). The common patterns of 
resistance to streptomycin, tetracyclines, sulfonamides, trimethoprim and ampicillin (and combinations thereof) 
frequently observed in the monitoring of E. coli isolates are probably related to the presence of class 1 or 
class 2 integrons, which generally carry genes conferring resistance to these antimicrobials (Marchant et al., 
2013; EFSA and ECDC, 2015). As a consequence, a substantial number of antimicrobials or antimicrobial 
classes used in Belgian swine production is likely to select for isolates with this resistance pattern (Chapter 
3). Also resistance to chloramphenicol is often found to be present in the multi-resistance pattern of 
streptomycin, tetracyclines, sulfonamides, trimethoprim and ampicillin (EFSA and ECDC, 2015). The most 
frequently encountered resistance mechanism against chloramphenicol is encoded by the chloramphenicol 
acetyltransferases (CAT) genes, commonly found on mobile genetic elements carrying additional resistance 
genes (Dowling, 2013a). Bacteria expressing the CAT genes show lower levels of resistance to florfenicol, 
sharing its mechanism of action with chloramphenicol, compared to chloramphenicol (Schwarz et al., 2004). 
Florfenicol resistance in Gram-negative bacteria is related to plasmid transfer of the floR gene and promotes 
the efflux of both forfenicol and chloramphenicol (Blickwede and Schwarz, 2004). Therefore, lower levels of 
florfenicol than chloramphenicol resistance in E. coli from the prevalence study indicate these old CAT 
resistance genes are still circulating and that the floR gene was only limited present (Chapter 5). The 
continued high chloramphenicol resistance level in E. coli (Chapter 5), despite its prohibition in food 
producing animals for more than 20 years, is therefore a result of the use of florfenicol and other 
antimicrobials (cross and co-selection). Moreover, the limited use of florfenicol in Belgian fattening pigs 
suggests that mainly co-selection is responsible for a persistent chloramphenicol resistance in E. coli from 
these pigs (Chapter 3). 
Resistance development against quinolones, categorized as critically important for humans and animals, 
occurs mainly by mutations, even though plasmid mediated quinolone resistance (PMQR) has been described 
(Strahilevitz et al., 2009). The prevalence study showed susceptibility results based on clinical breakpoints 
and revealed a higher percentage of E. coli clinically resistant to nalidixic acid (4.1%) compared to 
enrofloxacin (1.4%) (Chapter 5). These results were indicative for the development of quinolone resistance by 
a stepwise manner, as a single mutation in the quinolone resistance-determining region (QRDR) domain of 
the gyrA gene will confer resistance to the first generation quinolone, nalidixic acid, whereas it only decreases 
susceptibility to second generation quinolones, such as enrofloxacin (Giguère and Dowling, 2013). Only 
secondary mutations will then lead to clinical resistance in enrofloxacin. Mutational resistance can mask the 
presence of PMQR genes, as these genes result in a reduced susceptibility, similar to that conferred by first-
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step mutations, that is below the CLSI breakpoint for resistance (Strahilevitz et al., 2009). PMQR contributes 
to enlarge the mutant selection window (MSW), which is the drug concentration range within which QRDR 
mutants are selectively enriched (Cano et al., 2007). PMQR can therefore contribute to bacteria becoming 
fully resistant. Most recent results from the national monitoring program revealed a higher percentage of non-
WT E. coli strains for ciprofloxacin than for nalidixic acid, both quinolones, suggesting the prevalence of 
PMQR (CODA-CERVA, 2014b). The emergence of PMQR is of concern due to the possibility of horizontal 
transfer (Strahilevitz et al., 2009). Quinolones, mainly used in Belgium, for individually treatments of pigs 
during farrowing and sows, might contribute to the selection and spread of PMQR in E. coli mutants and 
therefore take part in therapeutic failure (Chapter 3, Chapter 6). Furthermore, PMQR genes were shown to 
be associated with other resistance elements on the same plasmid, for instance, with various genes encoding 
extended-spectrum-beta-lactamases (ESBLs) (Szmolka and  Nagy, 2013). The use of ceftiofur in piglets as a 
risk factor for an increased fluoroquinole resistance in E. coli as well as the opposite finding (enrofloxacin use 
as a risk factor for ceftiofur resistance) suggests the presence of PMQR in these E. coli strains (Chapter 6). 
Resistance determinant genotyping of these strains is needed to confirm these findings.  
Commensal E. coli are also useful as representatives of the Enterobacteriaceae to monitor the emergence 
and changes in the proportion of bacteria possessing extended-spectrum-beta-lactamases (ESBL). Several 
studies have detected ESBL producing E. coli in pigs, amongst other production animals (Hammerum et al., 
2014). The use of 3rd and 4th generation cephalosporins leads to ESBL-producing E. coli among food 
producing animals (Cavaco et al., 2008; Hammerum et al., 2014). Results from chapter 6 showed 
associations between 3rd generation cephalosporin use and resistance in young piglets. As described earlier, 
more stringent measures regarding this critically important antimicrobial class are needed in the light of an 
increased 3rd and 4th generation cephalosporin use in Belgian pig farms between 2004 and 2010 (Chapter 3), 
as well as for all animals in Belgium from 2010 onwards, described by the national antimicrobial consumption 
report (BelVet-SAC, 2015). In fattening pigs, resistance to third generation cephalosporin (ceftiofur), indicative 
of ESBL producing E. coli, was present at low levels (2.7%) (Chapter 5). Yet, it should be said that 
monitoring for ceftiofur resistance using selective media can detect ceftiofur resistant E. coli present as a 
minor component of the total bacterial microbiota in the test sample, which might only occasionally be 
detected by random sampling from non-selective culture plates (EFSA and ECDC, 2015). 
E. coli of animal origin with acquired resistance genes can be transmitted to humans via direct contact with 
animals, via food of animal origin, or via the environment (Hammerum and Heuer, 2009). These bacteria may 
subsequently colonize humans or may transfer resistance genes to other bacteria during passage through the 
intestinal tract. Transfer of resistance determinants from a (transiently) colonizing animal E. coli strain to 
human commensal microbiota has been observed in vivo, even in the absence of selective pressure 
(Hammerum and Heuer, 2009). Regarding the zoonotic potential of E. coli related to pigs, attention goes to 
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the extraintestinal pathogenic E. coli, causing meningitis, septicemia, urinary tract infections, pneumonia (Tan 
et al., 2011). In humans, the majority of infections caused by extraintestinal E. coli are not life-threatening 
(e.g., uncomplicated urinary tract infections), whereas other infections (e.g., bloodstream infections) may be 
lethal. Yet, accumulating data support the likelihood that animal reservoirs, including pigs, could be 
responsible for contamination of humans with resistant extraintestinal pathogenic E. coli strains through direct 
contact or the consumption of contaminated food (Johnson et al., 2005; Jakobsen et al., 2010). These 
bacteria may cause infections for which limited therapeutic options are available (Hammerum and Heuer, 
2009). In human medicine, urinary tract infections due to extraintestinal pathogenic E. coli are traditionally 
treated with ampicillin or trimethoprim-sulfamethoxazole. Resistance to these agents as well as to extended-
spectrum β-lactamases, aminoglycosides, tetracyclines, and fluoroquinolones is now frequently observed 
(Smith et al., 2007).  
The high antimicrobial resistance of E. coli in pigs (Chapter 5, Chapter 6), its potential to transfer resistance 
determinants to human bacteria as well as the potential role of animal-related resistant E. coli in human 
infections, emphasize the importance of including E. coli in monitoring studies. 
In Belgium, susceptibility testing on E. coli strains isolated from both clinically healthy and diseased animals is 
performed regularly (Butaye, 2012; DGZ, 2014). Thereto, micro-broth dilution and agar disk diffusion tests are 
both used. In general, there is a tendency to give preference to micro-broth dilution over agar disk diffusion 
since the dilution test is the more accurate test method for detection of acquired resistance (EFSA, 2008). 
Yet, both zone disk diameters and MICs, results from disk diffusion and dilution tests respectively, can be 
displayed in a population distribution offering the advantage of detecting non-wild type strains. Yet, more 
often, zone disk diameters are categorized into ‘susceptible’, ‘intermediate’ or ‘resistant’, suggesting the 
clinical effectiveness for a certain antimicrobial-bacterium. Differences in disk diffusion methodology or in 
clinical breakpoints complicates comparisons of susceptibility results and excludes them from monitoring 
studies for comparative reasons. The harmonization of veterinary antimicrobial susceptibility testing is an 
objective of VetCAST (2014). In the meantime, due to the use of the Normalized Resistance Interpretation 
(NRI) method, potential valuable susceptibility data on commensal E. coli from a single study can still be used 
and should not be excluded from these monitoring studies (Chapter 5). Moreover, laboratories often provide a 
huge source of historical antimicrobial susceptibility data, obtained from the routinely performed disk diffusion 
test. The interpretation of disk diffusion data could be improved in these individual laboratories using NRI, and 
the obtained data could be useful for comparative reasons during monitoring, provided that zone disk 
diameters have been recorded and saved. High quality records of the zone disk diameters can be achieved 
by automatic reading devices, which for instance will prevent the tendency of rounding down or up zone disk 
diameters to even numbers, typically seen for non-automatized reading. The use of automatic reading devices 
will equally increase the recording and saving of zone disk diameters. The need for higher quality standards 
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for susceptibility testing has been expressed by VetCAST, aiming for optimized methods for antimicrobial 
susceptibility testing of bacterial pathogens of animal origin and zoonotic bacteria (VetCAST, 2014).  
Also, veterinary specific breakpoints for E. coli from pigs are currently missing from the EUCAST and CLSI 
database (Chapter 5). The veterinary diagnostic microbiology laboratory urgently needs bacterial species-, 
animal host- and infection-specific breakpoints for the practice of evidence-based antimicrobial therapy by 
providing culture and susceptibility information to practitioners. Several authors have shown that antimicrobial 
resistance more frequently occurs in pathogenic than in commensal E. coli strains from pigs (Boerlin et al., 
2005; Hendriksen et al., 2008; Chantziaras et al., 2014). Although similar qualitative resistance patterns are 
being observed, i.e. increased levels of resistance to the same antimicrobials, between these commensal and 
pathogenic E. coli, results of clinical resistance of commensal E. coli cannot be used to predict the expected 
levels of resistance prevalence of pathogenic E. coli and vice versa.  
The harmonization of veterinary antimicrobial susceptibility testing and the setting of veterinary specific 
breakpoints in the European Union will be in line with the adoption of the EUCAST harmonized method and 
the establishment of clinical breakpoints for human medicine (Brown et al., 2015). By doing so, the future of 
the disk diffusion test will be secured for both human and veterinarian medicine (Matuschek et al., 2014). 
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CONCLUSIONS 
The high occurrence of resistance to antimicrobials in commensal E. coli and S. suis from Belgian pigs is 
likely to depend on a number of factors, of which the selective pressure exerted by antimicrobial use in pigs is 
extremely important. In practice the distinction between prevention and treatment is vague and much of the 
use of antibiotics that is claimed to be therapeutic is intended to control disease and often involves mass 
medication. By consequence, this use turns out to be at a permanent, even increased level in Belgian pig 
industry since it first records in 2003, despite the concerns expressed at that time. Proper monitoring of both 
antimicrobial usage and resistance is valuable as it detects evolutions in antimicrobial use and resistance 
linked to antimicrobial consumption. This warrants further actions to improve monitoring of antimicrobial use 
and resistance.  
 
More specifically, it can be recommended that: 
- A data collection system is installed covering the entire Belgian pig production in order to collect and 
quantify herd level-data. These data should be used to monitor use in time, to benchmark farmers and 
veterinarians, to identify ‘outliers’ for high and/or irresponsible antimicrobial use and to implement 
targeted intervention measures. 
- Colistin resistance in animal-related bacteria is monitored and that a risk assessment for human health is 
made in the event resistance determinants get organized on mobile genetic elements.  
- S. suis from healthy animals are included as a Gram-positive indicator bacterium when monitoring 
resistance over time.  
- Therapeutic failure of penicillin to treat S. suis infections is considered, in view of an increasing 
percentage of non- wild type strains. 
- Veterinary antimicrobial susceptibility testing is harmonized and that veterinary-specific resistance 
breakpoints are validated in order to facilitate the practice of evidence-based medicine.  
- Epidemiological cut-off values for both pathogenic and indicator bacteria, e.g. S. suis, are established as 
they make early detection of emerging antibiotic resistance possible. 
- The Normalized Resistance Interpretation (NRI) method is used to define the wild type population for 
disk diffusion results when wild type cut-offs are not available. NRI allows historical disk diffusion 
susceptibility data to be included in monitoring studies, provided that inhibition zone diameters are 
available.   
- In order to reduce antimicrobial resistance in piglets, control measures are implemented, at first, at the 
sow level, involving minimal antimicrobial use and high hygienic standards. 
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Since their discovery, antimicrobials have become indispensable tools in countering bacterial diseases in both 
humans and animals. Yet, their use is overshadowed by a phenomenon that has become increasingly more 
threatening over the last decades, namely antimicrobial resistance. Antimicrobial resistance in pathogenic and 
zoonotic bacteria results in decreased efficiency and/or therapeutic failure in both animals and humans. Even 
though pathogenic bacteria are generally most studied, commensal bacteria may play a key role in the 
dissemination and persistence of this resistance. 
As a general introduction, an overview is given on the antimicrobial use in production animals, with particular 
attention to the use of antimicrobials in pig production (Chapter 1.1.). In this chapter, background information 
is provided on the reasons for antimicrobial use and which antimicrobial classes and routes of administration 
are used. Also, the collection of antimicrobial consumption data for quantifying use is discussed. In addition to 
the collection of antimicrobial consumption data, the monitoring of antimicrobial resistance in bacteria in food-
producing animals is unmistakably important in the establishment of strategies for containing resistance. In 
chapter 1.2., the role of swine Escherichia coli and Streptococcus suis, both commensal bacteria potentially 
involved as pathogen and/or zoonotic bacteria in animals and humans, in monitoring programs is described. 
Monitoring resistance identifies trends in the emergence, spread and persistence of resistance to 
antimicrobials and is therefore a prerequisite for understanding the epidemiology of resistance. Chapter 1.3. 
reviews the key aspects and drivers of the four stages in the epidemiology of antimicrobial resistance in 
animal production, i.e. development, selection and spread, persistence and reversion or reduction.  
The objectives of this thesis, which are stated in chapter 2, were to determine the level of antimicrobial use 
on Belgian pig herds, the levels of epidemiological and clinical resistance in S. suis and E. coli from clinically 
healthy fattening pigs and to investigate whether the presence of antimicrobial resistant E. coli in sows and 
the administration of antimicrobials to sows and piglets during farrowing influenced the antimicrobial 
resistance in fecal commensal E. coli in sows and their offspring. 
In order to get insight in the quantitative (numbers of days a pig is treated over a lifespan of 1000 days) and 
qualitative (indications, prophylactic or metaphylactic use, active substances and administration routes used) 
aspects of antimicrobial group-level use at the herd level in Belgian pig production and to assess changes in 
the antimicrobial use since 2003, a cross-sectional study on 50 closed or semi-closed fattening pig herds was 
conducted (Chapter 3). Ninety-three percent of the group treatments were prophylactic whereas only 7% 
were metaphylactic. The most frequently used antimicrobials orally applied at group level were colistin 
(30.7%), amoxicillin (30.0%), trimethoprim-sulfonamides (13.1%), doxycycline (9.9%) and tylosin (8.1%). The 
most frequently applied injectable antimicrobials were tulathromycin (45.0%), long acting ceftiofur (40.1%) and 
long acting amoxicillin (8.4%). The treatment incidences (TI) based on the used daily dose pig (UDDpig or the 
actually administered dose per day per kg pig of a drug) for all oral and injectable antimicrobial drugs was on 
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average 200.7 per 1000 pigs at risk per day (min = 0, max = 699.0). This means that a pig is treated on 
average 201 days over a lifespan of 1000 days, or said differently, it is treated on average 20% of its lifespan. 
The TI based on the animal daily dose pig (ADDpig or the national defined average maintenance dose per day 
per kg pig of a drug used for its main indication) was slightly higher (average = 235.8, min = 0, max = 
1322.1). This indicates that in reality fewer pigs were treated with the same amount of antimicrobials than 
theoretically possible. Injectable products were generally overdosed (79.5%), whereas oral treatments were 
often underdosed (47.3%). Antimicrobial use was substantially higher in 2010 compared with what was found 
in 2003 (TIDDDApig and TIUDDApig equaled 178.1 and 170.3, respectively) suggesting that there was an increase 
in the average antimicrobial use in pigs in that period. In conclusion, this study shows that prophylactic group 
treatment was applied in 98% of the visited herds and often includes the use of critically important and broad-
spectrum antimicrobials. In 2010, in Belgium, the guidelines for prudent use of antimicrobials were not yet 
implemented in pig production. 
Antimicrobial resistance in bacteria can be monitored by using clinical or epidemiological interpretive criteria. 
The use of clinical interpretive criteria may be sufficient from the point of view of the clinician as it predicts the 
clinical outcome of the treatment in the patient at the prescribed drug dose. Yet, epidemiological cut-off values 
are more valuable to make comparisons between different studies, to monitor the evolution of antimicrobial 
resistance in time and to detect acquired resistance at an early stage. Therefore, both interpretive criteria 
were used to calculate the percentage of clinical resistant and non-wild type strains of S. suis and E. coli from 
clinically healthy pigs.  
In the antimicrobial resistance prevalence study on S. suis (Chapter 4), non-wild type percentages were high 
for tetracycline (98%), lincomycin (92%), tilmicosin (72%), erythromycin (70%), tylosin (66%), and low for 
florfenicol (0%) and enrofloxacin (0.3%). Clinical resistance percentages were high for tetracycline (95%), 
erythromycin (66%), tylosin (66%), and low for florfenicol (0.3%) and enrofloxacin (0.3%). For tiamulin, for 
which no clinical breakpoint is available, 57% of the isolates did not belong to the wild type population. 
Clinical resistance and non-wild type percentages differed substantially for penicillin. Only 1% of the tested S. 
suis strains was considered as clinically resistant, whereas 47% of the strains showed acquired resistance 
when epidemiological cut-off values were used. In conclusion, Minimum Inhibitory Concentration (MIC) values 
for penicillin are gradually increasing, compared to previous reports, although pigs infected with strains 
showing higher MICs may still respond to treatment with penicillin. The high rate of acquired resistance 
against tiamulin has not been reported before. Results from this study clearly demonstrate that the use of 
different interpretive criteria contributes to the extent of differences in reported antimicrobial resistance results. 
The early detection of small changes in the MIC population distribution of isolates, while clinical failure may 
not yet be observed, provides the opportunity to implement appropriate risk management steps.  
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In the absence of epidemiological interpretive criteria for E. coli-antimicrobial combinations, clinical breakpoints 
are used to interpret susceptibility test results obtained by disk diffusion. Yet, differences in the 
standardization of the methodology over time and between laboratories as well as differences between 
recommended clinical breakpoints result in a lack of comparability between the test results of disk diffusion, 
and preclude potentially valuable data, collected in different laboratories, from resistance monitoring studies. 
In chapter 5, Normalized Resistance Interpretation (NRI) was used on E. coli isolates from clinically healthy 
pigs at slaughter age and was shown to be a valid method to define the wild type population for outcomes 
with a normal distribution of inhibition zone diameters for the susceptible population. Percentages of non-wild 
type strains could therefore be determined and compared to clinical resistance percentages. In conclusion, 
until harmonization of the disk diffusion methodology is achieved, the NRI method might give rise to a wide 
application in monitoring resistance in veterinary medicine. Also, historical data, for instance from previous 
prevalence studies, might be included in monitoring programs for comparative reasons, provided that zone 
diameters have been recorded. 
The last study of this thesis investigated whether antimicrobial resistant E. coli in apparently healthy sows and 
antimicrobial administration to sows and piglets influenced antimicrobial resistance in fecal commensal E. coli 
from piglets (Chapter 6). 
Sixty sows from three herds and three of their piglets were sampled at several time points. Antimicrobial use 
data during parturition and farrowing were collected. Clinical resistance was determined for two isolates per 
sampling time point for sows and piglets using disk diffusion. Only 27.4% of E. coli isolates from newborn 
piglets showed no resistance. Resistance to one or two antimicrobial classes equaled 41.2% and 46.8% in 
isolates from sows and piglets, respectively, for the overall farrowing period. Multiresistance to at least four 
classes was found as frequently in sows (15.6%) as in piglets (15.2%). Antimicrobial resistance in piglets was 
influenced by antimicrobial use in sows and piglets and by the sow resistance level (p < 0.05). Using 
aminopenicillins and third-generation cephalosporins in piglets affected resistance levels in piglets (odds ratios 
[OR] > 1; p <  0.05). Using enrofloxacin in piglets increased the odds for enrofloxacin resistance in piglets 
(OR = 26.78; p < 0.01) and sows at weaning (OR = 4.04; p < 0.05). For sows, antimicrobial exposure to 
lincomycin-spectinomycin around parturition increased the resistance to ampicillin, streptomycin and 
trimethoprim-sulfadiazine in sows (OR= 21.33, OR= 142.74, OR= 18.03; p <  0.05) and additionally to 
enrofloxacin in piglets (OR= 7.50; p < 0.05). This study demonstrates that antimicrobial use in sows and 
piglets is a risk factor for antimicrobial resistance in the respective animals. Moreover, resistance determinants 
in E. coli from piglets are selected by using antimicrobials in their dam around parturition. 
In the general discussion (Chapter 7), first, it was discussed that the establishment of a data collection 
system (DCS), providing usage data at herd level on a continuous basis, is needed to make further actions 
possible, more specifically to identify outliers in quantitative and qualitative antibiotic use. S. suis is commonly 
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present in healthy animals and therefore subject to any antibiotic selection pressure from both parenteral and 
oral administration routes. Therefore, it may act as a Gram-positive indicator bacterium when monitoring 
resistance over time. The detection of higher levels of epidemiological compared to clinical resistance in S. 
suis from clinically healthy pigs has emphasized the role of epidemiological interpretive criteria in the 
detection of acquired resistance and in monitoring resistance over time. Thereto, the setting of epidemiological 
cut-off values for bacterial species, e.g. S. suis, is required. Also, validated veterinary-specific resistance 
breakpoints are needed to facilitate the practice of evidence-based medicine. There is a need for 
harmonization of veterinary antimicrobial susceptibility testing. Yet, until harmonization is achieved, the NRI 
method has shown to be valid for defining the wild type population for disk diffusion results. Antimicrobial 
exposure of sows prior to farrowing and during lactation can increase antimicrobial resistance in E. coli of 
their offspring. Therefore, sows act as a reservoir for resistant E. coli to their offspring. In order to reduce 
antimicrobial resistance in piglets, control measures should be implemented, at first, at the sow level, involving 
minimal antimicrobial use and high hygienic standards.  
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Sinds de ontdekking van antibiotica zijn het onmisbaar belangrijke middelen in de bestrijding van bacteriële 
ziekten bij mens en dier. Hun gebruik is echter overschaduwd door een gedurende de laatste decennia 
alsmaar toenemende dreiging, namelijk antibioticumresistentie. Antibioticumresistentie in pathogene en 
zoönotische bacteriën resulteert in een verminderde werking van antibiotica of zelfs in het falen van therapie 
bij dier en mens. Hoewel resistentie bij pathogene bacteriën het vaakst beschreven wordt, zijn commensalen 
van belang in de spreiding en persistentie van antibioticumresistentie.  
Als algemene inleiding van deze thesis werd een overzicht gegeven van het gebruik van antibiotica bij 
voedselproducerende dieren, waarbij extra aandacht werd geschonken aan het gebruik van antibiotica bij 
varkens (Hoofdstuk 1.1.). In dit hoofdstuk wordt informatie aangeleverd over de redenen van 
antibioticumgebruik en welke antibioticaklassen en toedieningswegen hiervoor toegepast worden. De 
datacollectie van antibioticumgebruik teneinde het gebruik te kunnen kwantificeren komt eveneens aan bod. 
Samen met het verzamelen van antibioticumgebruiksgegevens is de opvolging of monitoring van 
antibioticumresistentie bij bacteriën van voedselproducerende dieren van onmiskenbaar groot belang bij het 
opzetten van strategieën om antibioticumresistentie te beheersen. In hoofdstuk 1.2. wordt de rol van 
Escherichia coli en Streptococcus suis, beide commensale bacteriën die betrokken kunnen zijn als pathogeen 
en/of zoönotisch agens bij dieren en mensen, in monitoring programma’s beschreven. Het monitoren van 
resistentie spoort tendensen op in het ontstaan, de spreiding en de persistentie van antibioticumresistentie en 
is omwille daarvan een noodzaak om de epidemiologie van antibioticumresistentie te begrijpen. Hoofdstuk 
1.3. geeft een overzicht van de belangrijkste aspecten en drijfveren van de vier stappen in de epidemiologie 
van antibioticumresistentie in voedselproducerende dieren, met name, de ontwikkeling, de selectie en 
spreiding, de persistentie en de terugkeer naar gevoeligheid of reductie van resistentie.  
De doelstellingen van deze thesis, vermeld in hoofdstuk 2, zijn het bepalen van de mate waarin antibiotica 
gebruikt worden in Belgische varkensbedrijven, de mate waarin epidemiologische en klinische 
antibioticumresistentie voorkomen in S. suis en E. coli van gezonde vleesvarkens en het onderzoeken of 
antibioticumresistente E. coli bij zeugen en de toediening van antibiotica aan zeugen en biggen gedurende de 
kraamperiode invloed hadden op het voorkomen van antibioticumresistentie bij fecale commensale E. coli van 
zeugen en haar biggen.  
Om een idee te krijgen over de kwantitatieve (aantal dagen dat een varken behandeld is gedurende 1000 
dagen) en kwalitatieve (indicatie, preventief of metafylactisch gebruik, gebruikte actieve substanties en 
toedieningswegen) aspecten van antibioticumgebruik in groep voor individuele bedrijven in de Belgische 
varkensproductie werd een dwarsdoorsnede studie uitgevoerd op 50 gesloten of halfgesloten 
vleesvarkensbedrijven. Op basis hiervan konden ook vergelijkingen gemaakt worden met het 
antibioticumgebruik in 2003 (Hoofdstuk 3). Drieënnegentig procent van de groepsbehandelingen was voor 
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preventieve redenen en dus slechts 7% diende als metafylaxis. De antibiotica die vaakst oraal in groep 
werden toegediend waren colistine (30.7%), amoxicilline (30.0%), trimethoprim-sulfonamiden (13.1%), 
doxycycline (9.9%) en tylosine (8.1%). De vaakst toegediende injecteerbare antibiotica waren tulathromycine 
(45.0%), lang werkend ceftiofur (40.1%) en lang werkend amoxicilline (8.4%). De behandelingsincidentie (BI) 
gebaseerd op de werkelijk toegediende dagdosis (UDDpig uitgedrukt in mg per kg varken) voor alle orale en 
injecteerbare antibiotica bedroeg gemiddeld 200.7 per 1000 varkens (min = 0, max = 699.0). Dit betekent dat 
een varken gemiddeld 201 dagen op een levensduur van 1000 dagen behandeld wordt met een dergelijke 
dosis of dat hij 20% van zijn leven onder een antibioticabehandeling staat. De behandelingsincidentie (BI) 
gebaseerd op de gedefinieerde dagdosis (ADDpig uitgedrukt in mg per kg varken voor de belangrijkste 
indicatie) was hoger (gemiddelde = 235.8, min = 0, max = 1322.1). Dit betekent dat een lager aantal dieren 
behandeld werd met een zelfde hoeveelheid antibiotica dan theoretisch mogelijk. Injecteerbare producten 
werden overwegend overgedoseerd (79.5%), terwijl oraal toegediende middelen vaak ondergedoseerd werden 
(47.3%). Er kan een stijging in het gebruik van antibiotica verondersteld worden tussen 2003 en 2010 
(TIDDDApig and TIUDDApig bedroegen respectievelijk 178.1 and 170.3). Tot slot kon geconcludeerd worden dat 
98% van de bezochte bedrijven antibiotica preventief in groep toedient en dat het vaak om kritisch belangrijke 
en breed werkende antibiotica gaat. Er kan worden gesteld dat in 2010 in België de richtlijnen voor 
voorzichtig antibioticumgebruik niet werden toegepast in de varkensproductie. 
Antibioticumresistentie bij bacteriën kan opgevolgd worden door het gebruik van klinische of epidemiologische 
interpretatieve criteria. Het gebruik van klinische interpretatieve criteria voldoet aan de eisen van de clinicus 
aangezien deze de klinische uitkomst van een antibioticabehandeling aan de voorgeschreven dosis in een 
patiënt trachten te voorspellen. Epidemiologische interpretatieve criteria daarentegen, zijn van nut voor het 
vergelijken van antibioticumresistentie tussen verschillende studies, voor het opvolgen van evoluties in 
antibioticumresistentie in tijd en voor het ontdekken van nieuwe verworven resistenties op een vroeg stadium. 
Beide criteria werden daarom gebruikt bij het berekenen van de percentages van klinisch resistente stammen 
en stammen behorende tot de niet-wild type populatie van S. suis en E. coli afkomstig van gezonde varkens.  
In de prevalentiestudie van antibioticumresistentie bij S. suis (Hoofdstuk 4) waren percentages van niet-wild 
type stammen hoog voor tetracycline (98%), lincomycine (92%), tilmicosine (72%), erythromycine (70%) en 
laag voor florfenicol (0%) en enrofloxacine (0.3%). Percentages van klinische resistentie waren hoog voor 
tetracycline (95%), erythromycine (66%), tylosine (66%), en laag voor florfenicol (0.3%) en enrofloxacine 
(0.3%). In de afwezigheid van een klinisch breekpunt voor tiamuline werd enkel het percentage van stammen 
berekend die niet tot de wild type populatie behoorden (57%). De hoge mate van verworven resistentie tegen 
tiamuline werd eerder nog niet beschreven. Percentages van klinische resistentie en niet-wild type stammen 
verschilden aanzienlijk voor penicilline. Slechts 1% van de geteste S. suis stammen werd klinisch resistent 
beschouwd, terwijl 47% van de stammen verworven resistentie vertoonde gebaseerd op epidemiologische 
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interpretatieve criteria. Hieruit kan besloten worden dat de Minimale Inhibitorische Concentratie (MIC) 
waarden voor penicilline aan de stijgende hand zijn vergeleken met vorige rapporteringen. Varkens besmet 
met stammen die hogere MIC waarden tonen, kunnen echter nog succesvol behandeld kunnen worden met 
penicilline. Gevoeligheidsresultaten van deze studie tonen duidelijk aan dat het gebruik van verschillende 
interpretatieve criteria bijdragen aan verschillen in gerapporteerde antibioticumresistenties. Het vroegtijdig 
opsporen van kleine veranderingen in de MIC populatieverdeling van bacteriën biedt de mogelijkheid om 
stappen te zetten in het beheersen van antibioticumresistentie en aldus het risico voor dier en mens te 
beperken.  
Resultaten van de disk diffusie gevoeligheidstest worden geïnterpreteerd door middel van klinische 
breekpunten indien epidemiologische interpretatieve criteria voor bepaalde E. coli-antibioticum combinaties 
niet voorhanden zijn. Verschillen in standaardisatie van de gebruikte methodes in tijd en tussen laboratoria en 
verschillen in aanbevolen klinische breekpunten maakt het vergelijken van resultaten van de disk diffusie 
gevoeligheidstest echter niet betrouwbaar. Hierdoor kunnen potentieel nuttige gegevens afkomstig van 
verschillende laboratoria niet gebruikt worden voor het monitoren van resistentie. Hoofdstuk 5 omschrijft het 
gebruik van de ‘Normalized Resistance Interpretation’ (NRI) methode om de antibioticagevoeligheid van E. 
coli afkomstig van gezonde varkens voor slachten weer te geven. Er kon worden aangetoond dat de NRI 
methode waardevol is om de wild type populatie te omschrijven voor resultaten waarbij de inhibitie 
zonediameters van de gevoelige populatie een normale verdeling vertonen. Percentages van niet-wild type 
stammen konden hierdoor berekend en vergeleken worden met klinische resistentie percentages. Op basis 
van deze resultaten kan gesteld worden dat de NRI methode wereldwijd gebruikt kan worden om 
antibioticumresistentie te monitoren in de diergeneeskunde tot er harmonisatie van de disk diffusie methode 
bereikt is. Zo kunnen eveneens historische antibioticumresistentiegegevens, afkomstig van vroeger 
uitgevoerde prevalentiestudies, gebruikt worden in monitoringsprogramma’s, op voorwaarde dat de 
inhibitiezone diameters geregistreerd werden.  
De laatste studie van deze thesis had als doel te onderzoeken of antibioticumresistente E. coli van gezonde 
zeugen en het gebruik van antibiotica bij zeugen en biggen risicofactoren zijn voor het voorkomen van 
antibioticumresistentie bij fecale commensale E. coli van biggen (Hoofdstuk 6). Hiervoor werden 60 zeugen 
en 3 biggen per zeug bemonsterd op verschillende tijdstippen. Gegevens over antibioticumgebruik rondom 
werpen en tijdens de kraamperiode werden verzameld. Resultaten van de disk diffusie gevoeligheidstest 
werden geïnterpreteerd op basis van klinische breekpunten en dit voor 2 isolaten per bemonstering van 
zeugen en biggen. Slechts 27.4% van de E. coli isolaten van de pasgeboren biggen toonde volledige 
gevoeligheid aan de geteste antibiotica. Resistentie tegen 1 of 2 antibioticaklassen bedroeg 41.2% en 46.8% 
bij E. coli van respectievelijk zeugen en biggen geïsoleerd tijdens de kraamperiode. Multiresistentie tegen 
minstens 4 antibioticaklassen werd even vaak gevonden bij zeugen (15.6%) als bij biggen (15.2%). 
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Antibioticumresistentie bij biggen werd beïnvloed door het gebruik van antibiotica bij zeugen en biggen en 
tevens door de mate van voorkomen van antibioticumresistentie bij de zeug (p < 0.05). Het gebruik van 
aminopenicillines en derde generatie cefalosporines bij biggen beïnvloedde het voorkomen van 
antibioticumresistentie bij deze biggen (odds ratios [OR] > 1; p <  0.05). Ook het gebruik van enrofloxacine is 
een risicofactor voor het voorkomen van enrofloxacine resistentie bij biggen (OR = 26.78; p < 0.01) en bij 
zeugen rond speenleeftijd (OR = 4.04; p < 0.05). Bij zeugen verhoogde het gebruik van lincomycine-
spectinomycine rond werpen het voorkomen van resistentie tegen ampicilline, streptomycine en trimethoprim-
sulfadiazine bij de zeugen zelf (OR= 21.33, OR= 142.74, OR= 18.03; p <  0.05) en tevens het voorkomen van 
enrofloxacine resistentie bij biggen (OR= 7.50; p < 0.05). De conclusie die hieruit volgt, luidt dat het gebruik 
van antibiotica bij zeugen en biggen een risicofactor vormt voor het voorkomen van antibioticumresistentie bij 
deze dieren. Bovendien wordt door het gebruik van antibiotica bij zeugen rond werpen een selectiedruk 
uitgeoefend op de resistente E. coli van de biggen.   
In de algemene discussie (Hoofdstuk 7) wordt vooreerst de ontwikkeling van een datacollectiesysteem (DCS) 
besproken. Dit DCS moet het mogelijk maken om op basis van een voortgezette verzameling van 
antibioticumgebruiksgegevens van individuele bedrijven, gerichte stappen te ondernemen naar bedrijven met 
een onverantwoord kwantitatief en kwalitatief gebruik. S. suis kan als commensaal teruggevonden worden bij 
gezonde dieren en wordt daardoor blootgesteld aan een antibiotica selectiedruk na zowel parenterale als 
orale behandelingen. S. suis zou omwille daarvan dienst kunnen doen als indicatorbacterie om resistentie op 
te volgen in tijd. Het vaststellen van hogere percentages van niet-wild type stammen dan van klinische 
resistentie percentages bij S. suis afkomstig van gezonde dieren heeft het belang aangetoond van 
epidemiologische interpretatieve criteria in het aantonen van verworven resistentie en in de monitoring van 
resistentie in tijd. Het bepalen van deze epidemiologische interpretatieve criteria voor bacteriesoorten, zoals 
S. suis, verdient daarom aanbeveling. Ook de validatie van klinische breekpunten voor de diergeneeskunde is 
noodzakelijk om ‘evidence-based medicine’ te bewerkstelligen. Antibacteriële gevoeligheidstesten voor de 
diergeneeskunde dienen geharmoniseerd te worden. De NRI methode kan echter gebruikt worden om de 
wild-type populatie van bacteriesoorten te omschrijven tot wanneer deze harmonisatie bereikt is. 
Antibioticumgebruik bij zeugen rond werpen en tijdens de kraamperiode verhoogt het voorkomen van 
antibioticumresistente E. coli bij de zeugen. Doordat zeugen als reservoir van resistente E. coli fungeren voor 
hun biggen moeten controlemaatregelen voor resistentie geïmplementeerd worden op het niveau van de 
zeug. Dit omsluit zowel een verminderd antibioticumgebruik als strikte hygiëne maatregelen. 
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